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Hsp70 molecular chaperones play critical roles in the pathogenesis of many human diseases, 
including cancer and viral replication. Hsp70s bind polypeptides and couple ATP hydrolysis to 
alter substrate conformation and function.  However, ATP hydrolysis by Hsp70 is weak, but can 
be stimulated by J domain-protein chaperones.  To identify new targets of chaperone action, I 
performed a multi-copy suppressor screen for genes that improved the slow growth defect of 
yeast lacking YDJ1 but expressing a defective YDJ1 chimera.  Among the genes identified were 
MID2, which regulates cell wall integrity, and PKC1, which encodes protein kinase C, which is 
also linked to cell wall biogenesis.  Consistent with these data, I found that ydj1Δ yeast and yeast 
with temperature sensitive mutations in Hsp90 exhibit phenotypes consistent with cell wall 
defects but these phenotypes were improved by Mid2p or Pkc1p over-expression.  Mid2p over-
expression thickened the ydj1Δ cell wall, which is likely the basis for suppression of the ydj1Δ 
growth defect.  These data provide the first link between cytoplasmic chaperones and cell wall 
integrity, and suggest that chaperones orchestrate the biogenesis of this structure. 
Another J domain-protein is the Large Tumor Antigen (TAg) in the polyomavirus Simian 
Virus 40 (SV40).  TAg is required for viral replication and cellular transformation, and binds 
Hsp70.  Because of their roles in cancer and SV40 function, small molecule modulators that 
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inhibit Hsp70 or J-protein activity might represent novel anti-cancer and/or anti-viral agents.  To 
identify such agents, I screened a bank of small molecules and identified a compound, MAL3-
101, that had no effect on endogenous Hsp70 ATPase activity, but inhibited TAg stimulation of 
Hsp70 ATPase activity and reduced breast cancer cell proliferation.  Forty-two derivatives of 
MAL3-101 were then synthesized and twelve compounds inhibited breast cancer cell 
proliferation at lower concentrations than MAL3-101.  Reduction of cell proliferation correlated 
with reduced TAg stimulation of Hsp70 in vitro.  Intriguingly, one compound, MAL2-11B, also 
inhibited the ATPase activity of TAg.  This compound inhibited viral replication almost five-fold 
and SV40 DNA replication in vitro.  These data show that J-protein inhibitors may be viable 
treatments for breast cancer and polyomavirus infection. 
 v 
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1.0  INTRODUCTION 
Protein biogenesis is a complex process and newly synthesized proteins face many obstacles 
before they fully mature.  The proteins must properly fold, localize, and often be activated before 
they can properly function.  However, in the concentrated cellular milieu, these processes are 
difficult without assistance.  In addition, improperly folded proteins may aggregate or be targeted 
for degradation --- both processes have been found to be linked to disease.  To deal with this 
issue, cells have evolved complex molecular chaperone machinery to aid in protein maturation 
and localization.  Molecular chaperones aid in most aspects of protein maturation including: 
folding, assembly into multi-protein complexes, protein activation, and membrane translocation.  
In addition, chaperones help refold misfolded or aggregated proteins and aid in protein 
degradation.  Thus, chaperones are essential to process proteins responsible for most cellular 
pathways. 
The importance of molecular chaperones is highlighted by their roles in disease and 
disease prevention (BARRAL et al. 2004; JOLLY and MORIMOTO 2000).  For example a point 
mutation in a mitochondrial Hsp60 chaperone leads to the disease spastic paraplegia, probably 
due to misfolding of Hsp60 substrates (HANSEN et al. 2002).  Other diseases such as cystic 
fibrosis (AMARAL 2004) and Alzheimer’s disease (SMITH et al. 2005) are characterized by 
misfolded or aggregated proteins, and changes in chaperone levels can either aggravate or 
alleviate disease symptoms.  Finally, chaperones are upregulated in both cancerous and viral 
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infected cells and may serve a protective function for the diseased cells (CALDERWOOD et al. 
2006; SULLIVAN and PIPAS 2001). Unfortunately, few drugs that target chaperones have been 
identified, leaving a vast medicinal target untapped. 
Despite the ubiquitous roles of chaperones in cells, I have uncovered a novel link 
between cytosolic chaperones and yeast cell wall integrity.  Because the cell wall is considered a 
prime target for anti-fungals (GEORGOPAPADAKOU and WALSH 1996), this link suggests that 
cytosolic chaperones could be viable targets for new anti-fungal drugs.  Secondly, I have 
identified small molecule modulators that inhibit breast cancer cell proliferation and viral 
replication.  In turn, these could be the precursors to viable treatment options for many other 
diseases. 
1.1 CLASSES OF MOLECULAR CHAPERONES 
Many molecular chaperones were initially characterized as proteins upregulated in response to 
heat shock and other cellular stresses.  These proteins are traditionally named according to their 
size.  For example, Heat Shock Protein 70 (Hsp70) is a 70 kDa protein upregulated by stress.  In 
addition, some heat shock proteins have constitutively expressed counterparts, the Heat Shock 
Cognate (Hsc) proteins that properly fold “housekeeping” proteins in the absence of stress.  
Hsc70 is essential for growth under normal conditions and accounts for up to 1% of total cellular 
protein.  Hsp70 and Hsc70 have high sequence identity and are virtually identical in biochemical 
assays, but differ primarily in regulation (BRODSKY and CHIOSIS 2006).  Unless otherwise stated, 
the Hsp prefix will be used to describe characteristics common to both Hsp and Hsc family 
members. 
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Some molecular chaperones were independently discovered as Escherichia coli proteins 
required for λ phage replication.  Prior to replication, the origin of λ phage replication contains a 
complex of two λ phage proteins (λO and λP) and one bacterial protein (DnaB).  The activity of 
DnaB, a DNA helicase, is inhibited by the interaction with λP.  DnaK (Hsp70) and DnaJ (Hsp40) 
act in concert to rearrange this multi-protein complex at the phage origin in order to remove λP 
from DnaB and allow λ replication to begin (TAYLOR and WEGRZYN 1995).  DnaK and DnaJ are 
the best studied members of the Hsp70 and Hsp40 families and are considered the “prototypal” 
examples of their respective classes.     
Many classes of chaperones have been identified which bind diverse substrates and alter 
their conformations via ATP hydrolysis.  Under normal cellular conditions, chaperones fold 
newly synthesized proteins or aid in other maturation processes via this conformation change 
(HARTL and HAYER-HARTL 2002).  In hindsight, it is not surprising that molecular chaperones 
are required during times of stress or are corrupted during cancer and viral replication.  Under 
stressful conditions, properly folded proteins become misfolded and increased chaperone levels 
compensate by using ATP catalyzed conformational changes to unfold misfolded proteins or 
disrupt protein aggregates before aiding in protein refolding (MAYER and BUKAU 2005; 
WEIBEZAHN et al. 2005).  Thus, in the stressful environment of a tumor, chaperones play a 
protective role (BRODSKY and CHIOSIS 2006; JOLLY and MORIMOTO 2000).  Also, viruses like λ 
phage can commandeer the chaperone machine to allow viral replication by rearranging 
inhibitory subunits. 
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1.2 STRUCTURE AND FUNCTION OF SELECT CYTOSOLIC CHAPERONES AND 
COCHAPERONES 
This section focuses on four main classes of molecular chaperone: Hsp40, Hsp70, Hsp90, and 
the Hsp70 nucleotide exchange factors (NEFs).  All chaperones discussed in this study are listed 
in Table 1. 
1.2.1 Hsp70/Hsc70 
Members of the Hsp70/Hsc70 class of molecular chaperones are essential for a vast majority of 
the chaperone dependent processes already discussed, including protein folding, membrane 
translocation, disrupting protein aggregates, and rearranging multiprotein complexes (DESHAIES 
et al. 1988; GLOVER and LINDQUIST 1998; SZABO et al. 1994; UNGEWICKELL et al. 1995).  These 
highly conserved chaperones are found in all organisms.  To date, three Hsp70s have been 
identified in E. coli and this number increases to ~10 in higher organisms (MAYER and BUKAU 
2005).  Hsp70 function and specificity is highly regulated by cochaperones such as Hsp40s and 
nucleotide exchange factors (NEFs), which will be discussed in detail in Section 1.2.3. 
1.2.1.1 Structure of Hsp70 
All Hsp70s are composed of three domains, an ~44 kDa N-terminal ATPase domain, an ~15 kDa 
substrate binding domain, and an ~10 kDa C-terminal lid domain (FLAHERTY et al. 1990; WANG 
et al. 1993; ZHU et al. 1996).  The extreme C-terminus contains an EEVD motif that interacts 
with cochaperones that contain several degenerate 34 amino acid repeats, called tetratricopeptide 
repeats (TPRs).  Crystallographic studies of bovine Hsc70 show that the ATPase domain  
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Table 1:  Select examples of specific chaperone families 
Family Type Organism Protein Location 
E. coli DnaK Cytosol 
S. cerevisiae Ssa1-4p Cytosol 
S. cerevisiae Ssb1-2p Cytosol 
S. cerevisiae Kar2p ER 
H. sapiens Hsc70 Cytosol 
H. sapiens Hsp70 Cytosol 
Hsp70 N/A 
BYV p65 Nucleus/Cytosol
I E. coli DnaJ Cytosol 
I S. cerevisiae Ydj1p Cytosol 
II S. cerevisiae Sis1p Cytosol 
III S. cerevisiae Swa2p Cytosol 
III S. cerevisiae Sec63p ER 
I S. cerevisiae Scj1p ER 
III S. cerevisiae Jem1p ER 
I S. cerevisiae Mdj1p Mitochondria 
II H. sapiens HSJ1 Cytosol 
I H. sapiens DNAJ2 Cytosol 
III SV40 TAg Nucleus/Cytosol
III BKV TAg Nucleus/Cytosol
Hsp40 
III JCV TAg Nucleus/Cytosol
E. coli GrpE Cytosol 
S. cerevisiae Snl1p ER 
S. cerevisiae Fes1p Cytosol 
S. cerevisiae Sse1p Cytosol 
H. sapiens BAG-1 Cytosol 
H. sapiens HspBP1 Cytosol 
NEF N/A 
H. sapiens BAP ER 
S. cerevisiae Hsp82p Cytosol 
S. cerevisiae Hsc82p Cytosol 
H. sapiens Hsp90α Cytosol Hsp90 N/A 
H. sapiens Hsp90β Cytosol 
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contains two globular domains which are separated by a deep cleft which binds ATP (Figure 
1A).  These two globular domains have been further divided into subdomain IA, IB, IIA, and IIB 
(FLAHERTY et al. 1990).  Little change in the tertiary structure is seen by crystallography when 
ATP or ADP is bound in the active site (FLAHERTY et al. 1994), although more recent NMR 
analyses have uncovered some changes in conformation (REVINGTON et al. 2004; REVINGTON et 
al. 2005; ZHANG and ZUIDERWEG 2004).  The structure of the ATPase domain shows structural 
similarity to two proteins with little sequence identity, hexokinase and actin (FLAHERTY et al. 
1990; FLAHERTY et al. 1991).   
The structure of the substrate binding domain has been determined for DnaK (Figure 1B) 
and is composed of mostly β sheets, upon which hydrophobic peptides bind (ZHU et al. 1996).  
This peptide is sequestered by, but does not interact with, an α helical lid domain at the C-
terminus (ZHU et al. 1996).  The peptide interacts with the substrate binding domain in an 
extended conformation and several Hsp70 amino acids directly interact with the peptide.  A 
glutamine at position 433 forms a hydrogen bond to the peptide and appears critical to position 
the peptide.  This glutamine is found in at least 30 other Hsp70 sequences (ZHU et al. 1996).  
Most of the other residues that interact with the peptide are hydrophobic in nature.  While these 
residues are less conserved in other Hsp70s, they remain hydrophobic (ZHU et al. 1996).  The 
substrate binding domain and lid domain dictate substrate specificity via relative affinities for 
peptide sequences.  The Bukau lab determined that the preferred DnaK peptide contains a core 
sequence containing 4-5 hydrophobic residues flanked by 2 basic residues and strongly disfavors 
acidic residues (RUDIGER et al. 1997).  The best DnaK binding peptide discovered by the Bukau 
lab interacted with DnaK with very high affinity (KD=~100 nM), (RUDIGER et al. 1997) though  
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Figure 1:  The crystal structures of the Hsp70 ATPase, substrate binding, and lid domains.   
All β-sheets are shown in orange and all α helices are shown in pink.  (A) The bovine Hsp70 
ATPase domain, which binds and hydrolyzes ATP.  The two domains, I and II, form the cleft in 
which ATP binds.  The subdomains are labeled.  Figure adapted from FLAHERTY et al. 1990. 
(B) The DnaK substrate binding domain and lid domain crystallized in the presence of a peptide.  
The peptide, shown in white, binds in the β-sheet rich substrate binding domain and the α helical 
lid domain aids in high affinity peptide binding.  Figure adapted from ZHU et al. 1996. 
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this is higher than previously reported for other Hsp70s (BLOND-ELGUINDI et al. 1993; FLYNN et 
al. 1989). 
A flexible linker between the ATPase domain and substrate binding domain has made 
crystallization of the full length protein difficult.  The Sousa lab recently crystallized a bovine 
Hsc70 protein that contained both the ATPase domain and the substrate binding domain, but 
lacked the lid domain (JIANG et al. 2005).  In order to obtain high-quality crystals, they also 
mutated two charged residues on the surface of the ATPase domain and crystallized the proteins 
in conditions that contained high concentrations of the osmolyte, trimethylamine oxide (TMAO).   
In the final structure, the substrate binding domain folds onto the ATPase domain and interacts in 
a groove between domains IA and IIA.  Also, the substrate binding domain is partially unfolded, 
and some of the residues adjacent to the lid domain occupy the peptide binding site.  However 
because of chosen construct and crystallization conditions, and because nucleotide was absent 
from the nucleotide binding site, this structure is difficult to interpret. 
1.2.1.2 Mechanism of action 
Hsp70s function by binding substrates and using the energy from ATP hydrolysis to influence 
substrate binding (Figure 2).  The unstimulated rate of ATP hydrolysis ranges from 0.02 to 0.2 
min-1 (HA and MCKAY 1994; MCCARTY et al. 1995; THEYSSEN et al. 1996).  When Hsp70 is 
found in the ATP bound state, the lid domain is open and substrates have a low affinity for the 
peptide binding domain, resulting in a high on/off rate.  However, peptide binding can stimulate 
Hsp70 ATP hydrolysis 2-10 fold and cause the lid domain to clamp down onto the substrate 
(FLYNN et al. 1989; JORDAN and MCMACKEN 1995).  In ADP-bound Hsp70, the substrate 
interacts with the peptide binding domain with high affinity and thus has a low on/off rate 
(MCCARTY et al. 1995; RUSSELL et al. 1999).  After ADP is released, the Hsp70 rebinds ATP,  
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Figure 2:  The Hsp70 ATPase cycle.   
In the ATP bound state, the lid domain of Hsp70 is open and peptide associates with high on/off 
rate.  Often, substrate (S) is delivered to Hsp70 by a J-protein, though this is not required.  The J 
domain and substrate stimulate Hsp70 ATPase activity and leads to an Hsp70 conformational 
change in which the lid domain closes and the peptide has high affinity for Hsp70.  Nucleotide 
exchange factors (NEF) bind to the ATPase domain and stimulate nucleotide release to allow 
ATP rebinding to Hsp70.  Some components in this process are known to function as dimers, but 
monomers are shown for simplicity.   
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the lid domain opens, and peptide dissociation rates increase by 2-3 orders of magnitude and 
peptide affinity decreases by a factor of 10 (GISLER et al. 1998; MAYER et al. 2000).    
The conformation changes in Hsp70 are becoming better defined and in one recent 
example it was shown to require a proline at residue 143 and an arginine at residue 151 in the 
DnaK ATPase domain (proline 147 and arginine 155 in bovine Hsp70) (VOGEL et al. 2006).  
When ATP is bound to the ATPase domain, ATP binding is relayed to the substrate binding 
domain via a proline, potentially by cis-trans isomerization of the proline, which shifts the 
arginine toward the peptide binding domain.  When substrate binds to the peptide binding 
domain and Hsp40 interacts with the ATPase domain, the arginine is moved inward and the 
conformation of the proline is altered.  This conformation positions the ATP catalyzing residues 
in the ATPase domain in correct proximity to ATP and facilitates ATP hydrolysis.  As might be 
anticipated, mutation of the proline residue prevents the ATPase and substrate binding domains 
from communicating and accelerates the switch between the two conformations (VOGEL et al. 
2006).  Also, even a conserved mutation of arginine to lysine nearly abolishes allosteric cross-
talk between the domains and substrate binding stimulates ATP hydrolysis to only 6% of wild 
type levels (VOGEL et al. 2006). 
For most Hsp70 chaperones ATP hydrolysis is very weak and represents the rate-limiting 
step (MCCARTY et al. 1995; THEYSSEN et al. 1996).  In addition to stimulation by peptide, the 
Hsp70 ATPase cycle is stimulated by cochaperones such as Hsp40 and NEFs.  Hsp40s stimulate 
ATP hydrolysis directly (CHEETHAM and CAPLAN 1998; GASSLER et al. 1998; SUH et al. 1998) 
whereas NEFs aid in the release of ADP from Hsp70 to accelerate the ATPase cycle (ALBERTI et 
al. 2003; HARRISON 2003); these factors will be discussed in Sections 1.2.2 and 1.2.3.  Hsp40 
stimulation can increase ATP hydrolysis 2-10 fold (CYR and DOUGLAS 1994; WALL et al. 1994) 
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and the bacterial NEF GrpE can stimulate ADP release from DnaK by 5000 fold (PACKSCHIES et 
al. 1997).  These cofactors and peptide function together to regulate Hsp70 function.  In fact, 
DnaK ATPase activity can be stimulated >1000 fold when both DnaJ and substrate are present 
(LAUFEN et al. 1999; LIBEREK et al. 1991) 
1.2.2 Hsp40 
Members of the Hsp40 class of chaperones are obligate cochaperones of Hsp70s.  The primary 
role of Hsp40s is to stimulate Hsp70 ATP hydrolysis, though some Hsp40s also have a substrate 
binding domain and are responsible for delivering substrates to Hsp70s (HAN and CHRISTEN 
2003; LANGER et al. 1992; RUDIGER et al. 2001; SZABO et al. 1996; WICKNER et al. 1991).  All 
Hsp40s contain a J domain, named for its presence in DnaJ, so these proteins are often called J 
domain containing proteins or J-proteins.  There are six J-proteins in E. coli and between 20 and 
40 in yeast and higher organisms (QIU et al. 2006; WALSH et al. 2004).  The large number of J-
proteins, relative to Hsp70, is probably because they help define Hsp70 specificity. 
1.2.2.1 Structure and types of Hsp40s 
As noted above, the defining feature of Hsp40s is the J domain (Figure 3A).  The structures of 
seven J domains have been solved  and show that the J domain is comprised of four alpha helices 
(HENNESSY et al. 2005).  Helices II and III interact to form a finger-like projection and 
hydrophobic interactions between these helices are critical to maintain the structure of the J 
domain.  The loop between Helix II and III contains an invariant HPD motif which is essential 
for stimulating Hsp70 ATP hydrolysis.  Conserved residues in the J domain are seen on all four  
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Figure 3:  Key features of the Hsp40 class of molecular chaperones.   
(A) The structures of 7 J domains have been determined.  These include NMR structures from 
three E. coli DnaJ proteins (1XBL, 1BQZ, 1BQ0), human HDJ1 (1HDJ), and murine 
polyomavirus (1FAF) and crystal structures of E. coli Hsc20 (1FPO), SV40 TAg (1GH6), and 
bovine auxilin (1NZ6).  Figure adapted from HENNESSY et al. 2005.  (B) J-proteins are defined 
by their homology to DnaJ.  Type I J-proteins are exemplified by DnaJ and contain an N-
terminal J domain, a glycine/phenylalanine (G/F) rich region, and a cysteine rich domain that 
coordinates zinc atoms.  Type II J-proteins do not contain a cysteine rich domain and generally 
have an elongated G/F domain.  Type III J-proteins only contain the J domain which can be 
localized throughout the protein. 
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helices, though the importance of many of these residues has not been thoroughly investigated 
(HENNESSY et al. 2000).   
The prototypical Hsp40 is the E. coli DnaJ and all Hsp40s are defined by their similarity 
to DnaJ (Figure 3B) (CHEETHAM and CAPLAN 1998).  DnaJ is a type I Hsp40, and contains an N-
terminal J domain, a glycine/phenylalanine rich domain (G/F), and a cysteine rich domain.   In 
contrast, type II Hsp40s do not have a cysteine rich domain, and generally have a longer 
glycine/phenylalanine rich domain.  Finally, type III proteins only have the J domain which is 
not restricted to the N-terminus.  Type I and II Hsp40s bind to substrate through the G/F and 
cysteine rich domain and are bona fide Hsp40 chaperones. The differences between type I and 
type II Hsp40s help dictate substrate specificity (FAN et al. 2004).  Type III J-proteins (e.g. TAg 
discussed in detail in Section 1.5.2.1) are not involved in protein folding and are not considered 
molecular chaperones. 
1.2.2.2 Mechanism of action 
Many J domain containing proteins bind peptide substrate and deliver it to Hsp70 through a 
poorly characterized mechanism (HAN and CHRISTEN 2003; LANGER et al. 1992; RUDIGER et al. 
2001; SZABO et al. 1996; WICKNER et al. 1991).  Peptide binding and the J domain are required 
for maximal stimulation of Hsp70 ATPase activity.  The J domain binds the Hsp70 ATPase 
domain with a relatively low affinity [KD=20µM for DnaK/DnaJ, though a higher affinity (544 
nM) was determined by Biocore (RUSSELL et al. 1999; SUH et al. 1999)] primarily through helix 
II and the HPD motif as shown by DnaJ NMR perturbation studies (GREENE et al. 1998).  
However, recent studies using a mouse polyomavirus Type III J domain containing protein have 
shown that residues in helices III may also be important for Hsp70 interaction (GARIMELLA et al. 
2006).  However the J domain alone is sometimes insufficient for stimulating Hsp70 ATPase 
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activity, suggesting that for some J-proteins C-terminal regions of the protein are essential for 
Hsp70 interaction (SUH et al. 1999).  J domains stimulate Hsp70 through the proline switch and 
arginine relay (VOGEL et al. 2006) previously discussed in Section 1.2.1.2.   Mutations in the 
HPD loop and in some residues in helix II abrogate the ability of Hsp40s to stimulate ATP 
hydrolysis (GENEVAUX et al. 2002; HENNESSY et al. 2005; TSAI and DOUGLAS 1996; WALL et al. 
1994). 
The interaction of the J domain may also be mediated through domain IA in the Hsp70 
ATPase domain.  To identify Hsp70 residues important for an interaction with the J domain HPD 
motif, the Gross lab screened for mutants of DnaK that suppress two phenotypes associated with 
HPD mutations in DnaJ.  A DnaK R167H mutation, localized to domain IA, was discovered that 
suppresses the growth defect of cells containing DnaJ D35N and allows productive λ phage 
infections.  Surface plasmon resonance experiments indicated the DnaK R167H mutation 
restores a functional interaction with DnaJ D35N (SUH et al. 1998).  In fact, DnaK R167H bound 
3 fold better to DnaJ D35N than wild type DnaJ (SUH et al. 1998).  Further supporting the role of 
this residue in the J domain interaction, mutation of this residue in DnaK prevented a functional 
interaction with a wild type J domain (SUH et al. 1998).  At this point, it is uncertain whether the 
J domain directly binds the cleft near DnaK R167 or if this residue is indirectly involved in the 
stimulation of Hsp70. 
In addition to their role in stimulating Hsp70 ATP hydrolysis, many J-proteins also bind 
substrates.  The peptide binding domain of the yeast Type I Hsp40 Ydj1p bound to peptide has 
been crystallized (Figure 4) (LI et al. 2003b).  Three subdomains in the peptide binding domain 
are readily identified.  Domains I and III form an extended region of mostly β sheets and domain 
I binds to peptide.  Zinc binding in domain I and II allow domain II to extend from the end of  
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Figure 4:  Space-filling and ribbon representations of amino acids 110-337 of the Ydj1p substrate binding 
domain.   
The space-filling model indicates surface potential, and blue residues are positively charged and 
red residues are negatively charged.  The red box surrounds the peptide that was cocrystallized 
with Ydj1p.  The ribbon diagram labels the zinc binding domains (ZBDI and ZBDII) and the 
cysteines that coordinate the zinc molecules (orange spheres).  The C terminal domains (CTDI 
and CTDII) and the cocrystallized peptide (red ribbon) are also shown.  Figure adapted from LI 
et al. 2003. 
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domain I to form an structure that looks like a capital “L” (LI et al. 2003b).  Modeling of the 
Ydj1p dimer shows interactions between the tips of domain III create a central pocket between 
the two dimers.  The previously crystallized Type II Hsp40 Sis1p looked virtually identical (SHA 
et al. 2000).  As with DnaK, the preferred peptide binding residues of DnaJ were identified by 
the Bukau lab and contain eight aromatic or hydrophobic residues (RUDIGER et al. 2001).  While 
the DnaJ peptide preferences are slightly different than DnaK, which prefers 4-5 hydrophobic 
residues flanked by 2 basic residues (RUDIGER et al. 1997), most peptides that bind to DnaJ also 
bind to DnaK.  The Bukau lab proposed two hypotheses for substrate transfer from DnaJ to 
DnaK (RUDIGER et al. 2001).  The “handover” mechanism suggests that since DnaJ and DnaK 
bind similar peptides, DnaK displaces DnaJ from the substrate and binds the same residues.  A 
second hypothesis proposes that since the preferred residues are different, DnaJ and DnaK bind 
residues in close proximately and each protein occupies discrete positions on the substrate at the 
same time. 
1.2.2.3 Hsp70/Hsp40 specificity 
There has been much debate about how substrate-specific interactions with individual Hsp70 and 
Hsp40 are created.  Some specificity is certainly created simply by differential localization of 
proteins.  Membrane enclosed compartments such as the endoplasmic reticulum and 
mitochondria have dedicated Hsp70s and Hsp40s which are physically separated from the 
cytosolic chaperones.  However, specificity is also seen within a single compartment.  For 
example yeast Hsp70, Ssa1p, is stimulated 6.1 fold by a cytosolic partner, Ydj1p, but only 1.5 
fold by GST-63J (a chimeric protein containing GST fused to the J domain of Sec63p which 
resides in the ER lumen).  Similarly, Kar2p is stimulated 13.1 fold by its the J domain found in 
GST-63J, but only 1.4 fold by Ydj1p (MCCLELLAN et al. 1998).  J domain swapping experiments 
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have also been performed to address Hsp70/Hsp40 specificity (HENNESSY et al. 2005). These 
studies have shown that not all J domains can functionally substitute for each other and that J 
domains must code for some interaction specificity.  J domain swaps between the yeast cytosolic 
J-protein Sis1p, mitochondrial J-protein Mdj1p, and ER luminal J-proteins Scj1p with Sec63p 
were performed in the Silver lab (SCHLENSTEDT et al. 1995).  The J domains of mitochondrial 
Mdj1p and cytosolic Sis1p do not substitute for the ER luminal Sec63p J domain.  However, ER 
luminal Scj1p functionally substituted for Sec63p, which is perhaps not surprising since both 
proteins interact with the same Hsp70, Kar2p.  In some J-proteins the J domain appears sufficient 
to dictate specificity.  For example, the exposed regions of some type III J-proteins [e.g. 
polyomavirus tiny tumor antigen (tAg) and Sec63p] are extremely short and contain little other 
sequence information.  Despite this lack of additional sequences, residues in the Sec63p J 
domain allow productive interactions with BiP, but not Ssa1p (MCCLELLAN et al. 1998).  
However, none of these studies rule out the possibility that residues beyond the J domain play an 
additional role in determining specificity. 
1.2.3 Nucleotide exchange factors (NEFs) 
In the presence of a J domain containing protein, the rate-limiting step of the Hsp70 cycle 
becomes the release of ADP (BUKAU and HORWICH 1998).  Cells have evolved NEFs to remove 
ADP from the ATPase domain.  ATP then rebinds with high efficiency since it is found in high 
cytosolic concentrations.  Interestingly, three structurally distinct NEFs have been identified, 
GrpE in bacteria, and BAG-1 and HspBP1 in eukaryotes.  Also, recent studies have shown that 
the yeast Hsp110 homologue, Sse1p, acts as a NEF for Ssa1p (DRAGOVIC et al. 2006a; RAVIOL 
et al. 2006).  Each of these factors is considered in detail below. 
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1.2.3.1 GrpE 
GrpE was the first Hsp70 NEF identified and exchanges nucleotide on E. coli DnaK.  GrpE 
homologues have only been identified in bacteria and eukaryotic organelles of prokaryotic origin 
such as the mitochondria (HARRISON 2003).  GrpE was initially discovered as a protein required 
for λ phage replication (SAITO and UCHIDA 1977) and can  remove both ADP and ATP from 
DnaK (BREHMER et al. 2001), though the affinity of GrpE for DnaK is decreased in the presence 
of ATP (ZYLICZ et al. 1987)  In fact, GrpE reduces the affinity of ADP for DnaK 200 fold and 
stimulates nucleotide exchange 5000 fold (PACKSCHIES et al. 1997).   
GrpE has been crystallized as a dimer and consistent with this observation, previous 
experiments suggest that the ratio of DnaK to GrpE is 1:2 (HARRISON et al. 1997; SCHONFELD et 
al. 1995).  The monomer of GrpE consists of a long α helix, a small α helix and a C-terminal β 
sheet region.  In the dimer the α helices are aligned to form a four helix bundle with two β sheet 
protrusions.  The β sheets interact with domain IIB of DnaK and shift the domain outward by 
14°, which prevents high affinity nucleotide binding in the binding pocket (HARRISON et al. 
1997).  Thus, GrpE interferes with ATP binding by changing the conformation of the ATPase 
domain and does not directly interact with the ATP binding pocket (Figure 5A).  Overall, the 
GrpE/DnaK interaction increases protein folding by accelerating the DnaK ATP hydrolysis cycle 
(SZABO et al. 1994).  GrpE has also been reported to directly accelerate peptide release from 
DnaK (MALLY and WITT 2001), but this was disputed in a more recent study (BREHMER et al. 
2004).  
1.2.3.2 BAG-1 
BAG-1 was first identified as a Bcl-2 associated athanogene, which binds anti-apoptotic Bcl-2 
(TAKAYAMA et al. 1995) and was then discovered to associate with many others proteins,  
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Figure 5:  Crystal structures of the three classes of nucleotide exchange factors.   
(A)  Two representations of the GrpE NEF, which was crystallized as a dimer.  The monomers of 
GrpE are shown in yellow and blue, and the ATPase domain of Hsp70 is shown in red.  On the 
right, the 14° shift in the Hsp70 ATPase domain can be observed.  Figure adapted from 
HARRISON 2003.  (B)  The BAG domain of BAG-1 (red) is cocrystallized with the Hsp70 
ATPase domain (green).  Figure adapted from SONDERMANN et al. 2001.  (C)  Two 
representations of the HspBP1 core domain (green) are shown with the IIA and IIB subdomains 
of the Hsp70 ATPase domain (left) or a model of the entire Hsp70 ATPase domain (right).  
Figure adapted from SHOMURA et al. 2005. 
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including Hsp70 (TAKAYAMA et al. 1997).  The complete role of BAG-1 in the cell is currently 
unclear, but it has been shown conclusively to be a NEF for Hsp70 (HOHFELD and JENTSCH 
1997).  The BAG-1 mRNA codes for 4 isoforms, BAG-1L, BAG-1M, BAG-1, BAG-1S, which 
differ in length and sequence at the N-terminus.  All isoforms contain a C-terminal BAG domain 
which is essential for the interaction with the Hsp70 ATPase domain (ALBERTI et al. 2003).  A 
BAG-1 homologue, Snl1p, has been identified in S. cerevisiae (SONDERMANN et al. 2002).  
Snl1p interacts with Ssa1p, Ssa4p, and Ssb1 as shown by yeast two hybrid and 
coimmunoprecipitation  and stimulates nucleotide release by mammalian Hsc70 (SONDERMANN 
et al. 2002).  SNL1 is a multi-copy suppressor of growth defects seen in strains with mutations in 
nuclear pore associated proteins (HO et al. 1998) and Snl1p interaction with Hsp70 is required 
for this activity (SONDERMANN et al. 2002).  Based on these results, the Hartl lab proposed 
Hsp70 folds the nuclear pore associated proteins and over-expression of SNL1 increased the 
folding rate. 
The BAG domain consists of a 3 helix bundle that interacts with Hsp70 ATPase domains 
Ib and IIb (Figure 5B).  While the BAG domain is structurally very different from GrpE, it 
disrupts nucleotide in a similar fashion by rotating domain IIb 14°, and releases ADP from the 
nucleotide binding pocket (Figure 6) (SONDERMANN et al. 2001).  Unlike GrpE, BAG-1 is 
selective for ADP and only releases ADP from Hsp70 (BREHMER et al. 2001).   BAG-1 can 
stimulate the steady state ATPase activity of Hsp70, and has differing effects on Hsp70 substrate 
folding depending on stoichiometry between Hsp70 and BAG-1 (GASSLER et al. 2001). 
1.2.3.3 HspBP1 
A third class of NEF is the Hsp Binding Protein 1, HspBP1 which was first identified as an 
inhibitor of Hsp70 refolding at high concentrations of HspBP1 (RAYNES and GUERRIERO 1998).   
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Figure 6:  A representation of the interaction of Hsp70 with either HspBP1 or BAG-1.   
HspBP1 interacts with the Hsp70 ATPase subdomains IB and IIB and rotates them relative to 
each other.  BAG-1 also interacts with both domains, but only changes the conformation of 
subdomain IIB.  Figure adapted from SHOMURA et al. 2005. 
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Two HspBP1 homologues have been identified, Fes1p in yeast cytosol and BAP in the 
mammalian ER (CHUNG et al. 2002; KABANI et al. 2002a).  HspBP1 is a NEF for Hsp70 and 
facilitates luciferase folding in vivo (AHNER et al. 2005; KABANI et al. 2002b).  Interestingly, 
Fes1p is a NEF for two yeast cytosolic chaperones, Ssa1p and the ribosome-associated Ssb1p 
(DRAGOVIC et al. 2006b; KABANI et al. 2002a).  Also, fes1Δ cells are sensitive to cycloheximide, 
an inhibitor of protein translation, and contain increased levels of 80s ribosomes relative to wild 
type cells (KABANI et al. 2002a).  Taken together, these results suggest that Fes1p is important 
for folding newly synthesized polypeptides as they exit the ribosome. 
HspBP1 is structurally distinct from GrpE and BAG-1 and has a unique mechanism for 
nucleotide exchange.  The core domain of HspBP1 was crystallized and was composed entirely 
of α helices.  The arrangement of the helices leads to a slightly concave face of the molecule.  
The most closely related structure to HspBP1 is the Armadillo repeat, which is found in β catenin 
and importin-α (CONTI et al. 1998; HUBER et al. 1997).  The core domain of HspBP1 was also 
crystallized in association with lobe II of Hsp70.  (Figure 5C)  While HspBP1 has a similar 
overall binding affinity for the Hsp70 ATPase domain as BAG-1, it binds Hsp70 domain IIb with 
higher affinity than BAG-1, and does not interact with Ib very well (SHOMURA et al. 2005).  
Instead of simply disrupting domain IIb by 14°, HspBP1 disrupts lobes I and II relative to each 
other to release ADP (Figure 6) (SHOMURA et al. 2005). 
1.2.3.4 Sse1p 
Recently, the yeast Hsp110 molecular chaperone, Sse1p, was shown to exhibit nucleotide 
exchange activity (DRAGOVIC et al. 2006a; RAVIOL et al. 2006).  Hsp110s are distantly related to 
Hsp70s and have similar N-terminal ATPase domains, but the C-terminal putative substrate 
binding domain is not homologous to Hsp70.  In addition, Hsp110s also have extended regions 
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between the ATPase and C-terminal domains and at the extreme C-terminus.  Sse1p acts as a 
holdase, and prevents protein aggregation but cannot induce protein folding (BRODSKY et al. 
1999).  Sse1p is found in chaperone complexes with Hsp82p and the two yeast Hsp70s, Ssa1p 
and Ssb1p (LIU et al. 1999; SHANER et al. 2005).  A role in Hsp70 function was first hinted at by 
the discovery of Sse1p as a multi-copy suppressor of the ydj1-151 thermosensitive allele of the 
yeast Hsp40, YDJ1 (GOECKELER et al. 2002).  This suggested Sse1p, like Ydj1p, stimulates the 
Ssa1p ATP hydrolysis cycle. 
 Sse1p stimulates steady state ATPase activity of Ssa1p, but does not stimulate Ssa1p in 
single turnover ATPase assays, suggesting that it is involved in nucleotide binding or release 
(RAVIOL et al. 2006).   Fluorescent ADP release assays show that Sse1p stimulates nucleotide 
release of Ssa1p by 150 fold and Ssb1p by 80 fold (RAVIOL et al. 2006) and stimulates Ssa1p 
peptide release (DRAGOVIC et al. 2006a).  While Sse1p cannot fold luciferase independently, it 
can stimulate luciferase folding by Ssa1p in vivo and in vitro (DRAGOVIC et al. 2006a; RAVIOL et 
al. 2006). 
1.2.4 Hsp90/Hsc90 
Hsp90s, like Hsp70s, bind and release substrate proteins concomitant with ATP hydrolysis.  
However, unlike Hsp70 and Hsp40 which are involved in folding newly synthesized 
polypeptides, Hsp90 folds a specific set of client proteins that have neared their native 
conformation (TERASAWA et al. 2005; ZHAO and HOURY 2005).  A list of known Hsp90 clients is 
available on Didier Picard’s website, http://www.picard.ch/downloads/Hsp90interactors.pdf.  
Specifically, Hsp90 is responsible for activating proteins or holding them in a conformation 
conducive for interaction with required hormones or proteins.  For example, most Hsp90 clients 
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are hormone binding receptors, kinases, and transcription factors (PRATT and TOFT 2003).  Two 
Hsp90 homologues have been identified in S. cerevisiae (Hsp82p and Hsc82p) and 4 Hsp90s are 
found in human cells, including the cytoplasmic forms Hsp90α and Hsp90β, and single 
mitochondrial and ER forms (ZHAO and HOURY 2005).  
1.2.4.1 Structure of Hsp90 
Hsp90 contains an ~25 kDa N-terminal ATP binding domain, which is usually connected to the 
~35 kDa middle domain through a highly charged region and a C-terminal ~12 kDa dimerization 
domain (Figure 7).  The ATP binding domain contains an ATP binding pocket, which also binds 
the competitive inhibitor, geldanamycin (see details below) (PRODROMOU et al. 1997; STEBBINS 
et al. 1997).  The Hsp90 ATPase domain shows structural similarity to the GHKL family of 
ATPases, which include type II topoisomerases and the mutL mismatch repair enzyme (DUTTA 
and INOUYE 2000).  Hsp90, like other GHKL family members, contains a split ATPase domain, 
since optimal ATPase activity requires the adjacent middle domain.  The middle domain contains 
an acceptor site for the γ phosphate of ATP and may aid in the removal of the γ phosphate during 
ATP hydrolysis (MEYER et al. 2003).  The middle domain also contains a large hydrophobic 
patch that is responsible for client protein binding (MEYER et al. 2003).  The C-terminal 
dimerization domain is responsible for Hsp90 dimerization, which is required for client binding 
and optimal ATP hydrolysis (HARRIS et al. 2004; PRODROMOU et al. 2000). 
1.2.4.2 Mechanism of action 
In the nucleotide free state, the Hsp90 dimer exists in the “open” conformation in which the N-
terminal ATP binding domains are separated and client proteins interact freely in the region 
between the two dimers.  However, upon ATP binding, the N-terminal domains interact and  
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Figure 7:  The crystal structure of a dimer of Hsp90, bound to AMPPNP.   
The crystal structure on the left is colored to show the orientation of the domains of the two 
monomers.  The crystal structure on the right colors the monomers blue and orange to show the 
orientation of the monomers.  Figure adapted from PEARL et al. 2006.  
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form a “closed” state around the client protein.  Hsp90 is a relatively weak ATPase activity (0.44 
min-1 for yeast Hsp82p) (GRENERT et al. 1999; OBERMANN et al. 1998; PANARETOU et al. 1998) 
and many cochaperones including Hsp70 and Hsp40 are required for Hsp90 function.  After ATP 
hydrolysis, client proteins are released and Hsp90 is recycled for future folding cycles. 
The Hsp90 folding complex contains a large number of cochaperones, which differ 
somewhat depending on the substrate.  Hsp90 folding has been well characterized in vitro for 
progesterone receptor (PR) and this mechanism of action is probably very similar for the folding 
of other hormone receptors (DITTMAR and PRATT 1997; SMITH et al. 1992).  Hsp90 binds 
inactive hormone receptors and folds them into a hormone binding competent state until the 
hormone binds (Figure 8).  First, Hsp40 binds PR and delivers it to Hsp70 (HERNANDEZ et al. 
2002) where it stimulates Hsp70 ATPase activity to allow Hsp70 to clamp down on PR.  
Hsp70/Hsp40/PR then forms an intermediate complex with Hsp90 and Hsp Organizing Protein, 
HOP.  HOP simultaneously links Hsp70 to Hsp90 via two different TPR motifs (SCHEUFLER et 
al. 2000) and may transfer substrate from Hsp70 to Hsp90 (WEGELE et al. 2006).  HOP 
preferentially binds ADP bound Hsp70 (JOHNSON et al. 1998) and yeast HOP, Sti1p, stimulates 
Hsp70 ATP hydrolysis and inhibits Hsp90 ATPase activity (RICHTER et al. 2003; WEGELE et al. 
2003).  Interestingly, mammalian HOP does not directly regulate Hsp70 or Hsp90 ATPase 
activity, instead acting as a passive linker between the two (JOHNSON et al. 1998; WEGELE et al. 
2003).  The mature complex is formed when p23 replaces Hsp70/HOP and ATP binds to Hsp90.  
p23 only binds ATP bound Hsp90 and is thought to stabilize the complex (DITTMAR et al. 
1997)).  The final complex contains ATP bound Hsp90, Hsp40, p23 and PR.  The exact role of 
Hsp40 in the Hsp90 complex is currently unclear, but it appears to differ depending on the type 
of Hsp40 and the client protein (CINTRON and TOFT 2006; MURPHY et al. 2003). 
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Figure 8:  Hsp90 folding cycle for the Progesterone Receptor (PR).   
Ydj1p first binds and delivers PR to Hsp70 in the ATP bound state.  PR and Ydj1p stimulate 
Hsp70 ATP hydrolysis and substrate is transferred to Hsp70.  The intermediate complex is 
formed by the addition of Hsp90 (90) and HOP/Sti1p.  HOP serves as a linker between Hsp70 
and Hsp90.  The substrate is transferred to Hsp90 from Hsp70, which together with HOP leaves 
the complex.  ATP and p23/Sba1p bind to Hsp90 to stabilize the final “mature” complex.  Some 
components of this process are known to be dimers, but only the monomer is shown for 
simplicity.
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The Hsp90 cochaperone requirement is very different for the activation of protein kinases, such 
as Chk1 (ARLANDER et al. 2006).  Unlike hormone receptors, kinases only transiently associate 
with Hsp90 and represent a different class of Hsp90 client proteins.  Chk1 requires Hsp70, 
Hsp40, and Hsp90 for activation, suggesting that these chaperones are essential for all Hsp90 
client proteins (ARLANDER et al. 2006).  However, Chk1 also requires the kinase chaperone, 
Cdc37, and the kinase CK1 for complete activation.  Cdc37 has been shown to bind both Hsp90 
and client proteins and may be used to recruit Hsp90 to the client (HUNTER and POON 1997).  
CK1 phosphorylates Cdc37, which is required for Cdc37 function, and it is unclear if CK1 also 
phosphorylates Chk1.  While HOP and p23 are required for PR folding, they are not required for 
Chk1 activation.  In fact, addition of HOP enhances Chk1 activation but addition of p23 has no 
effect on activation, suggesting that these proteins are not required for all Hsp90 clients. 
1.3 THE FUNCTIONS OF SELECT CHAPERONES IN SACCHAROMYCES 
CEREVISIAE 
Many chaperones, including Ssa1p (Hsp70) and Hsp82 (Hsp90), are essential for the growth of 
the yeast Saccharomyces cerevisiae.  This section will describe a few examples of chaperone 
function in S. cerevisiae to illustrate how the chaperone mechanisms described earlier are 
utilized in the cell.  Also, examples of S. cerevisiae as a model system to study chaperone 
function are given. 
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1.3.1 Protein folding and refolding 
As mentioned previously, Hsp70s are required to fold newly synthesized peptides.  Hsp70s bind 
hydrophobic exposed residues in newly synthesized proteins and maintain their solubility by 
preventing unwanted hydrophobic interactions and aggregation.  Then, through successive 
ATPase cycles the proteins are bound and released from the Hsp70 substrate binding domain.  
The energy of ATP hydrolysis induces conformational changes that lead to proper folding of the 
substrate.  Hsp70s do not directly fold protein substrate; instead they prevent protein misfolding 
and maintain their solubility until they fold. 
Firefly luciferase has become a model substrate for chaperone-dependant folding in vitro.  
Specifically, once firefly luciferase is folded, it can act on the substrate luciferin and produce a 
fluorescent readout directly related to the amount of active luciferase.  This system has been 
adapted to probe the role of yeast chaperones during protein folding.  For example, cytosol 
containing Ssa1p is sufficient to refold denatured luciferase.  However, when cytosols 
immunodepleted for Ssa1p/Ssa2p are added to denatured luciferase, folding is impaired (BUSH 
and MEYER 1996).  Hsp40 cochaperones are also important for luciferase folding.  When using 
purified proteins, addition of Ssa1p to denatured luciferase has little effect on luciferase folding.  
However, addition of purified Ssa1p and Ydj1p stimulates luciferase refolding 20 fold (LU and 
CYR 1998a).  Interestingly, Sis1p, a second Ssa1p cochaperone, does not stimulate Ssa1p folding 
to the same extent as Ydj1p (LU and CYR 1998b).  This system has also been used to show that 
Hsp110 chaperones, like Sse1p, do not refold  luciferase, but can act as a “holdase” to retain the 
substrate in a folding competent state (GOECKELER et al. 2002). 
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1.3.2 Protein translocation across membranes 
Hsp70 and Hsp40 are essential for translocation into the Endoplasmic Reticulum (ER) and 
mitochondria.  In yeast, translocation can occur either co-translationally or post-translationally.  
When proteins are post-translationally translocated across the ER membrane, cytoplasmic 
chaperones such as Ssa1p (Hsp70) and Ydj1p (Hsp40) are required to maintain the solubility of 
proteins before translocation.  In fact, reduction of Ssa1p in the SSA1, SSA2, SSA4 triple 
knockout strain or shifting the ydj1-151 temperature sensitive strain to a nonpermissive 
temperature leads to an accumulation of ER and mitochondrial pre-proteins in the cytosol 
(CAPLAN et al. 1992; DESHAIES et al. 1988). In addition, both co- and post- translational 
translocation require ER lumen chaperones such a Kar2p (Hsp70) and Sec63p (Hsp40) 
(BRODSKY et al. 1995).  Accumulation of preproteins has also been seen in yeast containing 
thermosensitive alleles in kar2 and sec63 (ROTHBLATT et al. 1989; VOGEL et al. 1990).  In fact, 
Sec63p is a dedicated translocation-specific J-protein.  Other ER luminal J-proteins, Scj1p and 
Jem1p, do not appear to play a role in translocation as yeast containing mutations in these genes 
do not have translocation defects (NISHIKAWA et al. 2001). 
1.3.3 Activation of receptors/kinases 
Hsp90 is an essential protein in yeast and is responsible for folding numerous clients.  In fact, the 
Protein Kinase C (PKC) signaling pathway appears to be regulated by Hsp90.  A yeast two 
hybrid screen was performed to identify Hsp90 clients using the yeast Hsp90 isoform, Hsp82, 
which contained the E33A mutation as bait.  This mutation inhibits ATPase activity and prevents 
client protein release.  This screen identified many known Hsp90 cochaperones, including 
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Ydj1p, Sba1p (HOP), and Sti1p (HIP) (MILLSON et al. 2005).  The authors also identified Mpk1, 
a downstream kinase in the PKC pathway, as a novel Hsp90 client protein.  Interestingly, 
interaction of Mpk1p and Hsp82p increased after heat shock and mutation of Hsp82p led to 
decreased Mpk1p transcription (MILLSON et al. 2005).  These results suggest that Hsp90 is 
required for Mpk1p activation and links transcription of PKC pathway targets to the heat shock 
response.  
 S. cerevisiae can also be used as a model system to analyze hormone receptor folding in 
vivo.  The folding requirements of androgen receptor (AR) (CAPLAN et al. 1995), estrogen 
receptor (ER) (PICARD et al. 1990), and glucocortocoid receptor (GR) (PICARD et al. 1990) have 
been determined using yeast genetics.  For example, the Yamamoto lab showed that Hsp82p was 
required to hold GR and ER in a folding competent state in vivo (PICARD et al. 1990).  Ydj1p and 
Sse1p are also required for maximal receptor activation in vivo (CAPLAN et al. 1995; GOECKELER 
et al. 2002). 
1.3.4 Multiprotein complex rearrangement 
One of the best characterized roles of Hsp70/Hsp40 in multiprotein complex rearrangement is 
the removal of clathrin from coated vesicles (CCV).  Clathrin is a vesicle coat protein used 
during receptor mediated endocytosis and during Golgi-sorting events (BRODSKY et al. 2001).  
Vesicle uncoating utilizes Hsp70 and a specialized J-protein, auxilin.  Yeast auxilin, Swa2p, has 
an N-terminal clathrin binding domain, a TPR domain for Hsp70 interaction and a C-terminal J 
domain (GALL et al. 2000; PISHVAEE et al. 2000).  Swa2p binds clathrin through the N-terminal 
region and recruits Ssa1p (Hsp70) via the TPR and J domains (XIAO et al. 2006).  Indeed, the J 
domain of Swa2p stimulates Ssa1p ATPase activity by 20 fold (GALL et al. 2000).  In vitro 
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studies with mammalian auxilin show that the J domain stimulates Hsp70, which then binds 
tightly to clathrin and leads to distortion of the clathrin structure to induce vesicle uncoating 
(JIANG et al. 2000; UNGEWICKELL et al. 1995).     
1.4 CHAPERONES AND DISEASE 
As mentioned previously, chaperones play a role in a plethora of human diseases.  This section 
will focus on the roles of Hsp70/Hsp40 in a few select diseases. 
1.4.1 Aggregation diseases 
A large number of diseases are caused by the aggregation of proteins such as β Amyloid (Aβ) in 
Alzheimer’s disease, α synuclein in Parkinson’s disease, and prion protein (PrPSc) in Creutzfeldt-
Jakob’s disease (SELKOE 2003).  Alzheimer’s disease is characterized by the formation of 8-10 
nm amyloid fibrils of Aβ protein with a characteristic β sheet structure (SELKOE 2004).  For 
many years, it was debated whether the fibrils were responsible for, or a consequence of, 
Alzheimer’s disease.  It is currently hypothesized that the pre-fibril intermediates are the toxic 
stage of aggregate formation and that the fibrils are a protective way of sequestering the 
aggregation prone protein. 
The currently proposed mechanism for fibril formation is that Aβ is an inherently 
aggregation prone protein (BOOTH et al. 1997).  Properly folded Aβ can transition into a partially 
folded molten globule with exposed hydrophobic domains.  These domains can interact to form 
organized oligomers, which then act as seeds to convert other native proteins into the 
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aggregation prone state.  Many labs have shown that chaperones, including Hsp70 and Hsp40, 
are involved in preventing formation of the toxic intermediates, by binding hydrophobic patches 
in the molten globules and preventing their aggregation (EVANS et al. 2006; MUCHOWSKI et al. 
2000; RAMAN et al. 2005).  Thus, increased Hsp70 levels or activity may tip the equilibrium of 
Aβ folding/ aggregation towards folding.  A recent study by the Gestwicki lab showed that 
Hsp70/Hsp40 and Hsp90 inhibit Aβ aggregation in vitro (EVANS et al. 2006).  In fact, an Hsp70 
agonist also inhibited Aβ aggregation, further suggesting that chaperone modulation could be 
used to treat amyloid diseases. 
1.4.2 Cancer 
One defining characteristic of cancer cells is a misregulation of many essential proteins, 
including alterations of Hsp70 and Hsp90 levels.  Chaperones, including Hsp70 and Hsp90, are 
upregulated in various cancers including breast, lung, and cervical cancer (BONAY et al. 1994; 
CIOCCA et al. 1993; KIM et al. 1998a; MYUNG et al. 2004; RALHAN and KAUR 1995; VOLM et al. 
1995; YANO et al. 1996).  However, it is unclear if changes in expression lead to the cancerous 
phenotype or if these changes are in response to the cancerous phenotype.  Some studies have 
suggested that over-expression of chaperones is sufficient for transformation.  For example, 
Hsp70 over-expression in some primary cell lines is sufficient for transformation, and transgenic 
mice constitutively over-expressing Hsp70 develop T-cell lymphomas (SEO et al. 1996; 
VOLLOCH and SHERMAN 1999).  Other studies suggest that the reduction of Hsp70 levels by 
antisense RNA is sufficient to induce apoptosis (NYLANDSTED et al. 2000).  This phenomena 
appears to be breast cancer cell-specific because cell lines derived from breast tissue and lung 
fibroblasts do not undergo apoptosis when Hsp70 levels are decreased (NYLANDSTED et al. 
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2000).   Also, human hsc70 with missense mutations in the ATPase domain may be associated 
with sporadic breast cancer development, but the importance of this finding is unknown 
(BAKKENIST et al. 1999).   
Other studies have indicated that chaperones play a protective role as increased 
chaperone levels may help off-set stresses such as hypoxia and chemotherapeutic treatment.  In 
fact, Hsp70 over-expression in breast cancer tissues is correlated with increased resistance to 
chemotherapy and consequently poor overall prognosis (BARNES et al. 2001; CIOCCA et al. 1993; 
MELENDEZ et al. 2006). The action of Hsp70 may also be direct since Hsp70 is known to inhibit 
apoptosis through several mechanisms.  For example, Hsp70 inactivates the activity of pro-
apoptotic signaling kinases such as c-Jun N-terminal kinase (JNK1), prevents mitochondrial 
permeabilization and cytochrome c release, and inhibits the maturation of procaspases including 
procaspase-3 and procaspase-7 (GABAI et al. 2002; KOMAROVA et al. 2004; RASHMI et al. 2004).  
Prevention of apoptosis is especially problematic since many chemotherapeutic approaches are 
aimed at initiating apoptosis in cancer cells.  Together, these facts emphasize the importance of 
identifying chaperone modulators as anti-cancer drugs. 
1.4.3 Small molecule modulators of molecular chaperones 
Despite the numerous roles of chaperones in disease, currently very few drugs are available that 
target molecular chaperones.   Geldanamycin (GA) and GA derivatives bind Hsp90 with a much 
higher affinity than ADP or ATP and act as a competitive inhibitor of ATP binding (GRENERT et 
al. 1997; PRODROMOU et al. 1997; STEBBINS et al. 1997).  GA is proposed to mimic the ADP 
bound state of Hsp90, which favors client ubiquitination and subsequent degradation (ISAACS et 
al. 2003; NECKERS 2002).  For several decades, laboratory use of GA has altered a range of 
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tumorigenesis phenotypes, including cell growth inhibition and malignant to benign phenotypic 
conversion in such cells as breast cancer cells, prostate carcinoma cells, and Rous-sarcoma-
infected rat kidney cells (OCHEL et al. 2001).  While the precise mechanism of GA action is 
often unknown, its various effects are perhaps unsurprising considering the multitude of Hsp90 
activities in the cell.  For example, treatment of breast cancer, prostate cancer, and leukemia cell 
lines reduced the levels of mutant p53 by preventing Hsp90 from holding it in a stable complex 
(BLAGOSKLONNY et al. 1996; BLAGOSKLONNY et al. 1995).  The Hsp90 clients p210Bcr-Abl, HER-
2, and HIF-1α are implicated in several types of cancer development. GA treatment of these 
cancers destabilizes the proteins and leads to their degradation, which in turn triggers apoptosis 
(ISAACS et al. 2003).  However, inhibition of Hsp90 is often insufficient to treat cancer cells as 
the cells often compensate by over-expressing Hsp70 (BRODSKY and CHIOSIS 2006).   
Until recently, 15-deoxysperagulin (DSG) was one of the few Hsp70 modulators 
available.  DSG has been used as an immunosuppressive to inhibit kidney rejection after 
transplantation (TANABE et al. 2000).  In fact, ~70% of kidney transplant patients who were 
treated with DSG showed an excellent or good response.  However, recent studies show that 
other immunosuppressive regimens have a lower rate of kidney rejection (ISHIDA et al. 2007).  
DSG is probably an immunosuppressive because it interferes with the action of macrophages, 
cytolytic T cells, and B cells (HUGHES and GRUBER 1996).  The molecular target of DSG was 
identified as Hsp70 using a DSG-Sepharose column.  When cell lysates were applied to the 
column, only Hsp70 was bound to DSG in high quantities (NADLER et al. 1992). DSG interacts 
with Hsp70 with a relatively low affinity of KD = 4 µM, but also interacts with Hsp90 at a 
similar affinity KD = 5 µM (NADEAU et al. 1994).   DSG stimulates yeast and bovine cytosolic 
Hsp70 steady state ATPase activity between 38 and 47%, but has no affect on the yeast ER 
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Hsp70, Kar2p (BRODSKY 1999).  The low specificity and affinity prompted the Brodsky lab to 
identify a structural analog of DSG, NSC 630668-R/1 (R/1), which inhibits yeast Hsp70 ATP 
hydrolysis and J domain stimulation of Hsp70 in steady state ATPase assays (FEWELL et al. 
2001).  Interestingly, R/1 actually stimulates Hsp70 in single turnover assays.  However R/1 has 
poor solubility and low affinity for Hsp70, suggesting that more potent Hsp70 modulators need 
to be created. 
1.5 VIRUSES AND CHAPERONES 
It is quite common for chaperone expression to be upregulated during the course of viral 
infection, as has been documented for Simian Virus 40 (SV40), Human Immunodeficiency Virus 
(HIV), Herpes Simplex Virus (HPV), and other viruses (SULLIVAN and PIPAS 2001).  Once 
again, since chaperones are upregulated in response to cellular stress, it is often difficult to 
determine if this upregulation is in response to the stress upon viral infection or is required for 
the viral infection.   Indeed, chaperones are involved in many aspects of the viral infection, 
including capsid uncoating, DNA replication, and virion assembly (SULLIVAN and PIPAS 2002).  
Many viruses utilize host cell chaperones for these processes, as has been discussed for λ phage, 
however some viruses code for their own chaperones.  For example, beet yellows closterovirus 
(BYV) codes for an Hsp70-like protein with N-terminal ATPase activity (AGRANOVSKY et al. 
1997), which is required for assembly of BYV virion tails (AGRANOVSKY et al. 1991; 
ALZHANOVA et al. 2007).  Other viruses encode J-proteins which are used to corrupt host Hsp70 
function.  Perhaps the most studied instance of this can be found in the polyomavirus family.  
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These viruses code for a J domain containing protein which is essential for viral DNA replication 
and virion assembly. 
1.5.1 General characteristics of polyomaviruses 
Polyomaviruses infect a large number of organisms including humans, monkeys, rodents and 
birds.  To date, 18 polyomaviruses have been discovered (ALLANDER et al. 2007; GAYNOR et al. 
2007; JOHNE et al. 2005; JOHNE et al. 2006; PIPAS 1992).  Polyomaviruses are non-enveloped 
DNA viruses with doubled stranded DNA genomes which code for only a few proteins (AHUJA 
et al. 2005).  During polyomavirus infection, the virus enters the cells, uncoats, and releases its 
DNA.  Polyomavirus host cells tend to be terminally differentiated, quiescent cells, which do not 
express the genes required for viral replication such as DNA polymerase.  The early region of the 
polyomavirus genome is transcribed immediately after infection and includes the differentially 
spliced tumor antigens (TAgs) (Figure 9).  In order to replicate viral DNA, TAg interferes with 
cell cycle regulators such as p53 and Rb to initiate the cell cycle.  The late region of the viral 
genome includes the viral coat proteins, VP1, VP2, and VP3 and is transcribed late in infection 
after the viral DNA has been replicated.   Finally, the DNA is assembled into the capsid, host 
cells are lysed, and the viral progeny infect surrounding cells. 
Four human polyomaviruses have been identified.   BK virus (BKV) and JC virus (JCV) 
were named for the original patients from whom the viruses were isolated (GARDNER et al. 1971; 
PADGETT et al. 1971).  The newly identified KI polyomavirus (KIPyV) and WU virus (WUV) 
were named for the Karolinska Institutet and Washington University School of Medicine, 
respectively, where the viruses were identified (ALLANDER et al. 2007; GAYNOR et al. 2007).  In 
addition, SV40 was a contaminant of the original polio vaccine and has been studied extensively  
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Figure 9:  Genome map for the SV40 polyomavirus.   
The genome is separated into early gene products, Large TAg (LT), small tAg (sT), and 17kD 
TAg (17kT) and late gene products, VP1, VP2, and VP3.  Figure from AHUJA et al. 2005. 
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since its known introduction into humans (HILLEMAN 1998).  BKV and JCV have been 
definitively linked to kidney nephropathy and progressive multifocal leukoencephalopathy 
(PML), respectively and BKV, JCV, and SV40 have controversial links to human cancer (EASH 
et al. 2006; WHITE and KHALILI 2004). 
1.5.1.1 BK Virus (BKV) 
BKV was initially discovered in the urine of a renal transplant patient (GARDNER et al. 1971), 
but most humans have a latent infection.  Nearly half of all children under the age of three 
express BKV antibodies, and by age ten the number approaches 100% (BARBANTI-BRODANO et 
al. 1998).  These infections are usually subclinical, or cause upper respiratory or urinary tract 
infections.  The virus sets up a persistent infection in the kidneys, but seldom produces clinical 
symptoms in healthy individuals. However, in immunocompromised individuals the virus can 
reactivate and cause kidney nephropathy (COMOLI et al. 2006).  This is especially well-
documented in kidney transplant patients taking immunosuppressive drugs, where BKV 
associated nephropathy (BKVAN) is a major cause of kidney failure and subsequent rejection.  
BKV infection has also been connected to cellular transformation in cell culture, but the 
relevance of these data is debated (FIORITI et al. 2005).  
1.5.1.2 JC Virus (JCV) 
JCV is also an endemic virus with ~80% of adults possessing JCV antibodies (BARBANTI-
BRODANO et al. 1998) though JCV infections generally occur slightly later in life than BKV 
infections.  JCV infections are also usually subclinical, though occasionally JCV infections have 
been correlated with chronic meningoencephalitis.  After the initial infection, JCV causes a latent 
infection of the kidney and central nervous system (EASH et al. 2006).  In immunosuppressed 
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patients, JCV can reactive and cause progressive multifocal leukoencephalopathy (PML).  This 
disease is caused by the viral-induced destruction of myelin-producing glial cells, which leads to 
demyelination of the central nervous system and a variety of brain disorders and death (KHALILI 
et al. 2003).  Almost all PML cases are found in HIV positive individuals and 5% of all HIV 
positive patients have PML (BERGER 2003).  While JCV appears to transform cells in culture and 
cause tumors in animal models at a much higher rate than BKV infection, its role in human 
cancers is unclear (EASH et al. 2006). 
1.5.1.3 KI Virus (KIPyV) and WU virus (WUV) 
Little is known about the newly identified KI and WU polyomaviruses.  KIPyV was discovered 
in donated nasopharyngeal samples that were screened for novel human viruses by random PCR 
amplification (ALLANDER et al. 2007).  Further studies uncovered KIPyV in additional 
nasopharyngeal samples and feces, but not in urine or blood, suggesting it may not infect the 
kidney like other human polyomaviruses.  The KIPyV genome encodes the same proteins found 
in the human polyomaviruses, including large and small TAg and the viral coat proteins.  
Currently, this virus has not been linked to any human diseases.   
WUV was PCR amplified from the nasopharyngeal aspirate from a pneumonia patient 
and was subsequently found in other respiratory, but not urine, samples (GAYNOR et al. 2007).  
Sequence analysis indicated that WUV is most similar to KIPyV (64-71% identity between 
putative TAg and viral coat coding regions).  Also, preliminary studies suggest WUV is most 
prevalent in children under three or in immunocompromised adults, though its role in human 
disease is unclear. 
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1.5.1.4 Simian Virus 40 (SV40) 
The natural host of SV40 is the kidney of the Rhesus macaque monkey.   However, the original 
polio virus vaccine was produced on monkey kidney cells that contained SV40 as a contaminant 
and as a result millions of Americans were exposed to the virus.  Shortly after its discovery as a 
contaminant of the vaccine, SV40 was found to induce tumor formation in newborn baby 
hamsters that are immunocompromised and is actually among the most oncogenic 
polyomaviruses in mouse model systems.  However, to date, no definitive link between human 
cancers and SV40 has been established (POULIN and DECAPRIO 2006b).  Because SV40 TAg is 
sufficient to cause tumorigenesis in some cell lines (CHEN et al. 1992; IBARAKI et al. 1998), 
SV40 has become a model system for human cancer research.  The study of SV40 TAg has led 
to the elucidation of basic aspects of cell biology, including identification of the tumor 
suppressor p53, RNA splicing, and nuclear localization signals (CARBONE 2001).   
SV40 is also a model system for the study of BKV and JCV.  These viruses grow poorly 
in the laboratory, which makes them difficult to study or screen for potential treatments 
(FARASATI et al. 2005; KNOWLES and SASNAUSKAS 2003).  Luckily, since SV40 has been 
studied in the laboratory for years and many in vivo and in vitro assays have been developed to 
characterize its pathogenesis, it can serve as a model system for BKV and JCV infections. 
1.5.2 Functional domains of SV40 Large Tumor Antigen (TAg) 
Three alternately spliced TAg proteins are transcribed immediately after SV40 infection, large 
TAg, small tag, and tiny tag.  Large TAg is the 708 amino acid protein that contains many 
independently folding domains that allow this single protein to initiate the cell cycle and viral 
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DNA replication upon infection (Figure 10).  Unless otherwise stated, all references to TAg in 
this document refer to SV40 large TAg.  A description of the various domains of TAg follows. 
1.5.2.1 The TAg J domain 
The N-terminal 102 amino acids of TAg contain a J domain, which has been shown to interact 
with Hsp70 (SAWAI and BUTEL 1989; SULLIVAN et al. 2001).  This domain is also essential for 
DNA replication, virion assembly, and tumorigenesis (PEDEN and PIPAS 1992; PIPAS et al. 1983; 
SPENCE and PIPAS 1994b; SRINIVASAN et al. 1989) and mutations in the HPD motif disrupt these 
abilities (SRINIVASAN et al. 1997).  Amino acids 7-117 of TAg have been cocrystallized with the 
pocket region (amino acids 380-772) of the retinoblastoma (Rb) tumor suppressor (KIM et al. 
2001).  The pocket domain is conserved between Rb family members and is an essential region 
for tumor suppressor activity.  This structure shows that the J domain extends between residues 7 
and 102, which is followed by a flexible linker region that binds Rb (see below).  Several 
features unique to the TAg J domain were discovered.  First, α helix I of the J domain is 
extended and is about twice as long as seen in other J domains.  Second, the J domain contains 
an extended loop between helix III and IV that faces the Rb binding pocket (KIM et al. 2001).  It 
is unclear why TAg has this loop in the J domain, but it may in part be responsible for binding to 
other proteins. 
Consistent with this hypothesis, prior coimmunoprecipitation studies showed that large 
proteins of 185 kDa and 193 kDa interact with the TAg N terminus (KOHRMAN and IMPERIALE 
1992; TSAI et al. 2000).  The DeCaprio lab showed that p185 and p193 were identical and had 
homology to the E3 ubiquitin ligase Cul7 from the cullin family of proteins (ALI et al. 2004) 
which binds TAg through residues 69-83 in the extended loop domain (KASPER et al. 2005).   
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Figure 10:  Structural representation of the TAg monomer.   
The J domain (DnaJ), origin binding domain (obd), zinc binding domain (Zn-D), and ATPase 
domain (AAA+) are combined from previous NMR and crystal structures.  Dotted lines represent 
linker regions between the domains with unknown structure.  No structural information is 
available for the Host Range Domain, which is represented in yellow.  Figure from GAI et al. 
2004. 
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Cullins are scaffolds for the SCF multi-component complex that functions as an E3 ubiquitin 
ligase with Skp1 and F-box proteins.  Like other cullins, Cul7 binds the ring domain containing 
protein Roc1, the F-box protein Fbx29, and Skp1 to form an SCF-like complex (DIAS et al. 
2002).  TAg’s interaction with Cul7 is important for transformation, and is independent of other 
known interactions in the TAg N terminus (ALI et al. 2004; KASPER et al. 2005; KOHRMAN and 
IMPERIALE 1992). 
Like other J domains, the TAg J domain has specificity in its interactions with Hsp70 
chaperones as shown by in vivo domain swap experiments and biochemical analysis.  The TAg J 
domain can functionally replace the J domains of E. coli DnaJ and S. cerevisiae Ydj1p (FEWELL 
et al. 2002; KELLEY and GEORGOPOULOS 1997).  In addition, the TAg J domain stimulates the 
ATPase activity of mammalian and yeast Hsp70 in vitro (SRINIVASAN et al. 1997).   Also, if the 
TAg J domain is replaced by the J domain of JCV TAg, which is 75% identical (PIPAS 1992) or 
the J domains of human J-proteins DNAJ2 and HSJ1, these chimeric proteins can substitute for 
TAg in in vivo assays (CAMPBELL et al. 1997; SULLIVAN et al. 2000b)  However, not all J 
domains can substitute for the TAg J domain as the J domain of DnaJ and Ydj1p are unable to 
support SV40 viral replication or cellular transformation (SULLIVAN et al. 2000b).     
1.5.2.2 The N-terminal flexible linker domain 
The N-terminal linker of TAg consists of residues 103-134.  Despite its small size, several 
protein interaction sites and the nuclear localization sequence are found in this region.  One of 
the best characterized TAg targets is the protein associated with Retinoblastoma (Rb), and Rb 
family members, p130 and p107.  TAg binds Rb via a consensus Rb binding motif, LxCxE, at 
residues 103-107 (DECAPRIO et al. 1988).   Rb binds to the transcription factor E2F, and acts as a 
repressor, preventing cell cycle progression.  TAg binds to Rb and releases E2F from Rb to allow 
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E2F dependent transcription of S phase genes.  It was initially proposed that TAg sequestered Rb 
and prevented it from inhibiting E2F activity.  However, since both the LxCxE motif and a 
functional J domain are required to inhibit Rb, the chaperone model for E2F release was 
proposed (Figure 11) (BRODSKY and PIPAS 1998).  In this model, TAg forms a complex with 
Rb/E2F and Hsp70 through the LxCxE motif and the J domain.  The J domain stimulates Hsp70 
ATP hydrolysis, and the resulting energy is used to release E2F from Rb.  Much experimental 
evidence supports this theory.  First, TAg does not compete for E2F binding with Rb since the 
LxCxE and E2F binding sites are unique (KIM et al. 2001).  Second, TAg, Rb, and E2F can form 
a stable complex (SULLIVAN et al. 2000a).  Third, addition of Hsp70 and an ATP regenerating 
system releases E2F from Rb in an ATP dependent mechanism (SULLIVAN et al. 2000a).  Fourth, 
a D44N in the TAg J domain or mutation of the LxCxE motif inhibits E2F release from Rb 
(SULLIVAN et al. 2000a). 
Another TAg target is Bub1, a protein kinase involved in chromatid segregation during 
mitosis and that functions as a checkpoint for mitosis.  Bub1 was discovered via yeast two hybrid 
and co-immunoprecipitation experiments to interact with TAg (COTSIKI et al. 2004).  Bub1 
interacts with TAg residues 89-97, probably through a conserved WEXWW sequence, found in 
almost all large TAgs.  The Bub1 interaction with TAg is potentially important for 
transformation, since TAg mutants that do not bind to Bub1 are defective for inhibiting cellular 
transformation (COTSIKI et al. 2004).  This interaction may allow TAg to bypass a spindle 
checkpoint and proceed into mitosis. 
An unknown phosphatase is also predicted to bind to the N terminus of TAg.  During G0 
and G1 phase of the cell cycle, the Rb family member p130 exists in a hypophosphorylated form 
and is hyperphosphorylated during the G1 to S transition.  p130 is also degraded during late S 
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Figure 11:  The chaperone model for E2F release from Rb.   
In a quiescent cell, E2F dependent transcription is repressed by the tumor suppressor, Rb.  Rb, 
E2F, Hsp70 (70), and TAg form a complex and the TAg J domain stimulates the ATPase activity 
of Hsp70.  This energy is used to release Rb from E2F and allow synthesis of E2F-dependent 
genes. 
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and G2 phase in an SCF dependent manner (TEDESCO et al. 2002).   Expression of the TAg N-
terminal region with a functional J domain and LxCxE motif is sufficient to maintain p130 in a 
hypophosphorylated state (STUBDAL et al. 1997; STUBDAL et al. 1996).  In vitro experiments 
from the DeCaprio lab showed that this was due to the recruitment of a unknown phosphatase 
(LIN and DECAPRIO 2003).   
Finally, the TAg nuclear localization signal (NLS) is found from amino acids 126-132 
and has an extremely basic sequence, KKKRKV (KALDERON et al. 1984).  The TAg NLS was 
the first NLS identified and is considered a canonical NLS.  The TAg NLS binds importin α, 
which is responsible for transporting proteins with a canonical NLS into the nucleus (ADAM and 
ADAM 1994).  The NLS sequence is the minimal TAg sequence that can be inserted onto a 
cytoplasmic protein to redirect it to the nucleus and has become a model system to study nuclear 
import (LANFORD et al. 1986).   
1.5.2.3  Origin binding domain 
The origin binding domain is found from amino acids 135-249 and is required for TAg to bind to 
the SV40 DNA origin of replication.  The SV40 genome contains a 64 basepair origin of 
replication consisting of a central palindrome of four GAGGC basepairs flanked by an AT rich 
region and imperfect inverted repeats called the early palindrome.  Two TAg monomers bind to 
pentanucleotide repeats 1 and 3 and nucleate binding of double hexamers (JOO et al. 1998; JOO et 
al. 1997).  Assembly of the first hexamer aids in the assembly of a second hexamer to create a 
dodecamer through a cooperative mechanism (PARSONS et al. 1991).  The two halves of the 
dodecamer are arranged in a “head to head” manner. 
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1.5.2.4 Zinc binding domain 
The zinc binding domain is found from amino acids 250-370.  This was initially identified as a 
zinc finger domain since it contained the conserved zinc finger motif (Cx2Cx15Hx3H) in residues 
C302, C305, H317, and H320.  Mutations in these residues, and H313, of the zinc binding 
domain abolish viral replication, whereas mutations in all other residues in the sequence have no 
phenotype (LOEBER et al. 1989).  Recent crystallographic studies have suggested that this 
domain does not have the typical zinc finger structure, but instead appears more globular (LI et 
al. 2003a).  In addition, the structure confirms that C302, C305, H313, and H317 coordinate 
zinc.  The zinc binding domain is required for hexamerization, since an N-terminal truncation 
that removed all amino acids through C302 abolished hexamerization but an N-terminal 
truncation mutant through amino acid 256 that contained an intact zinc binding motif did not (LI 
et al. 2003a).  The zinc binding domain, due to its role in hexamerization, is also part of the 
minimal helicase domain. 
1.5.2.5 ATPase and p53 binding domain 
The ATPase/p53 binding domain is located between residues 371-624 and is essential for both 
viral replication and transformation.  The ATPase domain is a canonical AAA+ ATPase domain, 
which binds and hydrolyzes ATP (BRADLEY et al. 1987; ERZBERGER and BERGER 2006).  ATP 
binding, but not hydrolysis, is required for hexamerization (MASTRANGELO et al. 1989).  
Structural studies indicate that the TAg hexamer exists in an “all or none binding mode” in 
which all subunits exist in the same state: ATP bound, ADP bound, or nucleotide free (GAI et al. 
2004).  This suggests a concerted mechanism for ATP hydrolysis and ADP release.  In contrast 
to hexamerization, ATP hydrolysis is required for TAg helicase activity (MASTRANGELO et al. 
1989). 
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The ATPase domain overlaps with the p53 binding domain.  Early mapping studies 
suggested that the interaction of p53 with TAg was bipartite, and requires residues 350-450 and 
550-650 (KIERSTEAD and TEVETHIA 1993).  However, recent structural studies suggest this 
assignment is artificial, and the residues required for p53 binding cluster together (LI et al. 
2003a).  Also, the p53 residues important for TAg interaction cluster on the same side of the 
structure as the p53 DNA binding domain.  This suggests a simple model for how TAg prevents 
p53 from binding to promoters: TAg binds and prevents p53 from interacting with the promoters 
directly (LI et al. 2003a).  However, it is unlikely to be this simple because several studies 
suggest that the J domain is also involved in p53 disruption, though the mechanism is not well 
understood (QUARTIN et al. 1994; RUSHTON et al. 1997). 
1.5.2.6  Linker domain and host range domain 
Following the ATPase domain is a C-terminal linker domain (625-669) found in only a few 
polyomavirus TAgs.  This domain has no known biological role (PIPAS 1992).  At the extreme C-
terminus is the host range domain (670-708), which is required for SV40 growth in some cell 
lines.  Wild type SV40 can replicate in BSC40 and CV-1 monkey kidney cell lines.  However, 
mutations in the host range domain prevent viral replication in CV-1 cells but have no effect on 
SV40 growth in BSC40 cells (PIPAS 1985).  In addition, viruses with host range mutations are 
cold sensitive and cannot grow in either of the cell lines at 32°C (PIPAS 1985).  It is believed that 
host range mutations prevent proper virion assembly (SPENCE and PIPAS 1994a).  Recent studies 
have defined an acetylation site in the host range domain at K697 which is not required for host 
range function (POULIN and DECAPRIO 2006a). 
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1.5.3 SV40 replication 
SV40 DNA replication is a complicated task that requires most TAg domains.  TAg associates 
with the SV40 origin of replication via the origin binding domain.  ATP binding to the ATPase 
domain aids in high affinity binding to the ori and allows hexamerization and dodecamer 
assembly at the origin (MASTRANGELO et al. 1989).  The central cavity of TAg hexamers is 
positively charged, possibly aiding in the interaction with DNA (LI et al. 2003a).  The TAg 
hexamer partially melts the DNA and associates with proteins required for replication including 
topoisomerase, replication protein A (RPA), and DNA polymerase α primase (pol-prim).  After 
replication is initiated, a “polymerase switch” occurs and pol-prim is replaced by RF-C, PCNA, 
and DNA polymerase δ (YUZHAKOV et al. 1999).  The TAg dodecamer then acts as a helicase, 
hydrolyzing ATP, and unwinding the DNA.  To explain how TAg acts as a helicase, the Chen 
lab has proposed an “iris hypothesis” in which ATP hydrolysis is coupled to DNA melting (LI et 
al. 2003a).  Indeed, structural studies show several distinct structures of TAg that have different 
central channel widths and a slight twist of the zinc binding domain relative to the ATPase 
domain.  Conversion between these structures would expand and contract the central pore and 
twist the zinc binding domain relative the ATPase domain and TAg uses this twisting motion to 
melt the DNA. 
The TAg J domain is also essential for viral DNA replication in vivo, but its role is 
currently unclear.  Most mutations in the J domain lead to reduced DNA synthesis by the virus 
and little virus production (COLLINS and PIPAS 1995; PEDEN and PIPAS 1992).  However, in an in 
vitro replication assay, J domain mutants still replicate DNA (COLLINS and PIPAS 1995; 
WEISSHART et al. 1996).  Hsp70 is not required for a replication assay with minimal, purified, 
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components and addition of Hsp70 does not improve reaction efficiency (SULLIVAN and PIPAS 
2002).  Further study is needed to understand this discrepancy. 
1.5.4 Screen for novel TAg J domain mutants 
In order to better understand the role of the TAg J domain in viral replication and transformation, 
Sheara Fewell in the Brodsky lab screened for novel TAg J domain mutants using a TAg J 
domain-Ydj1p chimeric protein (T-Ydj1p) (FEWELL et al. 2002).  Random PCR mutagenesis of 
the TAg J domain and yeast recombination into a YDJ1 C-terminal gapped vector was used to 
identify 14 temperature sensitive point mutations in helix II and III of the TAg J domain.  Many 
of the residues were in conserved residues that were known to contact Hsp70 through NMR 
perturbation and other mutational studies (Figure 12).   
To better understand the molecular impact of the mutations, two solvent exposed 
mutations in the J domain were chosen for further study.  H42R is in the HPD motif and is 
predicted to interact with Hsp70.  K53R is on helix III and is not perturbed by Hsp70 binding.  A 
buried mutation in helix II predicted to disrupt the structure was also chosen, but the mutant was 
unstable.  When the H42R and K53R mutation were introduced into the SV40 genome, the virus 
was unable to replicate in BSC40 cells or transform a rodent cell line.  In addition, purified TAg 
containing either the H42R or K53R mutation was defective for stimulating Hsp70 ATP 
hydrolysis or dissociating Rb/E2F complexes.  Together, this analysis showed that chaperone 
function of TAg is directly related to virus function. Since K53R is on helix III of the J domain, 
which is not predicted to interact with Hsp70 but is essential for J domain activity, it could 
potentially interact with an unknown protein that affects TAg chaperone activity.  It is 
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Figure 12:  A yeast screen uncovers novel TAg J domain mutations.   
The mutants identified in the yeast screen (FEWELL et al. 2002) were mapped onto the structure 
of DnaJ.  The N-terminus is represented in red and the HPD is represented in purple.  The 
residues shown in yellow and green are perturbed by Hsp70 binding by NMR studies (GREENE 
et al. 1998), and a subset of these residues were mutated in the screen (green).  The blue residues 
were additional residues that were mutated in the screen.  The DnaJ residues Y25, H33, and K48 
correlate with Y34, H42, and K53 in the TAg sequence.  The DnaJ ribbon diagram was adapted 
from CHEETHAM and CAPLAN 1998. 
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 hypothesized that other proteins interact with the TAg J domain and aid in the release of E2F 
from Rb.  In vitro release of Rb from E2F by TAg is greatly enhanced by cell lysate, suggesting 
that a component of the lysate aids in this reaction.  Candidates for this component include 
cochaperones that stimulate the Hsp70 ATPase cycle, but further study is needed to discover 
which proteins are involved. 
1.6 DISSERTATION OVERVIEW 
Despite the fact that SV40 TAg has been studied for over 40 years many questions remain about 
how it replicates and transforms cells.  One particularly important region required for both of 
these functions is the N-terminal J domain.  Some aspects of the role of the TAg J domain in 
transformation have been well defined, such as the release of Rb from E2F.  However, even this 
story is incomplete as in vitro reconstituted Rb/E2F release assays require cell lysate.  In 
addition, the role of the J domain in other processes, such as viral DNA replication and virion 
assembly, is unclear.  This dissertation sought to answer questions that still surround the roles of 
the TAg J domain in replication and transformation.  In Chapter 2.0, I present a yeast multi-copy 
screen that sought to identify novel TAg J domain interacting proteins, such as the unidentified 
proteins in the cell lysate that aid in E2F release.  Although novel TAg J domain interacting 
proteins were not identified from this screen, a connection between yeast chaperones and cell 
wall assembly was revealed.  In Chapter 3.0, I discuss the identification of several classes of 
small molecule chaperone modulators that inhibit TAg J domain stimulation of Hsp70.  Some of 
these compounds inhibited breast cancer cell proliferation in the low micromolar range.  Finally 
in Chapter 4.0, I discuss the characterization of a small molecule that dramatically inhibits TAg J 
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domain stimulation of Hsp70 and endogenous TAg ATPase activity.  This compound inhibited 
both SV40 replication in vivo and SV40 DNA synthesis in vitro. 
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2.0  THE HSP40 MOLECULAR CHAPERONE YDJ1P, ALONG WITH THE 
PROTEIN KINASE C PATHWAY, AFFECTS CELL-WALL INTEGRITY IN THE 
YEAST SACCHAROMYCES CEREVISIAE 
2.1 INTRODUCTION 
Despite the many decades since the discovery of SV40 TAg, much is still not known about how 
it transforms cells.  In fact, novel TAg interacting proteins are still being identified.  As 
described in Section 1.5.4, there is evidence that novel TAg J domain interacting proteins exist 
and interact through helix III of the J domain.  In order to identify novel TAg J domain 
interacting proteins and/or to better understand the functional relationship of this domain to 
cellular physiology, I performed a multi-copy yeast suppressor screen to identify suppressors of 
the temperature sensitive phenotype of T(K53R)-YDJ1 in ydj1Δ yeast.  Indeed, I uncovered a link 
between cytosolic chaperones and the yeast cell wall.   
Cell wall biogenesis is an intricate cellular process, which has been best characterized in 
Saccharomyces cerevisiae (LESAGE and BUSSEY 2006; LEVIN 2005), but surprisingly few 
chaperones have been directly implicated in this process.  The yeast cell wall is composed of 
85% polysaccharides and 15% proteins (NGUYEN et al. 1998), which are found in two distinct 
layers.  The electron-transparent inner layer is composed of 80-90% β1,3-glucan chains and 1-
2% chitin, which are covalently “glued” together by β1,6-glucans (NGUYEN et al. 1998; OSUMI 
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1998).  In contrast, the electron dense outer layer is composed of glycosylphosphatidylinositol 
(GPI) and Pir glycoproteins (OSUMI 1998), which protect the cell wall and aid in cellular 
recognition.  GPI proteins are attached to the β1,3-glucan chains via β1,6-glucan, whereas Pir 
glycoproteins are linked directly to β1,3-glucans.  Synthesis of β1,3-glucan chains and chitin 
takes place at the yeast cell wall by known synthases (DOUGLAS et al. 1994; MAZUR et al. 1995; 
QADOTA et al. 1996; SANTOS and SNYDER 1997; VALDIVIA and SCHEKMAN 2003), but the 
location of β1,6-glucan synthesis is unknown, in part because the synthase has not yet been 
identified (SHAHINIAN and BUSSEY 2000).   
The primary component of the cell wall is β1,3-glucan.  Numerous genetic and 
biochemical assays suggest that Fks1p and Fks2p/Gsc2p are the catalytic subunits of the β1,3-
glucan synthase.  These multipass transmembrane proteins are localized to sites of polarized 
growth, yeast with mutations in these genes have decreased β1,3-glucan, and the fks1Δfks2Δ 
double knockout yeast strain is inviable (DOUGLAS et al. 1994; MAZUR et al. 1995).  
Unfortunately, in vitro recapitulation of β1,3-glucan synthesis has not been performed because 
purification of enzymatically active Fks1p and Fks2p/Gsc2p has been difficult.  Fks1p is 
expressed during mitotic growth and may require the PKC pathway (Figure 13) for expression 
since Fks1p expression is dependent on Swi4p and upregulated by hyperactivated Mpk1p (IGUAL 
et al. 1996; JUNG and LEVIN 1999), both downstream components of the PKC pathway.  Fks2p is 
expressed in the presence of limited glucose or on alterative carbon sources (MAZUR et al. 1995), 
and upon heat shock but may require the PKC pathway for continued expression (ZHAO et al. 
1998). 
The covalent linkages between the β1,3-glucan polymers is provided by β1,6-glucan.  At 
this time, the location of β1,6-glucan synthesis is unknown.  β1,6-glucan is entirely localized to  
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Figure 13:  The canonical PKC signaling pathway. 
See text for details. 
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the cell wall, suggesting it is synthesized at this site (MONTIJN et al. 1999).   However, β1,6-
glucan synthesis clearly requires the secretory pathway because a mutant allele in the gene 
encoding an ER luminal Hsp70, BiP, reduces the amount of β1,6-glucan at the cell wall when 
either of the two ER glucosidases are also disabled (SIMONS et al. 1998).  Mutations in numerous 
other genes in the secretory pathway also result in reduced β1,6-glucan at the cell wall 
(SHAHINIAN and BUSSEY 2000).  Finally, over-expression of several Golgi-resident proteins 
proposed to aid in β-glucan synthesis suppresses the growth defect in strains mutated for the 
gene encoding Pkc1p (NEIMAN et al. 1997; ROEMER et al. 1994).  Thus, the current model of 
β1,6-glucan synthesis suggests that it is synthesized at the cell wall, but requires a protein or 
precursor molecule that must transit the secretory pathway. 
Yeast cell wall composition is altered throughout the yeast cell cycle and in response to 
cell wall stress conditions.  Yeast have developed three MAP kinase pathways to regulate cell 
wall composition and integrity, the PKC and HOG pathways and the poorly characterized SVG 
pathway (GUSTIN et al. 1998; HEINISCH et al. 1999; MAGER and SIDERIUS 2002).  Cell wall 
integrity is highly regulated and it is not known how these pathways interact to maintain the cell 
wall.  Each pathway is activated in response to complex intracellular and extracellular cues, 
which alters cellular gene expression.  For example, the PKC pathway is induced by heat shock 
or hypotonic conditions whereas the HOG pathway is initiated by hypertonic conditions.  It is 
unknown how the SVG pathway is first induced, but it has been hypothesized that it is triggered 
in response to mannoprotein loss (LEE and ELION 1999).  Interestingly, cross-talk between the 
signaling pathways is common.  For example, many of the signaling proteins are shared between 
the HOG and SVG pathway, but separate responses can be detected.  Also, the PKC pathway is 
inhibited during conditions in which the HOG pathway is activated, and it has been hypothesized 
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that the SVG pathway takes over for the PKC pathway once the HOG pathway is activated 
(MAGER and SIDERIUS 2002).  In addition, genetic data suggest that the PKC and SVG pathway 
have overlapping functions.  For example, inactivation of the SVG and PKC pathways leads to 
synthetic growth defects (LEE and ELION 1999).  However, inactivation of the HOG and PKC 
pathways does not cause a growth defect. 
The PKC pathway is the primary signaling pathway responsible for maintenance of cell 
wall integrity (Figure 13) (GUSTIN et al. 1998).  In Saccharomyces cerevisiae, there is only one 
gene encoding protein kinase C (PKC1).  During the normal cell cycle, Pkc1p plays a role in cell 
wall synthesis of the growing bud.  The PKC pathway also maintains cell wall integrity during 
heat shock, hypotonic stress, and after exposure to cell wall-damaging drugs, and is activated 
during polarized cell growth, such as during shmoo formation, bud growth, and upon actin 
perturbation (LEVIN 2005).  It is proposed that detection of cell wall stress occurs through 
transmembrane proteins such as Mid2p and Wsc1p, which perform redundant functions, but do 
not share any sequence identity.  Mid2p and Wsc1p extend an extracellular domain, which is 
extensively modified by O-mannosylation, into the cell wall (PHILIP and LEVIN 2001; RAJAVEL 
et al. 1999).  It is hypothesized that this domain interacts with carbohydrates in the cell wall and 
senses cell wall stress.  This is relayed to the cytoplamic region of the proteins which interact 
with the nucleotide exchange factor Rom2p (and possibly Rom1p).  Rom2p is responsible for the 
removal of GDP from Rho1p which allows subsequent GTP rebinding.  This activated form of 
Rho1p then activates Pkc1p and initiates a kinase cascade through Bck1p (MAPKKK), Mkk1p 
and Mkk2p (MAPKK), and Mpk1p/Slt2p (MAPK), which then phosphorylates two transcription 
factors, Rlm1p and Swi4p (MADDEN et al. 1997; WATANABE et al. 1995).  Rlm1 activates genes 
that encode for components of the cell wall and factors responsible for cell wall synthesis and the 
 73 
SBF complex (Swi4p and Swi6p) activates G1/S specific cell wall genes (JUNG and LEVIN 1999; 
SPELLMAN et al. 1998). 
In this chapter, I describe the results of the yeast multi-copy suppressor screen in ydj1Δ 
yeast expressing a T-YDJ1 construct with the K53R mutation [T(K53R)-YDJ1].  I identified the 
yeast Hsp70, Ssa1p, as a suppressor of the K53R allele.  This indicates that the screen can 
identify proteins that interact with the TAg J domain (SRINIVASAN et al. 1997).  I also uncovered 
a previously unknown connection between Ydj1p and yeast cell wall biogenesis.  Specifically, I 
observed cell wall defects in ydj1Δ and Hsp90 temperature sensitive mutants, and discovered that 
up-regulation of the Protein Kinase C (PKC) pathway can rescue these defects.  These studies are 
the first to implicate cytosolic Hsp40 chaperones in maintenance of the yeast cell wall.  This 
chapter also includes a description of several mammalian proteins tested for their genetic 
interaction with the TAg J domain and the identification of a novel bacterial J-protein, HopI1.   
2.2 MATERIALS AND METHODS 
2.2.1 Yeast strains and methods 
S. cerevisiae yeast strains used in this chapter are listed in Table 2.   Unless otherwise indicated 
all yeast cultures were grown in yeast extract-peptone-dextrose (YPD) or selective synthetic 
complete medium (SC) with 2% glucose at room temperature or at 26° (ADAMS et al. 1997).  
Cell wall phenotypes were tested on YP or SC-ura medium with the addition of 0.4 M NaCl, 1 M 
sorbitol, or 20 μg/mL calcofluor white (CW), and 2% glucose.  Yeast transformation was 
performed by the lithium acetate procedure (ITO et al. 1983).  For all serial dilutions, overnight  
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Table 2:  Yeast strains utilized during this study 
Yeast Strain Genotype Source 
W303 MATα ade2-1 leu2-3,112 his3-11,15 trp1-1ura3-1 can1-100  This lab 
ydj1-151 MATα ade2-1 leu2-3,112 his3-11,15 trp1-1 ura3-1 can1-100   
ydj1-2::HIS3 LEU2::ydj1-151 
CAPLAN et al. 1992 
ACY95b MATα ade2-1 leu2-3,112 his3-11,15 trp1-1 ura3-1 can1-100   
ydj1-2::HIS3 pAV4 
CAPLAN et al. 1992 
JN516 MATα leu2-3,112 his3-11,15 ura3-52 trp1-Δ1 lys2 SSA1 
ssa2::LEU2 ssa3::TRP1 ssa4::LYS2 
BECKER et al. 1996 
JB67 MATα leu2-3,112 his3-11,15 ura3-52 trp1-Δ1 lys2                  
ssa1-45::URA3 ssa2::LEU2 ssa3::TRP1 ssa4::LYS2 
BECKER et al. 1996 
p82a MATa ade2-1 leu2-3,112 his3-11,15 trp1-1 ura3-1 can1-100 
hsc82::LEU2 hsp82::LEU2 pTGPD-HSP82 
NATHAN and LINDQUIST 
1995 
G313N MATa ade2-1 leu2-3,112 his3-11,15 trp1-1 ura3-1 can1-100 
hsc82::LEU2 hsp82::LEU2 pTGPD-HSP82-G313N 
FLISS et al. 2000 
G170D MATa ade2-1 leu2-3,112 his3-11,15 trp1-1 ura3-1 can1-100 
hsc82::LEU2 hsp82::LEU2 pTGPD-HSP82-G170D 
NATHAN and LINDQUIST 
1995 
STI1/SSE1 MATa GAL2 his2-11,15 leu2-3,112 lys1 lys2 trp1Δ1 ura3-52 NICOLET and CRAIG 1989 
sti1Δsse1Δ MATa GAL2 his2-11,15 leu2-3,112 lys1 lys2 trp1Δ1 ura3-52 
sti1::HIS3 sse1::KANR 
LIU et al. 1999 
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cultures were diluted back to early log phase (0.3-0.4 OD) and allowed to grow 2-5 hrs.  Cell 
densities were normalized to the lowest OD and cells were serially diluted ten-fold.  Unless 
specifically indicated, all growth assays were performed at 26°, 30°, 35°, and 37° for 3-7 days. 
2.2.2 Molecular techniques 
All plasmids used in this chapter are listed on Table 3.  T-YDJ1 and T(K53R)-YDJ1 constructs 
were derived from the pOW4 T-YDJ1 plasmid, which is derived from plasmid YCplac33 (GIETZ 
and SUGINO 1988) and contains the T-YDJ1 chimeric gene (FEWELL et al. 2002) expressed from 
the alcohol dehydrogenase 1 (ADH) promoter.  This chimera consists of amino acids 1-82 of T 
antigen, which encompasses most of the J-domain, and amino acids 71-409 of Ydj1p, which 
contains the Glycine/Phenylalanine-rich and zinc finger-like regions and thus the putative 
substrate binding domain (FAN et al. 2005; JOHNSON and CRAIG 2001; KIM et al. 2001).   pOW4 
T(K53R)-YDJ1 was created with the Quikchange Site-directed Mutagenesis Kit (Stratagene) 
using pOW4 T-YDJ1 as a template.  GPD314 was created by removing the strong glycerol 3-
phosphate dehydrogenase (GPD) promoter, Multiple Cloning Site, and CYC1 terminator from 
GPD425 with SacI and KpnI and inserting it into similarly digested pRS314.  The pOW4 T-
YDJ1 and pOW4 T(K53R)-YDJ1 vectors were digested with EcoRI and XhoI and the ~1.2 kb 
inserts were ligated into pGPD314 and pTEF414 (MUMBERG et al. 1995) to create GPD314 T-
YDJ1, GPD314 T(K53R)-YDJ1, TEF414 T-YDJ1 and TEF414 T(K53R)-YDJ1.  TEF414 contains 
the moderate Translational Elongation Factor (TEF) promoter.  TEF414 T(H42R)-YDJ1 was 
created with the Quikchange Mutagenesis Kit using TEF414 T-YDJ1 as a template.  The inserts 
in all constructs were subjected to DNA sequence analysis.  An additional mutation, D127G, was 
detected in all constructs at nucleotide 380 in a non-conserved residue between the 
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Table 3:  Plasmids used in this study 
Plasmid Gene Vector Reference/Source 
pCMS02-T-YDJ1 T-YDJ1 pOW4 WRIGHT et al. 2007 
pCMS08-T(K53R)-YDJ1 T(K53R)-YDJ1 pOW4 WRIGHT et al. 2007 
pCMS23-T-YDJ1 T-YDJ1 pGPD314 WRIGHT et al. 2007 
pCMS24-T(K53R)-YDJ1 T(K53R)-YDJ1 pGPD314 WRIGHT et al. 2007 
pCMS39-T-YDJ1 T-YDJ1 pTEF414 WRIGHT et al. 2007 
pCMS41-T(K53R)-YDJ1 T(K53R)-YDJ1 pTEF414 WRIGHT et al. 2007 
pCMS123-T(H42R)-YDJ1 T(H42R)-YDJ1 pTEF414 WRIGHT et al. 2007 
pAV4 YDJ1 pRS316 CAPLAN et al. 1992 
pCMS125-REC102 REC102 pRS426 WRIGHT et al. 2007 
pSR6     CHS5  pRS316  SANTOS et al. 1997 
pSR23 CHS5 pRS426 SANTOS et al. 1997 
p1245  MID2-HA YEp352 RAJAVEL et al. 1999 
p1300 MID2-GFP pRS314 RAJAVEL et al. 1999      
YEp/STM1 STM1 YEp213 HATA et al. 1998 
pCMS119-YLR149c YLR149c pRS426 WRIGHT et al. 2007 
SYP1pRS316 SYP1 pRS316 MARCOUX et al. 2000 
SYP1pRS426 SYP1 pRS416 MARCOUX et al. 2000 
YEp351-SSA1  SSA1 YEp351 E. Craig 
pRS426-GPD-(His)6-SSA1 SSA1 pGPD426 MCCLELLAN and BRODSKY 2000 
p1657 SLG-HA YEp352 RAJAVEL et al. 1999 
pSUS1 SUS1 pRS316 RODRIGUEZ-NAVARRO et al. 2004 
pFW46 CYC8 pRS316 WILLIAMS and TRUMBLY 1990 
pRT81 CYC8 YEp24 TRUMBLY 1988 
pCMS118-CIS1 CIS1 pRS426 WRIGHT et al. 2007 
pSKN1-IV SKN1 YCp50 ROEMER et al. 1993 
pThi4ura3 THI4 pRS416 SINGLETON 1997 
pFR22 (YEpU-PKC1) PKC1 YEp352 ROELANTS et al. 2004 
pDLB759 BCK1 YEp352 D. Lew/D. Levin 
pRS314 BCK1-20 BCK1-20 pRS314 LEE and LEVIN 1992  
pCMS147-BCK1-20 BCK1-20 pRS426 WRIGHT et al. 2007 
pDLB823 MKK1 pRS314 HARRISON et al. 2004 
pDLB824  MKK1DD  pRS314 HARRISON et al. 2004 
pCMS148-MKK1DD MKK1DD pRS426 WRIGHT et al. 2007 
pDLB758 MPK1 YEp352 D. Lew/D. Levin 
pNC267 STE7-myc 2μ, CYC1 ZHOU et al. 1993 
YEp352-Kss1 KSS1 YEp352 MA et al. 1995 
p181HOG1ha3  HOG1-HA YEplac181 WINKLER et al. 2002 
pCMS155-HOG1-HA HOG1-HA pRS426  WRIGHT et al. 2007 
p111PBS2 PBS2 YEplac111  WINKLER et al. 2002  
p112PBS2 PBS2 YEplac112 I. Ota 
pCMS154-Hsp82 Hsp82 pRS426 WRIGHT et al. 2007 
pcDNA3.1-BAG-1S BAG-1S pcDNA3.1 J. Hohfeld 
pCMS160-BAG-1S BAG-1S pGPD426 WRIGHT et al. 2007 
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pET-28a-HspBP1 HspBP1 pET28a RAYNES et al. 1998 
pCMS158-HspBP1 HspBP1 pGPD426 WRIGHT et al. 2007 
pP28-FlagPKCη PKCη pP28 LACHMANN et al. 2003 
pCMS159-PKCη PKCη pGPD426 WRIGHT et al. 2007 
pRC/CMV-193 Cul7 pRC/CMV TSAI et al. 2000 
pCMS157-Cul7 Cul7 pGPD426 WRIGHT et al. 2007 
JJ203 I-YDJ1 pTEF414 JELENSKA et al., 2007 
JJ204 I-YDJ1 pTEF414 JELENSKA et al., 2007 
JJ205 I(HPD/QAA)-YDJ1 pTEF414 JELENSKA et al., 2007 
JJ206 I(HPD/QAA)-YDJ1 pTEF414 JELENSKA et al., 2007 
pCMS166-I-YDJ1(03) I-YDJ1 pGPD426 JELENSKA et al., 2007 
pCMS167-I-YDJ1(04) I-YDJ1 pGPD426 JELENSKA et al., 2007 
pCMS168-I(HPD/QAA)-YDJ1(05) I(HPD/QAA)-YDJ1 pGPD426 JELENSKA et al., 2007 
pCMS169-I(HPD/QAA)-YDJ1(06) I(HPD/QAA)-YDJ1 pGPD426 JELENSKA et al., 2007 
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Glycine/Phenylalanine-rich and zinc finger-like regions of YDJ1 (CAPLAN and DOUGLAS 1991); 
however, the presence of this mutation did not affect the growth of yeast expressing T-Ydj1p 
relative to T(K53R)-Ydj1p.  
The yeast genes, REC102, YLR149c, CIS1 and HSP82, were amplified by PCR from 
genomic wild type yeast (W303) DNA with primers created against regions 50-200 bp upstream 
of the TATA box and 15-250 bp downstream of the stop codon.  The PCR products were 
digested with the appropriate restriction enzymes and ligated into pRS426 (CHRISTIANSON et al. 
1992).  The sequence of each insert was confirmed by sequence analysis.  pRS426 HSP82 had an 
A493T mutation at a non-conserved residue in the middle region of Hsp82p.   This mutation did 
not alter Hsp82p function since expression of the corresponding protein restored growth in the 
hsp82 G170D and hsp82 G313N temperature sensitive strains, and the protein was able to 
support cell growth as the only copy of Hsp82p in the cell (Figure 14).  To create a high-copy 
BCK1-20 expression vector, an ~6.5 kb fragment containing BCK1-20 under the control of the 
endogenous promoter was removed from pRS314BCK1-20 (LEE and LEVIN 1992) using XhoI 
and NotI and ligated into pRS426.  A high-copy version of MKK1DD was created by removing an 
~1.6 kb fragment containing MKK1DD under the control of the endogenous promoter from 
pDLB824 (HARRISON et al. 2004) using EcoRI and SacI and ligating this fragment into pRS426.  
To obtain the pRS426 HOG1-HA expression plasmid, an ~2.5 kb fragment containing HOG1-HA 
under the control of the endogenous promoter was PCR amplified from p181HOG1ha3 
(WINKLER et al. 2002) and ligated into pRS426.  The HOG1 PCR primers encompassed DNA 
~125 bp upstream of the TATA box and introduced two stop codons immediately downstream of 
the 3’ HA tag.   
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Figure 14:  HSP82 A493T can support cell growth as the only Hsp90 in the yeast cell.   
p82a yeast were transformed with HSP82 A493T or pRS426 and transformants were selected on 
SC-ura-trp. Three colonies from each transformation were then restreaked onto 5-FAA to 
remove the plasmid encoding HSP82, or onto YPD, SC-trp, or SC-ura.  Wild type yeast (W303) 
and ACY95b were also restreaked as controls and plates were incubated at 26° for 6 days.  As 
expected all colonies grew on YPD, but the W303 strain was unable to grow on SC-trp or SC-ura 
and the ACY95b strain was unable to grow on SC-trp.  Hsp82p A493T was able to function as 
the sole Hsp90 on 5-FAA compared to vector controls. 
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Several mammalian genes were PCR amplified from mammalian expression vectors and inserted 
into the yeast expression vector, pGPD426.  BAG-1S was PCR amplified from the pcDNA3.1-
BAG-1S vector using primers beginning at the ATG start site and ending 10 basepairs 
downstream of the stop codon.  The PCR product was digested with HindIII and XhoI and an 
~700 basepair insert was ligated into pGPD426. HspBP1 was PCR amplified from pET-28a-
HspBP1 (RAYNES and GUERRIERO 1998) using primers that began at the start codon and ended 
18 basepairs downstream of the stop codon.  I digested with BamHI and XhoI and inserted an ~1 
kb section of DNA into pGPD426.  PKCη was PCR amplified from pP28-FlagPKCη 
(LACHMANN et al. 2003) using primers that began at the start codon and ended at the stop codon.  
The PCR product was digested with EcoRI and SalI and an ~2 kb fragment was inserted into 
GPD426.  Cul7 was PCR amplified from pRC/CMV-193 (TSAI et al. 2000) using primers to the 
region 16 basepairs before the ATG and 24 basepairs downstream of the stop codon.  This was 
digested with SpeI and HindIII and an ~5.5 kb insert was ligated into GPD426.   
Two constructs that contained the HopI1 J domain were created.  The TAg J domain was 
removed from TEF414 T-YDJ1 by Joanna Jelenska in the Greenberg lab at the University of 
Chicago and replaced by the putative HopI1 J domain as described (JELENSKA et al. 2007) to 
create the I-YDJ1 plasmids.  pJJ203 codes for amino acids 355-424 of HopI1 and pJJ204 codes 
for amino acids 352-424 of HopI1.  The pJJ205 and pJJ206 constructs contain an HPD to QAA 
mutation in the HPD motif from pJJ203 and pJJ204, respectively.  The I-YDJ1 genes were 
removed from the appropriate vectors using EcoRI and XhoI and the ~1.2 kb fragments were 
inserted into GPD426.  All primer sequences used in this chapter are found in Table 4. 
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Table 4:  Primers used in this study 
Gene Oligonucleotide Restriction Site Sequence (5' to 3') 
TAg-H42R SWF11 N/A AAATGCAAGGAGTTTCGTCCTGATAAAGGAGGAG 
TAg-H42R SWF12 N/A CTCCTCCTTTATCAGGACGAAACTCCTTGCATTT 
TAg-K53R SWF9 N/A GAGATGAAGAAAAAATGAGGAAAATGAATACTCTG 
TAg-K53R SWF10 N/A CAGAGTATTCATTTTCCTCATTTTTTCTTCATCTC 
BAG1  - CMS92 XhoI CTACTCGAGCTGCTACACCTCACTCG 
BAG1 + CMS91 HindIII CTAAAGCTTATGAATCGGAGCCAGGC 
CIS1  - CMS07 EcoRI GATGAATTCGAGAGTCTCATCCATGCGGC 
CIS1 + CMS03 BamHI AGCGGATCCGACAGAAGCACCACTCTTGTGG 
Cul7  - CMS88 HindIII CTTAAGCTTCTACCCCCAACCCCATATCC 
Cul7 + CMS87 SpeI CTTACTAGTCTTCTGAGGTGCCACGATG 
HOG1  - CMS50 HindIII CAAAAGCTTCTCTGGTTACCCTACATGG 
HOG1 + CMS49 SacI CAAGAGCTCTCACTAAGCAGCGTAATCTGGACC 
HSP82  - CMS52 BamHI GACGGATCCCCTATTCAAGGCCATGATGTTC 
HSP82 + CMS51 SalI GTTGTCGACGCTACTAAGAGGATAAGAGATGG 
HspBP1  - CMS56 XhoI GACCTCGAGGCAAGAAGCCACCTGG 
HspBP1 + CMS55 BamHI CTCGGATCCATGTCAGACGAAGGCTCAAGG 
PKCη  - CMS94 SalI CTAGTCGACCTAGGGTTGCAATTCTGGAG 
PKCη + CMS93 EcoRI CTGGAATTCATGTCGTCTGGCACCATG 
REC102  - CMS02 EcoRI GATGAATTCGGAGAACTTGAAGGGCCGACC 
REC102 + CMS01 BamHI AGCGGATCCGCGCAACAGCACGTTAGTTCACC 
YLR149c  - CMS08 XhoI GCTCTCGAGGGCTGAAGTTCAACATAAGTC 
YLR149c + CMS05 BamHI AGCGGATCCCAGTTAGGGCTTCCTCTACGC 
  
Underlined characters represent the restriction site. 
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2.2.3 Low-copy suppressor screen in ydj1-151 
A pilot screen for suppressors of the T(K53R)-YDJ1 thermosensitive phenotype in the ydj1-151 
yeast was performed.  pOW4 T(K53R)-YDJ1 was transformed into the ydj1-151 strain and 
expression was verified by immunoblot using the anti-TAg J domain antibody 419 (HARLOW et 
al. 1981) (Figure 15).  A CEN-TRP1 yeast genomic library in a pRS200 vector (ATCC #77164) 
was transformed into these cells and transformants were selected on SC–ura-trp for 3-4 days at 
37°.  Approximately 6,000 colonies were screened and the fastest growing 20 colonies were 
restreaked on SC-ura-trp.  Of these, 8 colonies had improved growth compared to the vector 
control.  The plasmid DNA was rescued from these strains and retransformed into the ydj1-151 
strain to determine if the phenotype was plasmid dependent.  One plasmid partially restored 
growth after transformation and the plasmid DNA was sequenced at the University of Pittsburgh 
DNA Sequencing Facility using the T3 and T7 primers.  
2.2.4 High-copy suppressor screen in ydj1Δ 
To search for high-copy suppressors of the T(K53R)-YDJ1 thermosensitive phenotype in ydj1Δ 
yeast, a ydj1Δ strain (ACY95b) containing a pRS316 derived CEN-YDJ1 expression vector 
[pAV4, (CAPLAN et al. 1992)], was plated on 5-fluoroorotic acid (5-FOA) to select for yeast that 
had lost pAV4.  The surviving ydj1Δ cells were then transformed with TEF414 T(K53R)-YDJ1 
and grown on SC-trp medium and expression of T(K53R)-Ydj1p was verified by immunoblot 
analysis using both the anti-TAg J domain antibody 419 (HARLOW et al. 1981) and an antibody  
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Figure 15: T-Ydj1p and T(K53R)-Ydj1p are expressed in the both the ydj1-151 and ydj1Δ strains.   
Cell lysates from the indicated strains were resolved by SDS-PAGE and immunoblots were 
performed with either an αTAg or αYdj1p antibody.  Sec61p served as a loading control. 
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against Ydj1p (CAPLAN and DOUGLAS 1991) (Figure 15).  Next, a 2μ-URA3 yeast genomic 
library in the YEp24 vector (CARLSON and BOTSTEIN 1982) was introduced into these cells and 
transformants were selected on SC-ura-trp at 35° for 4 days.  Approximately 80,000 colonies 
were screened, and 61 colonies appeared to contain plasmids that suppressed the T(K53R)-YDJ1 
growth defect when restreaked onto SC-ura-trp at 35°.  The plasmid DNA from these cells was 
isolated and retransformed into ydj1Δ yeast expressing T(K53R)-Ydj1p.  Upon retransformation, 
21 plasmids improved growth to varying extents.  Of these, eight unique plasmids were obtained 
as assessed by restriction digest analysis and DNA sequence analysis from the University of 
Pittsburgh DNA Sequencing Facility using the primers KA109 and KA110 (kind gift from the 
Arndt lab, University of Pittsburgh). 
2.2.5 Biochemical and immunological methods 
To prepare cellular proteins for immunoblot analysis, 10 mL of yeast were grown to an OD of 
0.3-0.9 in the appropriate selective medium at room temperature and the cells were pelleted and 
resuspended in 0.8 mL of 100 mM Tris, pH 8.0, 20% glycerol, 1 mM dithiothreitol (DTT), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL leupeptin, and 0.5 μg/mL pepstatin A.  The 
cells were lysed by agitation with glass beads and crude protein concentrations were determined 
by measuring the A280.  Protein concentrations in each sample were normalized and total protein 
was resolved by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with the indicated 
antiserum.  Antiserum against ribosomal protein L3 (a kind gift of J. Warner, Albert Einstein 
College of Medicine), Sec61p (STIRLING et al. 1992) or Gas1p (DOERING and SCHEKMAN 1996) 
was used to establish loading controls.  Antisera against Sse1p (GOECKELER et al. 2002) and 
Ydj1p (CAPLAN and DOUGLAS 1991) were described previously.  Antiserum against Hsp82p was 
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provided by A. Caplan, Mount Sinai School of Medicine.  J. Pipas, University of Pittsburgh, 
provided antiserum against Cul7 originally from L. Field, Indiana University School of 
Medicine. Anti-Bag-1 C-16 antiserum (Santa Cruz Biotechnology) was provided by D. 
DeFranco, University of Pittsburgh.  Antiserum against HspBP1 was provided by V. Guerriero, 
University of Arizona.  Anti-Ssa1p antiserum was prepared by J. Brodsky, University of 
Pittsburgh, in rabbits using a GST-fusion protein that contained amino acids 586-831 of Ssa1p 
(provided by E. Craig, University of Wisconsin).  Antibodies against the HA epitope were 
obtained from Roche and antibodies against Pkc1p were obtained from Santa Cruz 
Biotechnology.  Bound antibodies were visualized using anti-mouse, anti-rabbit, or anti-sheep 
antibodies coupled to horseradish peroxidase and the Supersignal West Pico Chemiluminescent 
Substrate Kit (Pierce).  Chemiluminescent signal was detected using a Kodak 440CF Image 
Station and quantified using Kodak 1D (V. 3.6) software. 
2.2.6 Lyticase digestion assays 
Two sets of lyticase assays were performed to compare cell wall digestion rates.  The first set 
compared ydj1Δ yeast containing pAV4 (YDJ1) or vector control at room temperature and the 
second set compared wild type (W303) to ydj1Δ yeast at 30°.  The indicated strains were grown 
to exponential phase (0.4-1.0 OD).  Cells were washed in water and resuspended in 100 mM Tris 
pH 9.4, 10 mM DTT for 10-20 min.  Cells were then harvested and resuspended in lyticase 
buffer (0.7 M Sorbitol, 0.5% Dextrose, 10 mM Tris pH 7.4, 0.75% Yeast Extract, 1.5% Bacto 
Peptone) to 3 OD/mL. A total of 6 OD of each strain were incubated with or without 3µL of 
lyticase (SHEN et al. 1991).  Samples were incubated at room temperature or 30° and aliquots 
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were removed every 5 min during a 30 min timecourse and A600 was determined using a 
spectrophotometer.  
2.2.7 Immunoprecipitations 
Immunoprecipitations were performed as previously described (YAM et al. 2005) with minor 
alterations.  Briefly, 200 OD of cells were collected and resuspended in Buffer A (50 mM Tris 
pH 7.5, 10 mM HEPES pH 7.5, 100 mM KCl, 5 mM MgCl2, 10% Glycerol, 0.1% Triton, 1 mM 
PMSF, 1 μg/mL Leupeptin, 0.5 μg/mL Pepstatin A) and lysed by glass bead lysis.  The 
supernatant was incubated with the indicated antibody for 1 hr, followed by incubation with 
Protein A Sepharose (GE Healthcare) for 30 min.  The beads were washed twice with Tris-
buffered saline (TBS) plus 0.05% Tween and twice with TBS plus 1% Tween.  Immunoblots 
were performed as described in Section 2.2.5. 
2.2.8 Subcellular fractionation 
Sub-cellular fractionation of Mid2p was performed by differential centrifugation as previously 
described (KABANI et al. 2002a) with minor changes. A total of 100 ODs of either wild type 
(W303) or ydj1Δ yeast expressing Mid2p-HA were resuspended in 2 mL PLB (20 mM HEPES, 
pH 7.4, 100 mM NaCl, 20 mM MgCl2, 1 mM PMSF, 1 μg/mL leupeptin, 0.5 μg/mL pepstatin A) 
and cells were broken by glass bead lysis.  Unbroken cells were removed by centrifugation at 
1400 x g for 5 min and 1 mL of the supernatant (L) was subjected to a medium-speed spin 
(16,000 x g) for 15 min at 4°.  The pellet (P1) was resuspended in 250 μL PLB and half of the 
supernatant (S1) was saved.  The remaining supernatant was subjected to a high-speed spin 
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(150,000 x g) for 15 min at 4°.  The resulting pellet (P2) was resuspended in 100 μL PLB and the 
remaining supernatant (S2) was saved.  Total protein concentration in L, S1, P1, S2, and P2 was 
normalized by Coomassie Brilliant blue staining of polyacrylamide gels.  The samples were 
resolved by SDS-PAGE, and immunoblots were performed as described above. 
2.2.9 Immunofluorescence  
Indirect immunofluorescence microscopy was performed as described previously (COUGHLAN et 
al. 2004).  Briefly, wild type (W303) or ydj1Δ yeast strains over-expressing Mid2p-HA were 
grown to mid-log phase, fixed in 3.7% formaldehyde, and treated with 20 μg/mL zymolyase for 
45 min at 37°.  Cells were incubated with primary antibodies [HA 1:250 and Kar2p (BRODSKY 
and SCHEKMAN 1993) 1:250] overnight at 4° and in secondary antibodies (Alexa Fluor 488 goat 
anti-mouse 1:250, Alexa Fluor 568 goat anti-rabbit 1:250; Molecular Probes) for 2 hr at room 
temperature.  To visualize DNA, the cells were finally incubated in 2 μg/mL 4,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) for 5 min at room temperature. 
2.2.10  Electron microscopy 
Electron microscopy was performed as previously described (KAISER and SCHEKMAN 1990).  In 
brief, the indicated stains containing either the MID2-HA expression vector or YEp352 (HILL et 
al. 1986) were fixed in 2.5% glutaraldehyde, processed, sectioned, and affixed to 0.125% 
formvar-coated grids.  Sections counterstained with uranyl acetate and Reynold's lead citrate 
were examined on JEM-1011 or JEM-1210 (JEOL) transmission electron microscopes.  Cell 
wall thickness was measured using AMTv542 image capture software (Advanced Microscopy 
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Techniques).  A total of 12-16 similarly sized, budding cells from each culture were chosen, and 
the cell wall thicknesses at ten points around the mother cell were measured. The average for 
each cell was calculated and these numbers were averaged for each culture to determine the 
mean cell wall thickness. 
2.3 RESULTS 
2.3.1 Identification of the known ydj1-151 multi-copy suppressor, SSE1 
The Brodsky lab previously reported on a yeast TAg expression system in which the TAg J 
domain replaced the homologous domain in a yeast Hsp40, Ydj1p.  By PCR mutagenesis of the 
inserted J domain, new mutations in this domain were isolated, some of which conferred strong 
phenotypes when inserted into full-length TAg and into SV40 (FEWELL et al. 2002).  One mutant 
allele that conferred profound phenotypes was T(K53R)-YDJ1.  In order to understand better how 
specific Hsp40 mutations impact yeast cell growth, the T-YDJ1 chimera with the K53R mutation 
[T(K53R)-YDJ1] was cloned behind two constitutive promoters, the weak alcohol dehydrogenase 
1 (ADH) promoter and the strong glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter,  
and introduced into ydj1-151 yeast.   
To determine the ideal screening protocol, several growth conditions were tested (Table 
5) to identify conditions in which ydj1-151 yeast containing T(K53R)-YDJ1 were temperature 
sensitive relative to T-YDJ1.  Coexpression of T(K53R)-Ydj1p and Sse1p was used as a positive 
control for suppressor identification as SSE1 is a known suppressor of the ydj1-151 strain 
(GOECKELER et al. 2002).  In the strains containing T(K53R)-YDJ1 behind the GPD promoter, no  
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Table 5:  Initial screening conditions tested 
Yeast 
Strain Vector Conditions Tested 
Vectors 
Lacking 
Insert 
T-YDJ1+ 
vector 
T(K53R)-
YDJ1+ 
vector 
T(K53R)-
YDJ1+ 
SSE1 
ydj1-151 pOW4 26°, 3 d +++ +++ +++ +++ 
ydj1-151 pOW4 26°, 1 d; 35° 2 d + +++ +++ +++ 
ydj1-151 pOW4 26°, 1 d; 37° 2 d - +++ ++ ++ 
ydj1-151 pOW4 26°, 2 d; RP, 35° 2 d + +++ +++ +++ 
ydj1-151 pOW4 26°, 2 d; RP, 37° 2 d + +++ +++ +++ 
ydj1-151 pOW4 37°, 3 d - +++ - ++ 
ydj1-151 pGPD 26°, 3 d +++ +++ +++ +++ 
ydj1-151 pGPD 26°, 1 d; 35° 2 d ++ +++ +++ +++ 
ydj1-151 pGPD 26°, 1 d; 37° 2 d - +++ + + 
ydj1-151 pGPD  26°, 2 d; RP, 35° 2 d +++ +++ +++ +++ 
ydj1-151 pGPD 26°, 2 d; RP, 37° 2 d +++ +++ +++ +++ 
ydj1-151 pGPD 37°, 3 d - +++ - - 
Yeast 
Strain Vector Conditions Tested 
Vectors 
Lacking 
Insert 
T-YDJ1+ 
vector 
T(K53R)-
YDJ1+ 
vector 
T(K53R)-
YDJ1+ 
YDJ1 
ydj1Δ pGPD 26°, 3 d - ++ ++ +++ 
ydj1Δ pGPD 26°, 1 d; 35° 2 d - ++ ++ +++ 
ydj1Δ pGPD 26°, 1 d; 37° 2 d - ++ ++ +++ 
ydj1Δ pGPD 35°, 3 d - ++ ++ +++ 
ydj1Δ pGPD 37°, 3 d - + + +++ 
ydj1Δ pTEF 26°, 3 d - + + +++ 
ydj1Δ  pTEF 26°, 1 d; 35° 2 d - + - +++ 
ydj1Δ pTEF 26°, 1 d; 37° 2 d - - - +++ 
ydj1Δ pTEF 35°, 3 d - + - +++ 
ydj1Δ pTEF 37°, 3 d - - - +++ 
 
 RP=Replica plate 
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conditions were identified in which SSE1 was able to rescue growth relative to the vector control.  
However, using strains containing T(K53R)-YDJ1 behind the ADH  promoter, one condition (37° 
for 3 days) was identified in which ydj1-151 yeast containing T(K53R)-YDJ1 were temperature, 
but SSE1 over-expression rescued this defect.  These results suggest that T(K53R)-YDJ1 copy 
number is an important determinant of cell growth. 
Next, a low-copy suppressor screen was performed as described in Section 2.2.3 using a 
TRP marked library.  Upon transformation with the library, suppressors were screened at 37°.  
Unfortunately, slow-growing background yeast colonies were detected on all plates, including 
those not transformed with library DNA fragments.  I hypothesized this was due to reversion of 
the ydj1-151 allele during the transformation.  In small scale transformations ydj1-151 revertants 
were seldom produced, but it is possible that in a large scale transformation reversion was more 
prevalent.  Despite this, the fastest growing 20 colonies were restreaked and 8 colonies had 
improved growth relative to the vector control.  The plasmid DNA was rescued and one plasmid 
restored growth upon retransformation.  Sequence analysis revealed that this plasmid contained 
SSE1 and two novel genes, YPL107w and YPL105c.  Little is known about either protein, though 
YPL107w interacts with Vid22p, a protein involved in fructose-1,6-bisphosphatase degradation, 
by yeast two hybrid analysis (ITO et al. 2001).  YPL105c may function in protein synthesis since 
it associates with many translation and splicing factors (ITO et al. 2001).  Regardless, I concluded 
several things from this pilot screen.  First, I uncovered a known ydj1-151 suppressor, SSE1, 
indicating the potential validity of the screen.  Second, T(K53R)-YDJ1 expression level is 
important for identifying suppressors.  Third, screening in the ydj1-151 strain was difficult, 
probably due to reversion of the ydj1-151 allele.  
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2.3.2 Identification of suppressors of T(K53R)-YDJ1 and ydj1Δ yeast 
A second screen was performed that remedied the problems identified in Section 2.3.1.  First, I 
used the ydj1Δ strain to obviate reversion of the ydj1-151 phenotype.  Second, I cloned the 
T(K53R)-YDJ1 gene behind the moderate TEF promoter on a TRP plasmid (TEF414) as 
described in Section 2.2.2.  I chose this plasmid because a high-copy URA marked yeast genomic 
library was available, which could increase the sensitivity of the screen.  Expression of wild type 
T-YDJ1, but not T(K53R)-YDJ1 restored growth in the ydj1Δ strain at 35° (Figure 16).  Several 
screening conditions were tested and the ideal condition was determined to be continuous 
incubation at 35° (Table 5).  Next, a high-copy suppressor screen was performed to uncover 
suppressors of the temperature sensitive T(K53R)-YDJ1 phenotype, as described in  Section 
2.2.4.  Upon retransformation, eight unique plasmids were obtained that partially suppressed the 
T(K53R)-YDJ1 thermosensitive phenotype at 35° (Table 6).  Of note, none of the plasmids 
rescued the temperature sensitive phenotype to the levels seen when T-Ydj1p was expressed 
(Figure 16).  However, plasmid pCMS154 moderately rescued the T(K53R)-YDJ1 phenotype and 
was the strongest suppressing plasmid uncovered in the screen.   
To determine which of the genes in the eight isolated inserts conferred improved growth, 
13 individual genes were chosen for further analysis.  These included genes encoding 
chaperones, transcription factors, and proteins of unknown function, and several that had a 
common link to cell wall synthesis or integrity (see below).  Each gene was amplified by PCR 
and cloned into a pRS426 vector or was obtained from colleagues (Tables 3,6).  Next, the vectors 
were transformed into the ydj1Δ strain either containing or lacking the T(K53R)-YDJ1 expression 
vector and tested for their ability to rescue the temperature sensitive growth defect. It should be 
noted that ydj1Δ yeast lacking the T(K53R)-Ydj1p expression vector grew poorly at 
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Table 6:   Summary of the results obtained from the screen.   
Times 
Recovered Gene Plasmid Name Vector 
Improves 
T(K53R)-YDJ1 
growth at 
35°? 
Improves 
ydj1Δ 
growth at 
30°? 
6  
REC102     
CHS5      
CHS5       
MID2-HA     
MID2-GFP 
pCMS125-REC102 
pSR6 
pSR23 
p1245 
p1300 
pRS426    
pRS316   
pRS426   
YEp352   
pRS314 
-              
-              
-              
+++           
ND 
-             
-             
-             
+++          
+++ 
5 STM1           YLR149c 
Yep/STM1 
pCMS119-YLR149c 
YEp213     
pRS426 
-a                    
- 
-             
- 
3 
RIM1            
SYP1           
SYP1           
RPS14a 
ND 
SYP1pRS316 
SYP1pRS426 
ND 
ND          
pRS316    
pRS426       
ND 
ND            
-              
+             
ND 
ND           
-             
+            
ND 
2 
SSA1            
SSA1            
EFB1             
ERP2 
Yep351-SSA1 
pRS426-GPD-(His)6-SSA1 
ND 
ND 
YEp351     
pGPD426   
ND           
ND 
++            
+             
ND            
ND 
-b            
-b            
ND           
ND 
2 SLG1-HA p1657 YEp352 ++ +++ 
2 
SUS1            
CYC8         
CYC8             
YBR113w 
pSUS1 
pFW46 
pRT81 
ND 
pRS316       
pRS316       
YEp24        
ND 
-              
-              
++            
ND 
-            
+           
++          
ND 
1 
YDR020c       
FAL1          
CIS1            
SES1 
ND 
ND 
pCMS118-CIS1 
ND 
ND               
ND            
pRS426       
ND 
ND            
ND            
++            
ND 
ND           
ND           
-             
ND 
1 
 
SKN1             
THI4             
ENP2 
pSKN1-IV 
pThi4ura3 
ND 
YCp50     
pRS416       
ND 
+             
-              
ND 
-            
-            
ND 
 
 Eight unique plasmids were isolated in the screen that allowed growth of the ydj1Δ yeast 
expressing T(K53R)-Ydj1p at 35° upon retransformation, and the number of times each plasmid 
was identified is indicated. Select individual genes found on each plasmid isolated in the screen 
were tested for improved growth of T(K53R)-YDJ1 at 35° and ydj1Δ at 30°. Seven genes 
improved growth at 35° of ydj1Δ yeast expressing T(K53R)-Ydj1p and four genes improved the 
slow growth phenotype of ydj1Δ yeast at 30°. +++ = Moderate rescue, ++ = Weak rescue, + = 
Poor rescue ND = Not determined, a = Papillae colonies detected, b = ydj1Δ yeast with high 
copy SSA1 expression vectors grew worse than empty vector controls. 
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Figure 16:  pCMS154 in multiple copies moderately rescues the T(K53R)-YDJ1 growth defect at 35°.   
Ten-fold serial dilutions of ydj1Δ yeast expressing wild type T-Ydj1p or T(K53R)-Ydj1p, and 
containing a vector control, a Ydj1p expression vector (pAV4), or three plasmids recovered in the 
screen, pCMS153, pCMS154, and pCMS156, were plated on SC-ura-trp and grown for 5 days at 
the indicated temperatures.  The plasmid pCMS154 contains a yeast genome fragment that 
includes the genes REC102, CHS5, and MID2 and moderately improves the growth of yeast 
containing the T(K53R)-YDJ1 expression vector at 35°.  The plasmid pCMS156 contained the 
genes STM1 and YLR149c and led to papillae colony growth at 35° whereas the plasmid 
pCMS153 did not improve growth of the ydj1Δ strain containing the T(K53R)-YDJ1 expression 
vector at 35°. 
 96 
 97 
temperatures above 26°, and those containing the vector grew poorly above 30°, consistent with 
T(K53R)-Ydj1p exhibiting partial activity (FEWELL et al. 2002).   However, over-expression of 
seven genes suppressed the slow growth phenotype of T(K53R)-YDJ1 at 35° to varying degrees, 
and four of these (MID2, SLG1/WSC1, CYC8, SYP1) also improved the growth of the ydj1Δ 
strain lacking the expression vector variably at 30° (Table 6).  Notably, ydj1Δ yeast containing 
pCMS154 (which harbors MID2) or containing a vector engineered specifically for MID2 over-
expression conferred the same degree of rescue (Table 6, and Figure 18A, below).  Over-
expression of an eighth gene, STM1, did not alter the temperature sensitive phenotype but led to 
papillae colony formation [see Figure 16 for data on the abilities of MID2 (pCMS154) and STM1 
(pCMS156) containing plasmids isolated from the screen to suppress the temperature sensitive 
growth phenotype].   
Among the genes tested only one improved the growth of T(K53R)-Ydj1p-expressing 
yeast but had a negative effect on ydj1Δ yeast lacking the expression vector.  The gene is SSA1, 
which encodes a yeast Hsp70 that is known to interact with Ydj1p (Figure 17A-B) (BECKER et 
al. 1996; CYR et al. 1992; MCCLELLAN and BRODSKY 2000).  SSA1 over-expression in yeast 
containing YEp351 SSA1 was verified by immunoblot analysis (Figure 17C-D).  One 
interpretation of this result is that Ssa1p may directly bind the J domain in T(K53R)-Ydj1p and 
partially repair the lesion conferred by mutating lysine 53 (since only moderate rescue was 
observed). 
In contrast, four suppressors (MID2, SLG1/WSC1, CYC8, SYP1) were identified that 
suppressed to varying extents the phenotypes associated with both the deletion of the YDJ1 locus 
and the phenotype associated with the T(K53R)-YDJ1 expression vector (Table 6; see Figure 
18A-B for an example of studies with the rescue conferred by MID2).  To verify the expression  
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Figure 17:  SSA1 improves the growth of strains possessing the T(K53R)-YDJ1 thermosensitive phenotype. 
Cultures of ydj1Δ yeast expressing T(K53R)-Ydj1p were transformed with a high-copy SSA1-
containing or an empty vector and were serially diluted onto either SC-ura-trp or SC-ura.  Plates 
were incubated for 4 days.  High-copy SSA1 (A) allows some growth of ydj1Δ yeast containing 
the T(K53R)-YDJ1 expression vector at 35°, (B) but slows the growth of ydj1Δ yeast.  
Immunoblot analysis indicates that Ssa1p is over-expressed (C) 2.1 fold in the ydj1Δ strain 
expressing T(K53R)-Ydj1p and (D) 2.6 fold in the ydj1Δ yeast strain. 
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Figure 18:  MID2 suppresses the thermosensitive growth defect of ydj1Δ yeast.   
(A) ydj1Δ yeast expressing T(K53R)-Ydj1p were transformed with the MID2-containing 
multicopy plasmid isolated in the screen (pCMS154), an empty vector, or a multicopy MID2-HA 
containing vector, and were serially diluted onto SC-ura-trp.  Plates were incubated for 4 days.  
(B) High-copy MID2-HA also suppresses the growth defect in the ydj1Δ strain lacking the 
T(K53R)-Ydj1p expression vector, as assessed in part (A).  Mid2p is expressed in the T(K53R)-
YDJ1-containing ydj1Δ strain (C) as well as in the ydj1Δ strain (D) as indicated by immunoblot 
analysis. 
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of the strongest suppressor, Mid2p, an immunoblot analysis against the HA epitope tag (Figure 
18C-D) was performed and Mid2p resolved as three distinct bands of 40kD, 47kD, and 200kD.  
This is consistent with the presence of both immature and highly O-glycosylated forms of Mid2p 
(LOMMEL et al. 2004).  To determine if the observed improvement of growth was allele-specific, 
MID2-HA was over-expressed in the ydj1Δ strain containing the T(H42R)-YDJ1 expression 
vector, which contains an H42R mutation in the conserved HPD motif in the TAg J domain 
(FEWELL et al. 2002).  I found that MID2-HA over-expression also suppressed the slow growth 
phenotype of ydj1Δ yeast containing the T(H42R)-YDJ1 expression vector at 30° (Figure 19A).  
Taken together, these results suggest that MID2 suppression is independent of TAg J domain 
mutant alleles, but is instead the consequence of improved growth of the ydj1Δ strain. 
2.3.3 PKC1 and constitutively activated components of the PKC pathway improve the 
ydj1Δ slow-growth phenotype 
Mid2p and Slg1p/Wsc1p are plasma membrane proteins that sense yeast cell wall stress and 
activate the PKC pathway (PHILIP and LEVIN 2001), which leads to the transcription of genes 
involved in cell wall synthesis (JUNG and LEVIN 1999).  Since Mid2p and Slg1p/Wsc1p are 
components of the PKC pathway and several other of our identified suppressors (Table 6) — 
Syp1p (MARCOUX et al. 2000), Skn1p (ROEMER et al. 1994) and Cis1p (MANNING et al. 1997) 
— are genetically linked to PKC1 or MID2, the ability of PKC1 to suppress the ydj1Δ growth 
phenotype was investigated.  A 2μ PKC1 over-expression plasmid was transformed into ydj1Δ 
cells and ydj1Δ cells expressing T(K53R)-Ydj1p, and moderate rescues of  T(K53R)-YDJ1 
growth at 35° (Figure 20A) and ydj1Δ growth at 30° (Figure 20B) were observed.  The over-
expression of Pkc1p in these strains was verified by immunoblot analysis as shown in Figure  
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Figure 19:  MID2 and PKC1 improve the growth of the ydj1Δ yeast expressing T(H42R)-Ydj1p.   
ydj1Δ yeast containing T(K53R)-YDJ1 or T(H42R)-YDJ1 were transformed with (A) MID2 or 
(B) PKC1 or an empty vector and serially diluted onto SC-ura-trp and incubated for 4 days at the 
indicated temperatures. 
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Figure 20: Introduction of a high-copy PKC1 containing vector and over-expression of constitutively active 
components in the PKC pathway improve the slow growth phenotype of the ydj1Δ strain.   
A multi-copy PKC1-containing vector and a vector control were transformed into (A) ydj1Δ 
yeast expressing T(K53R)-Ydj1p and (B) ydj1Δ yeast, and the transformants were serially 
diluted ten-fold and incubated for 4 days at the indicated temperatures.  Immunoblot analysis 
indicates (C) 1.8 fold overexpression of Pkc1p in the ydj1Δ strain expressing T(K53R)-Ydj1p 
and (D) 3.1 fold overexpression of Pkc1p in the ydj1Δ strain.  (E)  Plasmids containing 
constitutively active, multi-copy BCK1-20 and MKK1DD alleles transformed into the ydj1Δ strain 
also improve the ydj1Δ temperature sensitive defect, though to a lesser extent than MID2 or 
PKC1. 
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20C-D.  Interestingly, over-expression of PKC1 also improved the growth of ydj1Δ yeast 
expressing T(H42R)-Ydj1p at 30° (Figure 19B). 
The PKC signaling pathway is initiated by the phosphorylation of Pkc1p and terminates 
with transcription factor activation via the Bck1p, Mkk1p/Mkk2p, and Mpk1 kinases (LEVIN 
2005).  To determine if over-expression of downstream members of the PKC pathway also 
rescued the ydj1Δ slow growth phenotype, plasmids engineered for the expression of 
constitutively active BCK1 and MKK1 alleles were introduced into the mutant strain.  BCK1-20 
has an alanine to proline mutation at position 1174, immediately upstream of the kinase domain, 
which is believed to mimic Bck1p phosphorylation by Pkc1p (LEE and LEVIN 1992).  MKK1DD 
contains two serine to aspartic acid mutations in the kinase domain, which mimics Mkk1p 
phosphorylation (HARRISON et al. 2004).  As shown in Figure 20E, over-expression of BCK1-20 
or MKK1DD slightly improved the ydj1Δ growth defect.  In contrast, over-expression of wild type 
Mkk1p or Bck1p failed to confer improved growth (Figure 21), consistent with the previously 
reported necessity of using constitutively active forms of these kinases (HARRISON et al. 2004; 
LEE and LEVIN 1992).  In any event, these results indicate that activation of the PKC pathway 
can ameliorate the ydj1Δ temperature sensitive growth phenotype. 
In addition to the PKC pathway, yeast have two other cell wall integrity pathways, the 
HOG and SVG pathways (MAGER and SIDERIUS 2002).   Each pathway is activated under 
different conditions, but cross-talk between the HOG and SVG pathways is common.  The HOG 
and SVG pathways even contain some common signaling proteins (GUSTIN et al. 1998; LEE and 
ELION 1999; O'ROURKE and HERSKOWITZ 1998).  To examine if over-expression of HOG and 
SVG pathway components impact the growth of ydj1Δ yeast, two genes in the HOG pathway 
(HOG1 and PBS2) and SVG pathway (KSS1 and STE7) were over-expressed in the ydj1Δ strain.   
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Figure 21:  Over-expression of BCK1 and MPK1 do not restore growth of the ydj1Δ strain.   
ydj1Δ yeast were transformed with a 2µ BCK1 and MPK1 plasmid or a vector lacking insert.  
The strains were serially diluted onto SC-ura and incubated at the indicated temperatures for 4 
days.  ydj1Δ yeast with the pAV4-YDJ1 expression vector were used as controls.  BCK1 and 
MPK1 did not improve the growth of the ydj1Δ strain relative to the vector control. 
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Hog1p and Kss1p are MAP kinases that initiate the expression of specific genes and Pbs2p and 
Ste7p are the MAPK kinases that phosphorylate Hog1p and Kss1p, respectively (BREWSTER et 
al. 1993; LEE and ELION 1999).  Previously, connections between the signaling pathways were 
examined by over-expressing STE7 in the mkk1Δmkk2Δ strain (YASHAR et al. 1995).  However, 
the over-expression of these proteins had no effect on the ydj1Δ slow growth phenotype (Figure 
22).  These results suggest that rescue of the ydj1Δ slow growth phenotype is limited to the PKC 
pathway and cannot be remedied by upregulation of alternative pathways that may sense cell 
wall integrity 
2.3.4 MID2 and PKC1 partially suppress the temperature sensitive phenotype of hsp82 
mutant strains 
Because Ydj1p functions in multiprotein chaperone complexes with Ssa1p, a cytoplasmic Hsp70,  
and the yeast Hsp90 homologue, Hsp82p (BECKER et al. 1996; CAPLAN et al. 1995; CYR et al. 
1992; KIMURA et al. 1995; MCCLELLAN and BRODSKY 2000), each of the seven suppressors was 
also over-expressed in the temperature sensitive SSA1 strain, ssa1-45, and Mid2p and Pkc1p 
were over-expressed in the temperature sensitive hsp82 G313N and hsp82 G170D strains 
(BOHEN and YAMAMOTO 1993; FLISS et al. 2000; NATHAN and LINDQUIST 1995).  None of the 
suppressors, including MID2 or PKC1 (data not shown; see Figure 23A for data on MID2 and 
PKC1), rescued the temperature sensitive phenotype of ssa1-45 yeast, even though immunoblots 
verified that Mid2p and Pkc1p were over-expressed (Figure 23B).  In contrast, over-expression 
plasmids encoding MID2-HA and PKC1 partially suppressed the growth defect of both hsp82 
G313N and hsp82 G170D (Figure 24A).  Since the Hsp90 complex contains several other 
cochaperones including Sti1p (HOP), Sba1p (p23), and Sse1p (Hsp110)  
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Figure 22:  Over-expression of SVG and HOG pathway members do not improve the growth of ydj1Δ yeast. 
(A)  KSS1 and STE7 or (B) PBS2 and HOG1 overexpression plasmids were transformed into 
ydj1Δ yeast and selected on the appropriate medium.  The yeast were serially diluted and 
incubated at the indicated temperatures for 4 days.  Yeast containing MID2 and YDJ1 expression 
vectors or plasmids lacking insert were used as controls.  (C)  Hog1p expression was verified 
using an antibody against the HA epitope tag. 
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Figure 23:  Multi-copy MID2 and PKC1-containing plasmids do not improve the temperature-sensitive 
growth defects of ssa1-45 temperature sensitive mutants. 
The ssa1-45 yeast strain was transformed with multi-copy MID2-HA or PKC1 containing vectors 
or with an empty vector.  This strain and an isogenic strain containing a wild type version of the 
mutated genes were serially diluted ten-fold on SC-ura for 3-4 days at the indicated 
temperatures.  (A) MID2-HA and PKC1 do not rescue the temperature sensitive growth 
phenotype of ssa1-45 yeast.  (B)  Over-expression of Mid2p-HA (left) and Pkc1p (right) in the 
ssa1-45 strain were verified by immunoblot analysis. 
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Figure 24:  Over-expression of MID2 and PKC1 suppress the growth defect of the hsp82 G170D and hsp82 
G313N strains.   
(A) hsp82 G170D or (B) hsp82 G313N yeast strains were transformed with a MID2 or PKC1 
overexpression vectors or a vector lacking insert and transformants were selected on SC-ura-trp.  
These strains and an isogenic wild type were serially diluted ten-fold and incubated at the 
indicated temperatures for 3 days.   Expression of Mid2p-HA and Pkc1p in the (C) hsp82 G170D 
or (D) hsp82 G313N yeast strains was verified by immunoblot. 
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(CHANG et al. 1997; FANG et al. 1998; LIU et al. 1999), we also examined whether the 
introduction of MID2 and PKC1 over-expression plasmids remedied the sse1Δsti1Δ temperature 
sensitive phenotype (LIU et al. 1999).  Little effect on cell growth was observed (Figure 25) at 
37°.  These data suggest that Mid2p or Pkc1p over-expression primarily impacts the growth of 
the Hsp40 and Hsp90 mutant strains, and suggest that Hsp40 and Hsp90 play a role in yeast cell 
wall integrity.  These combined data also suggest that the mode of Ssa1p-mediated suppression 
of the ydj1Δ strain when T(K53R)-Ydj1p is expressed (see Section 2.3.2) is distinct. 
Because over-expression of Mid2p and Pkc1p improved the growth of hsp82 mutant 
strains, we investigated whether over-expression of Hsp82p could rescue the ydj1Δ slow growth 
phenotype and if, like Ssa1p, Hsp82p also suppressed the T(K53R)-YDJ1 growth defect.  To this 
end, the HSP82 locus was PCR amplified from the yeast genome and inserted in the high-copy 
pRS426 vector, and the plasmid was transformed into both the ydj1Δ strain and into the ydj1Δ 
strain expressing T(K53R)-Ydj1p.  Despite two to three-fold over-expression, HSP82 was unable 
to rescue either the T(K53R)-YDJ1 or ydj1Δ temperature sensitive phenotypes (Figure 26). 
Chaperone levels are tightly regulated (HJORTH-SORENSEN et al. 2001; STONE and CRAIG 
1990) and basal chaperone expression levels might dictate whether a given chaperone can be 
over-expressed.  Thus, endogenous concentrations of Ssa1p and Hsp82p were determined in the 
presence or absence of Mid2p or Pkc1p over-expression in both the wild type and ydj1Δ strains.  
Not surprisingly, in ydj1Δ cells containing a vector control, Ssa1p is upregulated 1.6 to 2.7 fold 
and Hsp82p is upregulated 1.4 to 3.2 fold when compared to the wild type strain (Figure 27, 
compare lanes 1 and 4).  When Mid2p and Pkc1p are over-expressed, we observed a slight, 
additional, upregulation of Hsp82p in the ydj1Δ strain (Figure 27, lanes 2 and 3).  These results 
suggest that Hsp82p and Ssa1p and likely other gene products are induced to compensate for the  
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Figure 25:  Over-expression of MID2 or PKC1 does not restore growth in the sti1Δsse1Δ yeast strain. 
(A)  The MID2-HA and PKC1 expression vector or a vector lacking the insert was transformed 
into the sti1Δsse1Δ yeast strain.  The strains were serially diluted ten-fold and incubated at the 
indicated temperatures for 3 days.  (B)  Expression of Mid2p-HA was verified by immunblot 
using antibodies against the HA epitope tag. 
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Figure 26:  Introduction of a high-copy HSP82 containing vector does not improve the temperature sensitive 
phenotype of T(K53R)-YDJ1 or the slow growth phenotype of the ydj1Δ strain .   
A multi-copy HSP82-containing vector and a vector control were transformed into (A) ydj1Δ 
yeast expressing T(K53R)-Ydj1p and (B) ydj1Δ yeast, and the transformants were serially 
diluted ten-fold and incubated for 4 days at the indicated temperatures.  Hsp82p is overexpressed 
(A) 3.5 fold in ydj1Δ yeast expressing T(K53R)-Ydj1p and (B) 3.1 fold in ydj1Δ yeast. 
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Figure 27:  Hsp82p and Ssa1p are upregulated in the ydj1Δ strain.   
Mid-log phase cells from the indicated strains were lysed, protein levels were normalized, and 
total proteins were resolved by SDS-PAGE.  Immunoblots with the indicated antibodies were 
performed. 
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lack of Ydj1p, and may explain why Ssa1p or Hsp82p over-expression alone does not ameliorate 
the temperature sensitive phenotype of ydj1Δ yeast (Figure 17 and Figure 26). 
2.3.5 The ydj1Δ and hsp82 temperature sensitive strains show phenotypes consistent with 
cell wall defects  
Since the PKC pathway is involved in yeast cell wall maintenance (LEVIN 2005), mutation of 
pathway members leads to cell wall defects and several detectable growth phenotypes.  For 
example, the poor growth of pkc1Δ yeast is rescued by incubation in osmostabilizing reagents, 
such as 1 M sorbitol or 0.5 M NaCl (LEVIN and BARTLETT-HEUBUSCH 1992).   In addition, pkc1 
mutant yeast are sensitive to the cell wall dye calcofluor white (CW) (SCHMITZ et al. 2001), 
which binds and perturbs the architectural integrity of this structure.  Some studies have also 
shown that yeast with cell wall defects are more sensitive to lyticase treatment which digests the 
β1,3-glucan in the yeast cell wall.  Since the introduction of additional copies of MID2 and 
PKC1 affect the growth of ydj1Δ and hsp82 yeast, it was possible that these mutant strains also 
have cell wall defects, as hinted at by previous studies (LUSSIER et al. 1997; YANG et al. 2006).     
To begin to test this hypothesis, the lyticase digestion efficiencies of wild type or ydj1Δ 
yeast cell walls were compared.  Wild type and ydj1Δ yeast were treated with lyticase and culture 
density was compared to an untreated control.  However, ydj1Δ yeast were not preferentially 
digested by lyticase (Figure 28).  This suggests that the levels of β1,3-glucan are unaltered in 
ydj1Δ yeast.  Next, ydj1Δ cells with or without a YDJ1 single-copy expression vector (pAV4) 
were examined on medium supplemented with 0.4 M NaCl.  Growth of ydj1Δ yeast was partially 
restored in the presence of salt (Figure 29A).  In addition, the growth of wild type and ydj1Δ 
yeast was tested in the presence of sorbitol or CW.  As expected for strains having cell wall  
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Figure 28:  The cell wall in the ydj1Δ yeast strain is not preferentially sensitive to lyticase.   
Wild type (red triangle) and ydj1Δ (green circle) yeast were treated with lyticase and cell wall 
digestion was monitored over 30 min.  The starting density of each strain was normalized to 
100%.  The results were compared to samples of untreated wild type (blue diamond) and ydj1Δ 
(purple square) yeast. 
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Figure 29:  The ydj1Δ and hsp82 temperature sensitive mutant strains have phenotypes consistent with 
defects in cell wall synthesis.   
(A) Top, tenfold serial dilutions of  ydj1Δ yeast either expressing Ydj1p (“YDJ1”) or lacking the 
expression vector were plated on YPD  either lacking or containing 0.4 M NaCl, 1 M sorbitol, or 
20 μg/mL calcofluor white at the indicated temperatures for 3 days. Middle and bottom, wild 
type or ydj1Δ yeast were incubated on control or sorbitol or calcofluor white (CW)-containing 
media as above.  (B) HSP82 and hsp82 yeast were grown on either YPD or YPD with either 1 M 
sorbitol or 20 μg/mL CW at the indicated temperatures for 3 days.  All the yeast strains are ade- 
and have a pink coloration.  ydj1Δ yeast also obtained the pink coloration after longer 
incubations (not shown). 
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defects, the growth of ydj1Δ yeast was enhanced on 1 M sorbitol at 30° and was sensitive to CW 
at 23°.  The growth of hsp82 G313N strains was also restored on high sorbitol at 37° and showed 
sensitivity to CW at 23° (Figure 29B).   Notably, the growth of ydj1Δ on sorbitol resembled the 
growth seen upon over-expression of Mid2p or Pkc1p (Figure 18B and 20B).  When Mid2p or 
Pkc1p was over-expressed on high sorbitol containing medium, ydj1Δ cells grew at temperatures 
as high as 37° (Figure 30).  Mid2p or Pkc1p over-expression also rescued the CW sensitivity of 
the ydj1Δ strain at 30° (Figure 31).  These results indicate that ydj1Δ and Hsp82 mutant strains 
have a cell wall defect, and that Mid2p and Pkc1p may repair this defect. 
2.3.6 Mid2p is not dramatically mislocalized or aggregated in ydj1Δ yeast 
Ydj1p is involved in the translocation of nascent polypeptides into the ER (CAPLAN et al. 1992) 
and is able to retain aggregation-prone proteins in solution (CYR 1995).  I therefore hypothesized 
that Mid2p might be mislocalized or aggregated in ydj1Δ yeast, which would prevent accurate 
sensing of cell wall integrity and cause cell wall defects.  But, at least some of the over-
expressed Mid2p might escape to the plasma membrane and partially restore cell wall integrity.  
To test this hypothesis, the solubility of Mid2p was determined by differential centrifugation in 
wild type and ydj1Δ yeast strains over-expressing Mid2p-HA.  In both wild type and ydj1Δ yeast, 
the majority of the Mid2p-HA localized to the first pellet (P1; 76% and 80% of the total protein 
assayed, i.e., the “load”, respectively) (Figure 32A), consistent with Mid2p membrane residence.  
Sec61p, a component of the ER membrane translocon (DESHAIES et al. 1991), fractionated 
similarly.  In wild type yeast, 14% of the total Mid2p localized to the second pellet (P2), which is 
nearly identical to the amount of Mid2p found in the P2 from ydj1Δ  yeast (15%).  Intriguingly, 
only 1.6% of Mid2p fractionated in the second supernatant (S2), which represents clarified  
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Figure 30:  Mid2p or Pkc1p over-expression, coupled with growth on 1 M sorbitol, restores growth of the 
ydj1Δ strain to 37°.   
Ten-fold serial dilutions of ydj1Δ yeast over-expressing Mid2p, Pkc1p, or containing a vector 
control were plated on SC-ura or SC-ura+sorbitol and incubated for 4 days at the indicated 
temperatures. 
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Figure 31:  Over-expression of MID2 and PKC1 can partially restore growth of the ydj1Δ strain in the 
presence of calcofluor white (CW).   
PKC1 and MID2-HA overexpression vectors were transformed into the ydj1Δ strain.  These 
strains were serially diluted ten-fold onto (A) SC-ura or (B) SC-ura+CW and incubated at the 
indicated temperatures for 4 days.  Yeast containing an YDJ1 expression vector or a vector 
control were used as controls.  
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Figure 32:  Only a modest increase in Mid2p aggregation is evident in ydj1Δ yeast.   
(A) Wild type or ydj1Δ yeast over-expressing Mid2p were lysed and the sub-cellular 
fractionation of Mid2p was determined by differential centrifugation. Sec61p, a component of 
the translocon, is an integral membrane protein, whereas Sse1p, a cytoplasmic chaperone, is 
primarily in soluble fractions. L = Load; S1 = First, medium-speed supernatant; P1= First, 
medium-speed pellet; S2 = Second, high-speed supernatant; P2 = Second, high-speed pellet.  (B)  
Mid2p localization was determined by indirect immunofluorescence using an antibody against 
the HA epitope in wild type or ydj1Δ yeast over-expressing Mid2p.  For comparison, the ER was 
visualized using an antibody against the ER resident chaperone, Kar2p, and the nucleus was 
visualized with DAPI staining.  The distended ER and enlarged cell volume of ydj1Δ yeast is 
commonly observed. 
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cytosol (the cytosolic Sse1p chaperone was used as a marker) in ydj1Δ cells compared to 6.3% in 
wild type yeast.  The small decrease in the levels of soluble, cytosolic, Mid2p in fractionated 
lysates prepared from ydj1Δ yeast may be due to an increase in protein aggregation, although 
only a minor percentage of the total cellular Mid2p is affected. 
To investigate whether the sub-cellular localization of Mid2p was grossly altered when 
YDJ1 was deleted, indirect immunofluorescence microscopy was performed.  Mid2p-HA was 
over-expressed in wild type and ydj1Δ yeast and its location was determined using an antibody 
against the HA epitope tag.   As shown in Figure 32B, Mid2p clearly localized to the plasma 
membrane in wild type yeast, which is in agreement with previously published data (KETELA et 
al. 1999; RAJAVEL et al. 1999).  Some protein also resided in large intracellular bodies, which 
may be late secretory vesicles.  In ydj1Δ yeast, Mid2p localization was unchanged.  Together, 
these results suggest that Mid2p is not significantly mislocalized or aggregated in the ydj1Δ yeast 
strain.   
If Mid2p requires Ydj1p for localization or folding, a direct interaction might be 
detectable.  Co-immunoprecipitation experiments were performed to determine if Mid2p and 
Ydj1p are found in the same complex.  MID2-HA or an empty vector control was transformed 
into wild type and ydj1Δ yeast.  Mid2p-HA was then immunoprecipitated using an antibody 
against the HA epitope tag and co-precipitated chaperones were detected by Western blot.   
Despite the presence of Ydj1p, Ssa1p, and Hsp82 in the cell lysate, none of the chaperones were 
detected in a complex with Mid2p (Figure 33A).  Reverse reactions in which Ydj1p was 
immunoprecipitated with an anti-Ydj1p antibody did not detect any co-precipitated Mid2p, 
despite the presence of Mid2p in the cellular lysate (Figure 33B).  These results suggest that  
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Figure 33:  Mid2p does not co-immunoprecipitate with molecular chaperones.   
(A)  Mid2p-HA was precipitated from cellular lysate from the indicated strains using the 
antibody against the HA epitope tag.  The presence of co-precipitating molecular chaperones and 
the translocon was probed using antibodies against Hsp82p, Ssa1p, Ydj1p, and Sec61p.  (B)  
Ydj1p was precipitated from cellular lysate using an αYdj1p antibody.  Mid2p does not 
coimmunoprecipitate.  *=heavy chain IgG, PAS= protein A sepharose bead control. 
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Mid2p and Ydj1p do not directly interact and further eliminates the importance of Ydj1p in the 
folding and localization of Mid2p.   
In addition to its role in cell wall integrity, Mid2p has been implicated in actin 
cytoskeleton rearrangement (MARCOUX et al. 2000).  Therefore, it was formally possible that 
Mid2p over-expression rescues actin cytoskeletal defects in the ydj1Δ strain and thus improves 
growth.  To determine if the actin cytoskeleton was perturbed in the ydj1Δ strain, we used 
fluorescence microscopy to visualize cortical actin patches in wild type and ydj1Δ yeast.  In both 
strains, phalloidin staining showed several punctate “dots” around the yeast cell periphery 
(Figure 34), characteristic of cortical actin staining (ADAMS and PRINGLE 1984).   This result 
suggests that the actin cytoskeleton is not grossly affected in the ydj1Δ strain, and that Mid2p 
over-expression improves the growth of ydj1Δ cells through a different mechanism. 
2.3.7 MID2-HA over-expression thickens the cell wall of ydj1Δ yeast 
Another reason that Mid2p might improve the growth of ydj1Δ yeast is that Mid2p over-
expression may thicken the yeast cell wall (MARCOUX et al. 2000), possibly due to an increase in 
chitin  (KETELA et al. 1999). Thus, we hypothesized that extra copies of Mid2p would rescue 
ydj1Δ growth and the cell wall defect by strengthening and/or enlarging this structure.  To test 
this hypothesis, wild type or ydj1Δ cells lacking the T(K53R)-YDJ1 expression vector but 
containing the MID2-HA over-expression vector or an empty vector control were analyzed by 
electron microscopy.  We first noted that ydj1Δ cells were generally larger than wild type cells 
and contained an enlarged vacuole (Figure 35A), which is consistent with previously published 
data (CAPLAN and DOUGLAS 1991).  Next, the distance between the outside of the cell wall and 
the plasma membrane was measured in similarly sized budding wild type or ydj1Δ cells and the  
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Figure 34:  The actin cytoskeleton is not perturbed in the ydj1Δ yeast strain.   
Actin patches were visualized using phalloidin in wild type and ydj1Δ yeast.  Actin was detected 
in cortical patches around the cellular periphery.  DAPI was used to visualize the nucleus. 
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Figure 35:  Over-expression of Mid2p thickens the cell wall of ydj1Δ yeast.   
Wild type or ydj1Δ strains containing a MID2-HA expression vector or vector control were 
analyzed by electron microscopy.  (A) Two examples of single, budding yeast from each strain 
are shown.  Mid2p over-expression in the ydj1Δ strain thickens the entire cell wall (top) or at 
select locations (bottom-arrow) compared to the vector control.  Wild type yeast are shown at 
~25,000x magnification and ydj1Δ yeast are shown at ~15,000x magnification.  (B)  A higher 
magnification of ydj1Δ containing a MID2-HA expression vector or vector control is shown.  (C)  
The average cell wall thickness for each strain was calculated; cell wall thickness of ydj1Δ cells 
over-expressing Mid2p versus those containing the vector control, p<0.0001.  
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results were quantified as described in the Section 2.2.10.  Despite the difference in cell size, the 
cell wall thickness of the two strains was similar (Figure 35A).  This suggests that the cell wall 
defect in ydj1Δ yeast arises due to an aberrant cell wall composition.  Strikingly, over-expression 
of Mid2p in the ydj1Δ cells almost doubled the average thickness of the cell wall from 120 nm to 
214 nm (Figure 35B-C).  The increased thickness was seen in the inner electron transparent layer 
of the cell wall, which consists of β1,3-glucan, β1,6-glucan and chitin (OSUMI 1998).  
Occasionally the increased cell wall thickness was localized to a single region of the yeast cell 
wall (see the region identified by the arrow in Figure 35A), but in most cells the increased 
thickness was present throughout the cell periphery.  Interestingly, over-expression of Mid2p did 
not uniformly increase the thickness of the cell wall in the wild type yeast strain, though yeast 
with a thicker cell wall in limited regions around the cell were observed in some cases.  Overall, 
I conclude that Mid2p over-expression rescues the ydj1Δ cell wall defect by increasing its 
thickness. 
2.3.8 Directed screening does not identify “factor X” 
As hoped, the yeast suppressor screen identified several genes that rescued to some degree the 
slow growth phenotype of ydj1Δ yeast expressing T(K53R)-Ydj1p.  However, it is unlikely that 
these proteins encode Factor X (SULLIVAN and PIPAS 2002), a putative TAg-interacting protein 
(See Discussion).  Thus, I examined the effects on T(K53R)-Ydj1p-expressing ydj1Δ yeast when 
known or suggested TAg interactors were simultaneously produced.  I first investigated whether 
BAG-1 or HspBP1 expression alter the T(K53R)-YDJ1 thermosensitive phenotype because these 
mammalian NEFs are known to interact with Hsp70 and promote ADP dissociation (ALBERTI et 
al. 2003; KABANI et al. 2002b; RAYNES and GUERRIERO 1998).  Thus, the defect in J domain-
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Hsp70 function evident in T(K53R)-Ydj1p-expressing ydj1Δ yeast might be repaired by 
producing a factor that enhances the Hsp70 ATPase cycle.  Over-expression of BAG-1S or 
HspBP1 did not restore growth to the ydj1Δ strain expressing T(K53R)-Ydj1p at 35° (Figure 
36A-B).  Interestingly, BAG-1S, but not HspBP1, partially restored growth of the ydj1Δ strain 
(Figure 37A-B) at 30°.  This indicates that BAG-1S may stimulate the Ssa1p ATP hydrolysis 
cycle in the absence of Ydj1p.  
I also tested the effect of expressing Cul7 and PKCη in the ydj1Δ strain expressing 
T(K53R)-Ydj1p.  Cul7 is a member of an SCF ubiquitin ligase complex that helps direct specific 
proteins for proteasomal degradation (ALI et al. 2004; DIAS et al. 2002).  Cul7 binds to the TAg J 
domain in the extended loop between helices III and IV (KASPER et al. 2005), a region that is 
encoded in the chimeric T-YDJ1 construct used in our studies.  PKCη is a human PKC isoform 
from a novel class of PKC proteins.  PKCη functionally substitutes for Pkc1p in yeast cells since 
it rescues pkc1Δ yeast (NOMOTO et al. 1997).  However, Cul7 over-expression had no effect on 
ydj1Δ cells expressing T(K53R)-Ydj1p, and even made ydj1Δ cells grow poorer than vector 
controls (Figures 36C and 37C).  Expression of PKCη in ydj1Δ cells with or without T(K53R)-
Ydj1p was toxic (data not shown).  Thus, unlike SSA1 or MID2, Cul7 and PKCη cannot suppress 
defects in the Ydj1p chaperone defects. 
2.3.9 HopI1 contains a bona fide J domain 
Pseudomonas syringae is a gram negative bacterium that is the causal agent of leaf spot, leaf 
blight, and canker disease (SETUBAL et al. 2005).  P. syringae infection interferes with host cell 
processes through the secretion of effector proteins into the cell by a type III secretion system 
(NOMURA et al. 2005; TANG et al. 2006).  These effectors are often required for infection by  
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Figure 36:  HspBP1, BAG-1S and Cul7 do not improve growth in the ydj1Δ strain expressing T(K53R)-Ydj1p.   
HspBP1, BAG-1S, and Cul7 expression vectors or vector controls were transformed into the 
ydj1Δ strain expressing T(K53R)-Ydj1p and selected for on SC-ura-trp.  The strains were serially 
diluted ten-fold and incubated for 4 days at the indicated temperatures.  Yeast containing a T-
YDJ1 expression vector were used as a control.  Expression was verified by immunoblot and 
Sse1p, Sec61p, and Gas1p were used as loading controls. 
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Figure 37:   HspBP1, BAG-1S and Cul7 do not improve growth in the ydj1Δ strain.   
MID2-HA, HspBP1, BAG-1S, and Cul7 expression vectors or vector controls were transformed 
into the ydj1Δ strain and selected for on SC-ura.  The strains were serially diluted ten-fold and 
incubated for 4 days at the indicated temperatures.  HspBP1, BAG-1S and Cul7 were expressed 
as verified by immunoblot, using Sse1p, Sec61p, and Gas1p were as loading controls. 
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suppressing the plant defenses and facilitating bacterial growth.  The effector protein, HopI1 
plays a role in bacterial virulence, since the disruption of the gene with a transposon led to 
reduced bacteria titer and decreased chlorosis, or yellowing of the leaves (GUTTMAN et al. 2002).  
HopI1 has a C-terminal region that has homology to the J domain (GUTTMAN et al. 2002).  
To determine if the putative J domain of HopI1 is a functional J domain, the 
corresponding domain in YDJ1 was replaced with the HopI1 J domain (I-YDJ1).  The chimeric 
gene was then inserted behind the moderate TEF and strong GPD promoters as described in 
Section 2.2.2.  I found that the introduction of these vectors, but not a vector control, into the 
ydj1Δ yeast strain significantly improved growth at 30° (Figure 38A).  Because the HPD motif in 
J domain-containing proteins is essential for interaction with Hsp70s, the HPD motif was 
mutated to QAA (I(HPD/QAA)-YDJ1). The introduction of these constructs failed to 
complement the ydj1Δ slow growth phenotype (Figure 38A) and in fact inhibited growth when 
the protein was driven by the GPD promoter.  Expression of the chimeric proteins was verified 
by immunoblot (Figure 38B).  These data suggest that the mutated version of I-Ydj1p fails to 
interact with Hsp70 and may act as a dominant negative, one that binds client proteins but lacks 
the ability to bind to Hsp70.  Mutation of H42R in the T-YDJ1 HPD motif also leads to this 
dominant negative phenotype (Figure 19).  Taken together, these results indicate that HopI1 
contains a functional J domain. 
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Figure 38:  The introduction of an I-YDJ1-containing vector improves the growth of ydj1Δ yeast at 30°. 
Ten-fold serial dilutions of ydj1Δ yeast containing the indicated plasmids were plated on SC-trp 
or SC-ura and grown for 5 days at the indicated temperatures.  A Ydj1p expression plasmid 
(pAV4) and the SV40 TAg/YDJ1 chimera (T-YDJ1) were used as positive controls.  (B) 
Expression was confirmed by immunoblot analysis. 
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3.0  IDENTIFICATION OF HSP70 MODULATORS THAT INHIBIT BREAST 
CANCER CELL PROLIFERATION 
3.1 INTRODUCTION 
The Hsp70 class of molecular chaperones is essential for normal cell function and misregulation 
of these proteins can cause or worsen diseases, including breast cancer (BARNES et al. 2001; 
CIOCCA et al. 1993).  In addition, simply decreasing Hsp70 levels can be sufficient to cause 
apoptosis in breast cancer cells (NYLANDSTED et al. 2000).  To this end, we sought to identify 
Hsp70 modulators that could inhibit Hsp70 ATPase activity and induce apoptosis.  Two Hsp70 
modulators, DSG and R/1 (discussed in Section 1.4.3) served as starting compounds for these 
studies.  However, both DSG and R/1 have relatively low affinities for Hsp70, and also may not 
be specific for inhibition of Hsp70.  In fact, DSG binds to both Hsp70 and Hsp90 with relatively 
similar affinities (NADEAU et al. 1994).   Finally, R/1 is fairly insoluble which makes in vivo use 
difficult.  Thus, I hoped to identify more potent, specific, and soluble structural analogs of DSG 
and R/1 which could induce apoptosis in breast cancer cells. 
In this chapter, I discuss the identification of small molecule modulators that inhibit 
breast cancer cell proliferation.  I screened structural analogs of DSG and R/1 for modulation of 
Hsp70 ATPase activity or the Hsp70/J domain interaction and identified several new classes of 
chaperone modulators.  I discuss in detail the compound MAL3-101, which selectively inhibited 
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TAg stimulation of Hsp70 and also inhibited breast cancer cell proliferation in two cell lines.  To 
identify more potent analogs of MAL3-101, chemical derivatives were synthesized and tested in 
the breast cancer proliferation assays. Distinct chemical classes of MAL3-101 derivatives also 
inhibited breast cancer cell proliferation, some at lower concentrations than MAL3-101.  Like 
MAL3-101, many of these compounds also inhibit TAg stimulation of Hsp70.  These 
compounds may be precursors for more specific and potent compounds that can be used to treat 
breast cancer. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Ssa1p and TAg were purified as described previously (CANTALUPO et al. 1999; MCCLELLAN and 
BRODSKY 2000).  The Hlj1p J domain containing the first 89 amino acids of the yeast Hsp40, 
Hlj1p, fused to GST at the N- terminus and containing a hexahistidine tag at the C-terminus was 
purified as described previously with minor modifications (YOUKER et al. 2004).  A saturated 
overnight culture of E. coli containing the GST-Hlj1p-6His expression vector was diluted to 0.05 
OD/mL in 1 L and incubated at 30° for 2 hrs until the culture density was 0.14 OD/mL.  Protein 
expression was induced with 0.2 mM IPTG for 7 hrs until the culture reached a density of 0.7 
OD/mL.  The cells were harvested, resuspended in 25 mL Buffer 88 (20 mM HEPES, pH 6.8, 
150 mM KOAc, 5 mM MgOAc, 250 mM sorbitol) and frozen in liquid nitrogen.  The initial 
batch purification was performed as described previously (YOUKER et al. 2004) and dialyzed 
overnight into Hsp70 dialysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 2 mM MgCl2, 0.8 
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mM DTT, 5% glyercol).  The protein was then added to 2 mL of Q Sepharose beads re-
equilibrated in dialysis buffer and rotated for 2 hrs at 4°.  Bound protein was eluted with dialysis 
buffer that had increasing amounts of NaCl up to 1M.  The flowthrough and 50 mM NaCl 
elutions, which had the majority of the Hlj1p chimera as assessed by Coomassie stained SDS-
polyacrylamide gels were pooled, concentrated, and frozen in liquid nitrogen. 
The purified Ydj1p was provided by Sheara Fewell and purified as described in (CYR et 
al. 1992). Two purified DnaK proteins, a near full length version containing amino acids 2-638 
and a truncated version containing amino acids 2-605 were provided by Erik Zuiderweg from the 
University of Michigan  These proteins were purified over an ATP agarose column and excess 
ATP was removed by PD10 buffer exchange.  Human Hsp70 (corresponding to the gene, 
HSPA1A) was provided by Doug Placais and purified from bacteria or was purchased from 
Stressgen (NSP-555).   
3.2.2 Single turnover ATPase assay 
Single turnover ATPase assays were performed as described (FEWELL et al. 2004).  In short, 25 
µg of Hsp70 (Ssa1p or human Hsp70) was combined with 25 µM ATP and 100 µCi α32P-ATP in 
Single Turnover Complex Buffer (STCB) (100 mM KCl, 25 mM HEPES pH 7.5, 11 mM 
MgOAc) and incubated for 30 min on ice to allow the Hsp70-ATP complex to form.  
Purification over a NICK column (GE Healthcare) removed the unbound ATP from the Hsp70-
ATP complex.  Peak fractions were combined and glycerol was added to a final concentration of 
10%.  The samples were frozen in single-use aliquots in liquid nitrogen.  For each reaction in 
which endogenous Hsp70 ATPase activity was measured, tubes were rapidly thawed at 30° and 
combined with DMSO or an equal volume of the test compound.  Aliquots of 6 µL were 
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removed during a 10 min timecourse and combined with 2 µL 4x Stop Solution (2 M LiCl, 4 M 
Formic Acid, 36 mM ATP).  Reactions were spotted in duplicate on thin layer chromatography 
plates (Selecto Scientific, #11078) and developed in 0.5 M LiCl, 1M Formic Acid.  Percent ATP 
hydrolyzed was determined by phosphorimager analysis.   In reactions where TAg or Ydj1p was 
added, the initial reaction included the co-chaperone and the thawed Hsp70-ATP complex was 
added immediately to the reaction, already at 30°.  After 60 sec, the compound or DMSO were 
added and the reaction was continued for 9 min.  For all reactions in which the endogenous 
Hsp70 ATPase activity was assessed, the values at the zero sec timepoint were set to 0, and for 
all cochaperone stimulated reactions the values at the 60 sec timepoint were set to 0.   Results 
from multiple experiments were averaged and kinetic data were obtained using KaleidaGraph.  
The results were fit to a single exponential using the equations:  m1*(exp(-m2*m0))+m3; 
m1=60, m2=0.08, m3=100 or m1*(1-exp(-m2*m0)); m1=100, m2=0.005, where m1=reaction 
amplitude, m2=rate of hydrolysis and m3=total ATP hydrolyzed.  The first equation was used for 
the experiments described in 3.3.1 and the second equation was used to quantify all other 
reactions. The second equation was used to ensure a more representative fit for the data.  Similar 
kinetics was obtained using either equation.  All error bars represent standard deviations of the 
data. 
3.2.3 ATPase assay 
Purified protein and test compounds were preincubated on ice in 50 mM HEPES pH 7.4, 50 mM 
NaCl, 2 mM MgCl2, 10 mM DTT for 15 minutes.  The reaction was started by adding 1 nmol 
ATP and 0.2 µCi α32P-ATP and moving the reaction to 30°.  A 30 min timecourse was 
performed and aliquots were removed and added to Stop Solution.  Duplicate reactions were 
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plated on TLC plates and developed in 0.5 M LiCl, 1M Formic Acid.  Total pmol ATP 
hydrolyzed was determined by phosphorimager analysis.  The percent hydrolysis at the zero 
timepoint was subtracted from the percent hydrolyzed at each timepoint, and the data were 
averaged.  The data were then fit to a linear regression that originated at the origin.  All error 
bars represent standard deviations of the data. 
3.2.4 Assays for interactions between Hlj1p and Ssa1p 
A total of 5 µg GST-Hlj1p-6His was prebound to 12.5 µL glutathione agarose beads in GST 
binding buffer (20 mM Tris pH, 8.0, 100 mM KCl, 5 mM MgCl2, 0.1% NP40, 2% Glycerol, 1 
mM DTT, 1 mM EDTA, 1 mM PMSF) and rotated for 1 hr at 4°.  The unbound GST-Hlj1p-6His 
was removed with 2 washes of GST binding buffer.  A total of 3 µg Ssa1p was preincubated with 
nucleotide and MAL3-101 or DMSO for 12 min before it was added to the bead suspension and 
rotated for 2 hrs at 4°.  The final concentration of MAL3-101 was 30 µM.  After 2 hrs, the beads 
were washed with 50 µL GST binding buffer two times, resuspended in TCA Sample Buffer, and 
the bound proteins were resolved via SDS-PAGE.  The gel was stained with Coomassie Brilliant 
Blue and quantified using the Kodak 440CF Image Station and quantified using Kodak 1D (V. 
3.6) software.  Three reactions were performed in the presence of either ATP or ADP.  The 
experimental data were averaged and the reactions performed in the presence of ATP were 
normalized to 100%.   
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3.2.5 Cell proliferation assays 
The cell proliferation assays were performed as previously described (CORY et al. 1991; 
MINGUEZ et al. 2003) using the breast cancer cell lines SK-BR-3 and MDA-MB-468 and the 
“normal” fibroblast cell line WI-38.  Briefly, the indicated cells were plated in 96 well plates and 
allowed to attach and grow for 48 hrs.  The test compounds or DMSO were titrated (0.08-50 µM) 
into the wells and incubated with the cells for 3-6 days.  The cells were treated with 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), 
which is converted by succinate dehydrogenase to a formazan in living cells.  The absorbance of 
the formazan was measured at A490.  The concentration of compound where proliferation is 50% 
of the DMSO control was then calculated and is stated below as GI50.  
3.3 RESULTS 
3.3.1 The identification of Hsp70/J-domain modulators 
I sought to identify compounds with structural similarity to DSG and R/1 which could modulate 
the endogenous Hsp70 ATPase activity or the J domain-stimulated Hsp70 ATPase activity.  The 
isolation of such compounds could lead to the identification of a Structure Activity Relationship 
(SAR) for these effects.  A total of 30 compounds from either the National Cancer Institute 
(www.dtp.nci.nih.gov) or the University of Pittsburgh Center for Chemical Methodologies and 
Library Development (UPCMLD) were identified in substructure analogy searches by Dr. Billy 
Day, Department of Pharmaceutical Science, with structural similarity to R/1.  The structures of  
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select compounds are shown in Figure 39.  To determine the effects of these compounds on 
endogenous Hsp70 ATPase activity, Dr. Sheara Fewell, a previous post-doc in the lab, tested the 
compounds in a single turnover assay at three concentrations.  In these assays, Ssa1p was 
prebound to ATP and ATP hydrolysis was measured independent of ATP binding or release 
(FEWELL et al. 2004).  Ssa1p was chosen since it can be purified with high yield and with few 
contaminants. In contrast, mammalian Hsp70 tends to have a higher starting percentage of 
hydrolysis in single turnover assays, which makes quantification more difficult, and contains 
more impurities.  Seven compounds stimulated the rate of ATP hydrolysis by ≥ 2.5 fold at 300 
µM (Table 7).  The strongest stimulator, MAL3-90 stimulated the rate of Ssa1p ATPase activity 
5.2 fold, which was nearly comparable to R/1 (Figure 40A).   
Next, the effect of the compounds on J-protein stimulation of Ssa1p was tested.  First, I 
showed that in equimolar amounts to the concentration of ATP-bound Ssa1p, SV40 TAg and 
Ydj1p stimulate Ssa1p ATP hydrolysis 6-8 fold in a single turnover assay (Figure 40B-C).  I then 
tested the effects of the 12 compounds from the UPCMLD on TAg and Ydj1p stimulation of 
Ssa1p in the single turnover assays.  Five compounds (MAL3-38, MAL3-39, MAL3-54, MAL3-
90, and MAL3-101) altered TAg stimulation of Hsp70 ≥ 2 fold (Table 8), and most compounds 
had similar effects in the presence of Ydj1p [e.g. MAL3-38 and MAL3-90 (Figures 40B-C)].  
Interestingly, these compounds had several different effects on cochaperone-stimulated Hsp70 
ATP hydrolysis.  One class of compounds, which included MAL3-55, stimulated the rate of 
Ssa1p ATP hydrolysis but inhibited TAg stimulation of Hsp70.  This was generally seen as a 
decrease in the rate of ATP hydrolysis and subsequently a decrease in the amplitude of the 
reaction.  A second set of compounds, exemplified by MAL3-90, strongly increased the rate of 
TAg stimulation of Hsp70, but had an overall inhibitory effect due to a decrease in reaction  
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Figure 39: Structure of select chaperone modulators, including parental compounds 15-Deoxyspergualin 
(DSG) and NSC 630668-R/1 (R/1). 
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Table 7:  The effect of the DSG and R/1 analogs on Ssa1p ATPase activity 
 100 µM 300 µM 600 µM 
 
Drug 
Rate ATP 
Hydrolysis* 
Fold 
Change 
Rate ATP 
Hydrolysis* 
Fold 
Change 
Rate ATP 
Hydrolysis* 
Fold 
Change 
DMSO 2.0 ± 0.1      
R/1   11.6 ± 1.0 5.8   
624392 ND ND 1.6 ± 0.1 -1.3 1.4 ± 0.2 -1.4 
642393 ND ND 1.2 ± 0.3 -1.7 ND ND 
624903 ND ND 0.9 ± 0.3 -2.2 ND ND 
624904 ND ND 1.4 ± 0.1 -1.4 ND ND 
624905 ND ND 1.7 ± 0.2 1.2 ND ND 
624906 ND ND 1.1 ± 0.2 -1.8 1.8 ± 0.7 -1.1 
624907 ND ND 2.4 ± 0.5 1.2 ND ND 
624908 ND ND 1.8 ± 0.1 -1.1 ND ND 
625194 2.0 ± 0.2 1 3.6 ± 0.2 1.8 2.7 ± 0.4 1.4 
625195 6.1 ± 0.5 3 3.4 ± 0.3 1.7 2.5 ± 0.3 1.3 
625512 2.3 ± 0.2 1.2 6.2 ± 0.7 3.1 6.0 ± 0.5 3 
625513 2.2 ± 0.2 1.1 3.9 ± 0.3 2 4.9 ± 0.8 2.5 
632006 ND ND 2.8 ± 0.3 1.4 1.0 ± 0.2 2 
655302 ND ND 3.8 ± 0.5 1.9 1.5 ± 0.3 -1.3 
ααδ9 ND ND 1.2 ± 0.2 -1.7 ND ND 
ML2-193 3.2 ± 0.4 1.6 6.2 ± 0.5 3.1 4.5 ± 0.5 2.3 
ML2-194 2.5 ± 0.3 1.3 4.1 ± 0.7 2.1 2.7 ± 0.1 1.4 
ML2-214 1.8 ± 0.2 -1.1 3.4 ± 0.5 1.7 1.6 ± 0.3 1.3 
ML2-215 2.3 ± 0.1 1.2 4.3 ± 0.4 2.2 4.2 ± 1.4 2.1 
MAL3-38 3.5 ± 0.2 1.8 6.1 ± 0.8 3.1 4.1 ± 0.6 2 
MAL3-39 ND ND 2.1 ± 0.4 1 1.4 ± 0.7 -1.4 
MAL3-40 3.5 ± 0.3 1.8 5.4 ± 0.5 2.7 6.0 ± 0.7 3 
MAL3-51 ND ND 1.7 ± 0.3 -1.2 1.6 ± 0.2 -1.3 
MAL3-53 3.7 ± 0.2 1.9 4.9 ± 0.6 2.5 9.1 ± 1.0 4.6 
MAL3-54 ND ND 2.2 ± 0.3 1.1 2.5 ± 0.2 1.3 
MAL3-55 1.3 ± 0.1 -1.5 2.8 ± 0.2 1.4 5.6 ± 0.9 2.8 
MAL3-87 3.8 ± 0.3 1.9 4.5 ± 0.6 2.3 5.2 ± 0.7 2.6 
MAL3-88 2.9 ± 0.3 1.5 3.1 ± 0.4 1.3 4.7 ± 0.7 2.4 
MAL3-90 4.1 ± 0.6 2 10.3 ± 1.7 5.2 13.3 ± 1.6 6.7 
MAL3-91 3.6 ± 0.3 1.8 5.8 ± 1.2 2.9 9.9 ± 1.3 5 
MAL3-101 ND ND 2.1 ± 0.3 1 2.4 ± 0.2 1.2 
 
*=Rates of ATP hydrolysis are multiplied by 1000; ND=Not determined. 
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Table 8:  The effect of the DSG and R/1 analogs on TAg stimulation of Ssa1p ATP hydrolysis 
 
Drug 
Rate ATP 
Hydrolysis* 
 
Fold Change 
DMSO 12.6 ± 0.3 — 
R/1 8.3 ± 0.8 -1.5 
MAL3-38 25.5 ± 8.7 2 
MAL3-39 4.5 ± 1.2 -2.8 
MAL3-40 18.9 ± 9.4 1.5 
MAL3-51 11.1 ± 0.2 -1.1 
MAL3-53 15.5 ± 3.1 1.2 
MAL3-54 2.5 ± 1.7 -5.1 
MAL3-55 6.8 ± 1.6 -1.8 
MAL3-87 22.8 ± 9.4 1.8 
MAL3-88 19.0 ± 5.6 1.5 
MAL3-90 52.7 ± 14.3 4.2 
MAL3-91 18.0 ± 6.0 1.4 
MAL3-101 3.1 ± 0.3 -4.0 
  
*=Rates of ATP hydrolysis are multiplied by 1000. 
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Figure 40:  MAL3-38 and MAL3-90 stimulate the ATPase activity of Ssa1p, but inhibit J-protein stimulation 
of Ssa1p ATP hydrolysis in single turnover assays.   
(A)  300 µM MAL3-38 (open circles), and MAL3-90 (open squares) stimulate Ssa1p ATP 
hydrolysis relative to a DMSO control (filled circles).  This stimulation is similar to that seen 
with R/1 (open triangles).  (B)  300 µM MAL3-38 initially increases the rate of J-protein 
stimulation of Ssa1p ATP hydrolysis, but inhibits the overall reaction by decreasing the reaction 
amplitude.  Equimolar amounts of wild type TAg (filled circles) and Ydj1p (filled squares) 
stimulate Ssa1p ATP hydrolysis to similar levels.  MAL3-38 inhibits the stimulation by TAg 
(open circles) and Ydj1p (open squares).  (C)  Like MAL3-38, 300 µM MAL3-90 inhibits J-
protein stimulation of Ssa1p ATP hydrolysis by decreasing the reaction amplitude.  Equimolar 
amounts of wild type TAg (filled circles) and Ydj1p (filled squares) stimulate Ssa1p ATP 
hydrolysis to similar levels.  MAL3-90 inhibits the stimulation by TAg (open circles) and Ydj1p 
(open squares).  The arrow indicates that the compounds were added at 60 sec.  
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amplitude (Table 8, Figure 40C).  In fact, compounds that strongly stimulated Ssa1p ATP 
hydrolysis were also more likely to stimulate the rate of TAg action on Hsp70 and lead to an 
overall inhibition of the reaction by decreasing the final amplitude.   
Interestingly, three compounds, MAL3-39, MAL3-54 and MAL3-101, inhibited TAg 
stimulation of Hsp70 ATPase activity, but had no effect on endogenous Hsp70 ATPase activity 
(Figures 41A-B).  This suggests that the compounds may prevent the interaction between Hsp70 
and the J domain or prevent Hsp70 from changing conformation in response to the J domain.  
Intriguingly, the effect of MAL3-101 on TAg stimulation of Hsp70 ATP hydrolysis may be 
specific as MAL3-101 had no affect on Ydj1p stimulation of Ssa1p (Figure 41C).  However, 
MAL3-101 is not a general inhibitor of TAg activity as Dr. Fewell showed it has no effect on 
TAg ATPase activity independent of Hsp70 and the J domain (FEWELL et al. 2004).  In 
conclusion, I helped identify several classes of Hsp70 modulators, including a class that 
selectively inhibits cochaperone activity.  
3.3.2 Characterization of MAL3-101 
MAL3-101 represents a member of a unique class of Hsp70 modulator, which selectively 
inhibits stimulation of Hsp70 by TAg.  To better understand the action of this compound on 
Hsp70 activity in vitro, I titrated MAL3-101 into the single turnover assay in the presence of 
TAg.  At lower compound concentrations (30 µM and 100 µM), MAL3-101 had little effect on 
TAg stimulation of Hsp70 (Figure 42A), indicating a concentration dependent effect of the 
compound.  However, increasing amounts of TAg overcame the inhibition seen with 300 µM 
MAL3-101 (Figure 42B).         
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Figure 41:  MAL3-39 and MAL3-101 selectively inhibit J-protein stimulation of Ssa1p.   
(A)  300 µM MAL3-39 or (B) 300 µM MAL3-101 were added to reactions that either contained 
1 µg TAg (open squares) or lacked TAg (open circles).  These reactions were compared with 
DMSO controls in the presence (filled squares) or absence (filled circles) of TAg.  (C)  MAL3-
39 (open squares) and MAL3-101 (open diamonds) had no affect on Ydj1p stimulation of Ssa1p 
compared to a DMSO control (filled circles).  Ssa1p treated with DMSO in the absence of 
cochaperone (filled circles) was used as a control.  
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Figure 42:  Concentration dependence of MAL3-101 and TAg in the single turnover assays.   
(A)  TAg stimulated Ssa1p ATP hydrolysis was determined in the presence of DMSO (filled 
squares), 30 µM MAL3-101 (open circles), 100 µM MAL3-101 (open squares), or 300 µM 
MAL3-101 (open triangles).  An unstimulated Ssa1p reaction is shown (filled circles).  (B)  TAg 
stimulated Ssa1p ATP hydrolysis was determined in the presence of DMSO (filled circles) or 
300 µM MAL3-101 and increasing amounts of TAg.  TAg concentrations are 0.02 µM TAg 
(open circles), 0.05 µM TAg (open squares), 0.11 µM TAg (open triangles), 0.22 µM TAg 
(open, inverted triangles), 0.67 µM TAg (crosses). 
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I hypothesized that if MAL3-101 interfered with the interaction between the J domain 
and Hsp70, this could be shown using coprecipitation studies.  To test this hypothesis, I 
incubated GST-Hlj1p-His with glutathione beads and examined whether 30 µM MAL3-101 
could interfere with Ssa1p binding to GST-Hlj1p-His.  If the MAL3-101 inhibited the interaction 
between the J domain and Ssa1p, a decrease in the amount of co-chaperone bound to Ssa1p in 
the presence of ADP would be predicted.  When the level of Hsp70 associated with GST-Hlj1p-
His in the presence of ATP was normalized to 100%, little difference between the amount bound 
to Ssa1p in the presence of ADP was seen (70% Ssa1p bound with DMSO compared to 73% of 
Ssa1p bound with MAL3-101) (Figure 43).  This result suggests that MAL3-101 has little effect 
on the binding between the two domains. However, this experiment has many caveats.  First, the 
concentration of MAL3-101 used was quite low.  At this concentration, little effect on TAg 
stimulation of Ssa1p was detected.  Second, MAL3-101 shows some specificity for J domain 
inhibition as it inhibits TAg-stimulated Ssa1p ATP hydrolysis, but not Ydj1p-stimulated 
hydrolysis.  It is possible that MAL3-101 has no effect on GST-Hlj1p-His stimulation of Ssa1p.  
Therefore, coprecipitation experiments should be repeated using TAg.  Third, these experiments 
require a stable interaction between the J domain and Hsp70, which is not always seen in vitro 
(RUSSELL et al. 1999).  It is possible that MAL3-101 can only inhibit the transient interaction 
between the J domain and Hsp70.  However, these results suggest MAL3-101 may inhibit the 
conformational change induced by J domain interaction with Hsp70, not the actual interaction. 
3.3.3 Identification of a putative, minimal pharmocophore 
Due to the low number of Hsp70 modulators available and their relative complexity, determining 
a SAR has proven difficult.  However, based on the analysis of the compounds described in  
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Figure 43:  MAL3-101 does not interfere with Ssa1p binding to GST-Hlj1p-His.   
Purified GST-Hlj1p-His was bound to glutathione beads and incubated with the indicated 
nucleotide and purified Ssa1p that had been preincubated with 30 µM MAL3-101 or DMSO.  
The amount of Ssa1p bound to GST-Hlj1p-His was visualized on a Coomassie blue stained SDS-
polyacrylamide gel.  The amount of Ssa1p bound to GST-Hlj1p-His was normalized to 100.  A 
representative gel is shown. 
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Figure 44: Structures of compounds that were proposed to contain the putative minimal pharmocophore. 
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Section 3.3.1, compounds, JB-78, JB-99, JB-102, JB-116, MAL2-11B, and MAL2-216, were 
obtained from UPCMLD, and their structure is shown in Figure 44.  These compounds contain 
many of the same structural characteristics as the DSG and R/1 analogs, but were much smaller 
in mass and were predicted to have higher solubility.  These six compounds were also chosen to 
allow the identification of the minimal pharmocophore.  They may also prove valuable in vivo 
due to their higher solubility.   
I tested JB-78, JB-99, JB-102, JB-116, MAL2-11B, and MAL2-216 in single turnover 
assays to determine if they altered Ssa1p ATP hydrolysis or TAg stimulation of Ssa1p.  Five 
compounds stimulated Ssa1p ATP hydrolysis ≥ 2.7 fold (Table 9, Figure 45A) at 300 µM.  
Interestingly, these 5 compounds mimicked MAL3-90 when TAg was added to the experiment 
and increased the rate of TAg stimulation of Ssa1p between 2-7 fold, but decreased the reaction 
amplitude by almost half (Figure 45A).  These results are also consistent with the observation 
that compounds that dramatically stimulate Hsp70 ATPase activity also stimulate TAg activity.  
The effects of the compounds were also tested by Fengfeng Xu, a rotation student in the lab, for 
their impact on endogenous Hsp70 activity with both Ssa1p and mammalian Hsp70 (Stressgen), 
and similar results were obtained.  Interestingly, the compounds seemed to have a greater effect 
on mammalian Hsp70 ATP hydrolysis than Ssa1p.  Future experiments will determine if the 
compounds also have a greater effect on TAg stimulation of mammalian Hsp70 ATP hydrolysis. 
Perhaps the most interesting compound in this set was MAL2-11B.  This compound had 
no effect on endogenous Hsp70 hydrolysis when tested with the two Ssa1p preps or mammalian 
Hsp70 (Figure 45B, data not shown).  However, the compound dramatically inhibited TAg 
stimulation of Ssa1p, much more dramatically than MAL3-101 at 300 µM (Figure 45B).  As  
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Figure 45:  Two classes of compounds identified with a minimal pharmocophore.   
(A) MAL2-216 and (B) MAL2-11B were added at 300 µM to the single turnover assay in the 
presence (light blue) or absence (dark blue) of 1 µg TAg.  DMSO treated Ssa1p ATP hydrolysis 
in the presence (red) or absence (black) of TAg was used as a control.  (C) TAg stimulated ATP 
hydrolysis was determined in the presence of DMSO (red), 30 µM MAL2-11B (purple), 100 µM 
MAL2-11B (green), and 300 µM MAL2-11B (blue).  A reaction without TAg is shown in black. 
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Table 9:  The effects of the compounds with a “putative minimal pharmocophore” on Ssa1p stimulated ATP 
hydrolysis and TAg stimulation of Ssa1p ATP hydrolysis. 
 Endogenous Ssa1p TAg stimulated-Ssa1p 
 Rate ATP 
Hydrolysis* 
Fold 
Change Amplitude
Rate ATP 
Hydrolysis*
Fold 
Change Amplitude
DMSO 1.5±0.1  52.1 6.3  79.7 
JB-78 3.1±0.3 2.1 50.0 20.3 3.2 42.3 
JB-99 4.0±0.4 2.6 42.1 33.7 5.3 45.5 
JB102 3.8±0.4 2.5 45.2 9.0 1.4 47.6 
JB-116 4.4±0.7 2.9 36.4 18.5 2.9 49.4 
MAL2-216 4.5±0.2 3.0 45.8 16.7 2.7 46.7 
MAL2-11B 1.5±0 1.0 52.1 2.8 -2.3 43.9 
  
*=Rates of ATP hydrolysis are multiplied by 1000. 
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shown previously (Figure 42A), MAL3-101 had little effect on TAg stimulated ATP hydrolysis 
at 30 µM or 100 µM.  However, even at these concentrations, MAL2-11B significantly inhibited  
TAg stimulation of Ssa1p ATP hydrolysis (Figure 45C).  This suggests that MAL2-11B may be 
a more potent Hsp70 co-chaperone modulator than MAL3-101.  
3.3.4 MAL3-101 inhibits breast cancer cell proliferation 
Since the six compounds identified in Section 3.3.3 may contain the minimal pharmocophore, 
have a lower mass, and likely are more soluble than previous compounds, they were tested for 
their effects on breast cancer cell proliferation.  MAL3-101 was also tested since previous 
studies had suggested it was membrane permeable (FEWELL et al. 2004).  These compounds 
were titrated onto SK-BR-3 breast cancer cells by Guangyu Zhu in the Billy Day lab, 
Department of Pharmaceutical Sciences, University of Pittsburgh, and after 3-4 days he 
determined the number of living cells using MTS, a colorimetric indicator of cell number.  The 
concentration at which 50% of the treated cells are present relative to the DMSO control (GI50) 
was determined.  Based on his data, MAL3-101 inhibited SK-BR-3 cell proliferation at a GI50 of 
9.3 µM and was the only compound tested to inhibit proliferation at a concentration lower than 
15 µM (Table 10).  A similar GI50 of 8.4 µM was observed when MAL3-101 was titrated onto a 
second breast cancer cell line, MDA-MB-468.  However, in these assays, MAL3-101 may not be 
specific for breast cancer cell proliferation (Table 11).  MAL3-101 also inhibited WI-38 
fibroblast cells at a GI50 of 15 µM.  Assuming all the compounds were able to enter the cell, two 
conclusions can be made.  First, despite their shared kinetics, MAL3-101 and MAL2-11B act 
differently on breast cancer cells.  Second, compounds that prevent a functional interaction 
between Hsp70 and J-proteins may be a viable treatment for breast cancer.  However, additional  
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Table 10:  The effect of the compounds on SK-BR-3 cell proliferation. 
  SK-BR-3 SK-BR-3 
Exposure time/d 3 4 
MAL2-216 (μM) >50 ND 
MAL3-27 (μM) >50 41±2 
JB-78 (μM) >50 41±2 
JB-99 (μM) 38±4 38±8 
JB-102 (μM) >50 40±0 
JB-116 (μM) >50 37±2 
MAL3-101 (μM) 9.3±2.2 11±2 
Taxol (nM) 3.7±0.5 5.9±0.8 
  
 
 
Table 11:  MAL3-101 inhibits cell proliferation. 
 SK-BR-3 SK-BR-3 MDA-MB-468 WI-38 
Exposure time/d 3 4 6 5 
MAL3-101 (μM) 9.3±2.2 11±2 8.4±1.0 15±12 
Taxol (nM) 3.7±0.5 5.9±0.8 1.7±0.4 >50 
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compounds will need to be identified which are more specific for the chaperone isoforms that 
may be specifically induced in breast cancer cells. 
3.3.5 Some MAL3-101 derivatives inhibit breast cancer cell proliferation 
The study presented above suggests that the isolation of MAL3-101 analogs might identify 
additional inhibitors of breast cancer cell proliferation, perhaps with greater potency, and identify 
a functional group that is required for this activity.  To this end, the Wipf lab at the UPCMLD 
synthesized 43 derivatives of MAL3-101 (WERNER et al. 2006).  Like the previous UPCMLD 
compounds, the chemical derivatives of MAL3-101 were created through successive Biginelli 
and Ugi reactions.  Fifteen compounds were synthesized using only the first Biginelli reaction, 
varying the aldehyde group present.  These products were combined with m-butyl-isocyanide 
and various combinations of aldehydes and amines to create the final products via Ugi 
condensation reactions.  In addition, the free diacid of MAL3-101 was created by hydrolysis of 
MAL3-101. 
These 43 compounds were screened for inhibition of breast cancer cell proliferation by 
Guangyu Zhu in the Day lab, as described above.  Seventeen compounds, including MAL3-101, 
inhibited breast cancer proliferation (Table 12).  These compounds were from two chemical 
classes of MAL3-101 derivatives.  These classes were compounds synthesized through the 
combined Biginelli and Ugi reactions with the aldehyde group varied in the Biginelli reaction or 
the amine group varied in the Ugi reaction.  The GI50 for the active compounds ranged from 6 ± 
0.4 µM to 42.6 ± 6 µM, with 9 compounds showing GI50 values < 10 µM.  In this assay, the GI50 
for MAL3-101 was 27 ± 2 µM, which was a slightly higher concentration than seen in previous 
assays and may suggest prep-to-prep variability.  Since the GI50 values are lower than those  
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Table 12:  Select MAL3-101 derivatives inhibit SK-BR-3 cell proliferation. 
SK-BR-3 Ssa1p ATPase TAg Stimulated 
 Class Chemical modification GI50 
Fold 
Change Amplitude 
Fold 
Change Amplitude 
 DMSO CONTROL    61.212  83.993 
MAL3-101 MAL3-101   27±2 1.7 48.045 -2.0 71.802 
MAL3-51 MAL3-51    >50 1.1 93.148 -2.0 88 
MAL2-11B Biginelli acid p-biphenylcarboxaldehyde >50 1.1 54.09 -3.5 49.2 
MAL2-10A Biginelli acid benzaldehyde >50         
MAL2-06A Biginelli acid 2-naphthaldehyde >50         
MAL1-274 Biginelli acid p-chlorobenzaldehyde >50 1.3 64.585     
MAL2-13 Biginelli acid p-nitrobenzaldehyde >50         
DMT002272 Biginelli acid o-biphenylcarboxaldehyde >50 1.0 74.968 -5.0 84.299 
MAL2-116-17 Biginelli acid m-nitrobenzaldehyde >50        
MAL2-116-20 Biginelli acid p-trifluoromethylbenzaldehyde >50         
DMT003034 Biginelli acid cyclohexylcarboxaldehyde >50 1.0 75.915 1.5 69.337 
DMT003036 Biginelli acid p-tert-butylbenzaldehyde >50 1.0 74.042 -3.5 55.686 
DMT003038 Biginelli acid cyclopropylcarboxaldehyde >50 1.1 48.254 1.0 68.45 
DMT003116 Biginelli acid p-cyclohexylbenzaldehyde >50 -1.1 76.868     
DMT003042 Biginelli ester p-biphenylcarboxaldehyde >50 2.6 42.709 -1.2 68.72 
DMT003044 Biginelli ester benzaldehyde >50 2.3 39.671 -1.3 54.295 
DMT003046 Biginelli ester cyclopropylcarboxaldehyde >50 1.9 48.008 1.0 74.625 
DMT003020 Free diacid   >50 1.1 60.406 -2.2 43.801 
DMT003024 MAL3-39-like    >50 2.3 41.691 -5.0 95.147 
DMT003082 Ugi-1 p-trifluoromethylbenzaldehyde >50 1.0 65.746 -4.8 98.535 
DMT003084 Ugi-1 p-tert-butylbenzaldehyde 29±0 1.2 56.496 -5.2 102.43 
DMT003086 Ugi-1 m-nitrobenzaldehyde 6.0±0.4 1.1 74.295 -1.5 65.423 
DMT003088 Ugi-1 benzaldehyde 6.5±0.7 1.1 76.802 -1.1 73.963 
DMT003090 Ugi-1 p-chlorobenzaldehyde 16±6 1.5 49.917 -1.9 73.243 
DMT003092 Ugi-1 p-nitrobenzaldehyde 6.9±0.4 1.0 52.617 -3.2 84.597 
DMT003094 Ugi-1 naphthaldehyde 10±1 1.0 65.291 -2.9 86.443 
DMT003096 Ugi-1 o-biphenylcarboxaldehyde 17±3 -1.1 56.078 -4.0 81.841 
DMT003100 Ugi-1 cyclohexylcarboxaldehyde 6.3±1.0 1.2 65.173 -2.1 90.129 
DMT003132 Ugi-1 cyclopropylcarboxaldehyde 6.2±0.4 1.2 74.185 -2.6 86.045 
DMT003134 Ugi-1 p-cyclohexylbenzaldehyde 42±6 2.2 36.44     
DMT002218 Ugi-2 benzaldehyde >50 3.2 34.654 1.1 68.669 
DMT002220 Ugi-2 p-hydroxybenzaldehyde >50 11.8 40.818 9.2 48.389 
DMT002222 Ugi-2 p-biphenylcarboxaldehyde >50 9.9 32.744 6.0 37.403 
DMT002260 Ugi-2 m-ester-benzaldehyde >50 3.7 29.923 1.1 50.224 
DMT002262 Ugi-2 acetaldehyde >50         
DMT002264 Ugi-2 cyclohexylcarboxaldehyde >50         
DMT003058 Ugi-2 2-pyridinecarboxaldehyde >50 4.2 32.815 5.5 29.619 
DMT003112 Ugi-2 3-ester-4-hydroxybenzaldehyde >50 19.1 31.362 2.1 61.348 
DMT003114 Ugi-2 p-oxymethylester 48±5 1.1 55.201 1.2 67.145 
DMT002286 Ugi-3 cyclohexenylethylamine 39±6 6.1 33.853 -1.2 64.808 
DMT003052 Ugi-3 methoxyethylamine 8.8±0.3 1.5 54.419 -1.8 77.53 
DMT003102 Ugi-3 benzylamine 14±2 1.5 57.099 -3.6 104.92 
DMT003104 Ugi-3 phenethylamine 32±2 12.3 29.349 1.3 39.578 
DMT003106 Ugi-3 2-pyridinemethylamine 7.1±0.4 1.0 63.43     
DMT003108 Ugi-3 2-pyridineethylamine 7.5±0.8 -1.1 81.21     
DMT003110 Ugi-3 tryptamine >50 1.0 67.792     
PTX(nM) CONTROL   6.1±1.2 N/A N/A N/A N/A  
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obtained with MAL3-101, these results indicate that more potent inhibitors of breast cancer cell 
proliferation were identified. 
The compounds were then examined via single turnover ATPase assay to determine if the 
effect on breast cancer cell proliferation was correlated to chaperone modulating activity.  The 
compounds were tested for their effect on Ssa1p ATP hydrolysis and TAg stimulated ATP 
hydrolysis as described in Section 3.3.1.  The chaperones modulators fell into distinct classes 
that were directly related to the chemical modifications made during synthesis (Table 12).  The 
compounds that inhibited breast cancer cell proliferation had little effect on Ssa1p ATP 
hydrolysis, but all inhibited TAg stimulation of Ssa1p, to varying degrees similar to the action of 
MAL3-101.  However, not all of these compounds inhibited breast cancer cell proliferation.  For 
example, compounds that included just a Biginelli product with variations in the aldehyde group 
had virtually no effect on endogenous Ssa1p ATP hydrolysis, but inhibited TAg stimulation of 
Ssa1p ATP hydrolysis.  Despite similar attributes, compounds in this class have no effect on 
breast cancer cell proliferation.  This is exemplified by MAL2-11B (Figure 44B), which was 
described in Section 3.3.3 and was resynthesized and re-examined here.  This indicates that a 
specific effect on cochaperone stimulation is not a predictor of effect on breast cancer cell 
proliferation. 
In addition, other novel classes of chaperone modulators were identified.  One class was 
the ester modification of select Biginelli aldehydes.  These compounds (e.g. DMT003042, Figure 
46) moderately stimulated Ssa1p ATP hydrolysis, but had no effect on TAg stimulated ATP 
hydrolysis in single turnover assays.  Other compounds (e.g. DMT2220, Figure 46) dramatically 
stimulated both Ssa1p ATP hydrolysis and TAg stimulated Ssa1p ATP hydrolysis.  These 
compounds had similar properties to MAL3-90, which was discussed in 3.3.1.  Once again, this  
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Figure 46:  Representative members from each of the classes of MAL3-101 derivatives.   
These include Class B- Biginelli ester DMT003042, Class C- Ugi-1 DMT003096, Class D- Ugi-
2 DMT002220, Class E- Ugi-3 DMT003102.  The DMSO control reactions with 1 µg TAg (red 
squares) or without TAg (black squares) can be compared to compound treated reactions in the 
presence of TAg (green triangles) or absence of TAg (blue triangles).  An example of Class A- 
Biginelli acid MAL2-11B can be seen in Figure 45B. 
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correlates stimulation of Ssa1p ATP hydrolysis with increase in TAg stimulation of Ssa1p.  
However, not all inhibitors of TAg stimulated Hsp70 ATPase activity reduced breast cancer cell 
proliferation.  This may arise if the compounds are not membrane permeable, inactivated, or 
target different intracellular co-chaperones.  In conclusion, this approach identified several 
classes of Hsp70 modulators and correlated inhibition of cochaperone stimulation of Hsp70 
ATPase activity to inhibition of breast cancer cell proliferation. 
3.3.6 Novel Hsp70 modulators inhibit mammalian Hsp70 ATP hydrolysis 
Based on our studies, the Gestwicki lab in the Life Sciences Institute at the University of 
Michigan created structurally similar compounds using a different synthetic protocol.  These 
compounds were built from three hydrophobic amino acids upon which a Biginelli reaction was 
performed (see Figure 47A for representative structures).  The Gestwicki lab had shown that 
some of these compounds (SW01, SW03, and SW07) are Hsp70 agonists and others (SW02, 
SW04, SW05, SW06, and SW08) are antagonists using a luciferase refolding assay (J. 
Gestwicki, unpublished data).  In this assay, luciferase is denatured by guanidine HCl and diluted 
into rabbit reticulocyte lysate (RRL), which contains sufficient chaperones to allow luciferase 
refolding.   
 To determine if these compounds were Hsp70 modulators, I tested their effects on the 
ATPase activities of several Hsp70s.  First, I tested the effects of the compounds on two different 
DnaK constructs.  This Hsp70 was chosen because the Gestwicki lab hoped to map the 
compounds’ binding sites on DnaK using NMR.  The two constructs contained amino acids 2-
638 (full length) or amino acids 2-605 (truncated), which is currently being used in the NMR 
studies (E. Zuiderweg, University of Michigan, personal communication).  A total of 10 µg of  
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Figure 47:  SW02 and SW03 inhibit Hsp70 ATP hydrolysis, but do not alter the total J-protein stimulated 
ATP hydrolysis.    
(A)  The structure of SW02 and SW03. (B) The ATPase activity of 10 µg Hsp70 was monitored 
in the presence of DMSO (diamonds), 500 µM SW02 (squares), or 500 µM SW03 (triangles).  
(C) GST-Hlj1p-His stimulated Hsp70 ATPase was determined in a similar ATPase assay.  The 
amount of pmol hydrolyzed per min was calculated. 
 187 
 188 
each DnaK protein was incubated with 10 µM SW01 or 100 µM SW02, SW03, SW04, SW06, 
and SW07, and tested in an ATPase assay.  The concentrations were suggested by J. Gestwicki 
and were based off previous, unpublished, in vivo and in vitro results.  This ATPase assay 
approximates steady state conditions as ATP binding, hydrolysis, and release are measured.  The 
compounds showed little effect on the ATPase activity of either construct (Table 13), and the 
greatest effect observed was an ~24% decrease in full length DnaK ATPase activity in the 
presence of SW03. 
 I hypothesized that these compounds might have a more profound effect at a higher 
concentration or on human Hsp70 ATPase activity since they are active in the luciferase assay, 
which includes the mammalian Hsp70 found in RRL.  I therefore tested the effects of 500 µM 
SW02 and SW03 on the ATPase activity of human Hsp70.  These compounds were chosen since 
SW03 was an agonist and SW02 was an antagonist in the luciferase assay.  Both SW02 and 
SW03 decreased Hsp70 ATPase activity by 31% and 54% respectively (Figure 47B).  This result 
was unexpected since the compounds had differing effects on luciferase refolding, but could 
signify a difference between the two assays.  For example, the ATPase assays utilize purified 
proteins in the absence of substrate, whereas the luciferase assay is performed in cell lysate and 
includes luciferase as a substrate.  I also tested the compounds for inhibition of GST-Hlj1p-His 
stimulation of Hsp70 ATP hydrolysis in the ATPase assays.   Like MAL3-101, neither SW02 nor 
SW03 had a significant effect on stimulation (Figure 47C, data not shown).  
 Since these compounds were structurally similar to MAL3-101, SW01 and SW02 were 
also tested for their effect on breast cancer proliferation as described above.  SW01 was used 
instead of SW03 because it is believed to be cell permeable (J. Gestwicki, personal 
communication).  The concentration of both drugs needed to inhibit 50% of the cell proliferation 
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Table 13:  The SW compounds have little effect on DnaK ATP hydrolysis. 
 DnaK (2-638) DnaK (2-605) 
 pmol ATP 
hydrolyzed/min % DMSO 
pmol ATP 
hydrolyzed/min % DMSO 
DMSO 4.3456 --- 3.5971 --- 
SW01 4.358 100.3 3.8983 108.4 
SW02 3.7368 86.0 3.7974 105.6 
SW03 3.2947 75.8 3.2436 90.2 
SW04 3.5569 81.9 3.4544 96.0 
SW06 3.7814 87.0 3.3286 92.5 
SW07 4.4799 103.1 3.4948 97.2 
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 was > 50 µM.  Assuming the compounds enter the cells, this indicates that MAL3-101, SW01, 
and SW02, while Hsp70 modulators, have different in vivo activities.  Alternatively, it is possible 
that the cells modify or destroy the compounds, thus rendering them inactive. 
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4.0  A NOVEL SMALL MOLECULE INHIBITS SV40 PRODUCTION BY 
PREVENTING VIRAL DNA SYNTHESIS 
4.1 INTRODUCTION 
Human polyomaviruses can cause several diseases, including BKVAN and PML (BARBANTI-
BRODANO et al. 1998; BERGER 2003).  The recent identification of the KI polyomavirus 
(ALLANDER et al. 2007) indicates that other human polyomaviruses probably exist that may also 
cause human disease.  Unfortunately, few anti-viral compounds have been identified as potential 
treatments for these infections.  Since BKV and JCV are difficult and time-consuming to grow in 
the laboratory, screening for novel drugs using these viruses has been problematic.  However, 
since SV40 is highly similar to JCV and BKV and can be easily maintained in the lab, SV40 has 
become a model system for the study of human polyomaviruses.  The SV40 TAg J domain is 
required for many aspects of viral replication, including cell cycle initiation, DNA replication, 
and virion assembly (SPENCE and PIPAS 1994b; SRINIVASAN et al. 1997; SULLIVAN et al. 2000a).  
As discussed in Section 1.5.2.2, the TAg J domain initiates S phase in non-proliferating kidney 
cells by releasing E2F from Rb.  Also, most viruses that encode J domain mutations in TAg 
cannot replicate their DNA in vivo, and the few that can replicate DNA cannot form mature 
virions (SPENCE and PIPAS 1994b). 
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Many other proteins, including the Hsp70 and Hsp90 chaperones, play a role in viral 
replication.  In addition to viral corruption of cellular Hsp70 via TAg J domain, Hsp70 is 
implicated in other aspects of the SV40 life cycle.  For example, Hsp70 is probably involved in 
viral uncoating immediately after infection.  Hsp70 co-precipitates with the viral coat protein, 
VP1, 3 hours after infection, and is required to disassemble virus particles in vitro (CHROMY et 
al. 2006).  Hsp70 is also involved in viral coat assembly late in infection and binds the viral coat 
proteins VP1, VP2, and VP3 (CRIPE et al. 1995).   The bacterial DnaK, DnaJ, and GrpE 
chaperones also assemble capsid-like particles in vitro (CHROMY et al. 2003), suggesting that the 
ability of chaperones to assemble capsids is conserved.  Unlike the role of Hsp70 in virion 
assembly, Hsp90 is probably involved in TAg folding.  Hsp90 and TAg co-precipitate from cells, 
and it is likely that Hsp90 only binds immature TAg proteins since Hsp90 bound denatured TAg 
but not wild type TAg in vitro (MIYATA and YAHARA 2000).  Furthermore, addition of GA to 
TAg-expressing cells reduces the amount of intracellular TAg (MIYATA and YAHARA 2000).  
Taken together, these results suggest that Hsp90 binds immature TAg and that inhibition of 
Hsp90 leads to increased degradation of TAg.  This is consistent with other reports indicating 
that premature dissociation of Hsp90 ligands effects their degradation (SCHNEIDER et al. 1996). 
Since polyomavirus replication requires the viral-encoded TAg, specific TAg inhibitors 
could represent a novel class of replication inhibitors with potentially minimal side effects.  
Thus, I hypothesized that previously identified inhibitors of TAg J domain stimulation of Hsp70 
might inhibit viral replication.  To test this hypothesis, I decided to better characterize three 
compounds, MAL3-101, MAL2-11B, and MAL3-51 in vitro and determine if they inhibited 
SV40 replication in vivo.  As presented in Chapter 3.0, MAL3-101 and MAL2-11B inhibit TAg 
stimulation of Ssa1p’s ATPase activity, but have no effect on endogenous Ssa1p ATPase 
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activity.  Also, MAL3-101 and some MAL3-101 derivatives inhibit breast cancer cell 
proliferation.  This suggested that MAL3-101 is membrane permeable and targets at least one 
aspect that is vital for cell physiology.  Further, as MAL3-101 inhibited TAg, but not Ydj1p 
stimulation of Hsp70, it might exhibit some selectivity for TAg and not target all Hsp70/J 
domain interactions in the cell.  MAL2-11B was chosen because this compound fell into a 
different class of chaperone modulators than the MAL3-101 derivatives that inhibited breast 
cancer cell proliferation.  Specifically, MAL2-11B had a much more dramatic effect on TAg 
stimulation of Ssa1p, and may be a more potent compound in vivo.  Finally, I used MAL3-51 as 
a negative control since it is structurally similar to the previously identified chaperone 
modulators, but had no effect on Ssa1p ATP hydrolysis or on TAg stimulated Ssa1p ATP 
hydrolysis (FEWELL et al. 2004).   
In chapter 4.0, I present evidence that MAL3-101 and MAL2-11B have strikingly 
different effects in in vitro ATPase assays, despite similar attributes in single turnover assays.  
MAL2-11B, and to a lesser extent, MAL3-101, slightly inhibited the ATPase activities of Hsp70 
and Hsp90, suggesting that MAL2-11B might affect a broader range of proteins than MAL3-101.  
To further assess specificity, I investigated the effect of the compounds on TAg ATPase activity.  
In addition to dramatically inhibiting TAg stimulation of Hsp70, MAL2-11B also inhibited TAg 
ATPase activity independent of its effect on the TAg J domain.  To determine whether the 
activity of other AAA+ ATPases are altered by MAL2-11B, I incubated the hexamer of 
Minichromosome Maintenance proteins 2-7 (MCM2-7) in the ATPase assays.  Like TAg, the 
MCM hexamer plays an important role in eukaryotic DNA replication (MAIORANO et al. 2006).  
Indeed, MAL2-11B drastically reduced MCM ATPase activity.  Using viral plaque assays, I then 
showed that MAL2-11B, but not MAL3-101 inhibited SV40 replication by approximately 4.5 
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fold.  These results are consistent with the inhibition of both endogenous TAg ATPase activity 
and J domain-mediated stimulation of Hsp70 by MAL2-11B.  Finally, MAL2-11B inhibited 
DNA replication in vitro, a process that requires a functional TAg ATPase domain but not a 
functional J domain.  These data suggest that MAL2-11B and related compounds may serve as a 
novel class of AAA+ ATPase inhibitors that prevent SV40 viral replication. 
4.2 MATERIALS AND METHODS 
4.2.1 Reagents 
Ssa1p and TAg was purified as described previously (CANTALUPO et al. 1999; MCCLELLAN and 
BRODSKY 2000).  Purified MCM 2-7, kinesin, Hsp70, and wild type and the 5061 mutant form of 
TAg, were kind gifts from Matt Bochman, Troy Krzysiak, Doug Placais, and Paul Cantalupo, 
respectively.  Cidofovir was provided by Dr. Abhay Vats, from the Children’s Hospital of 
Pittsburgh.  Mammalian Hsp90α was purchased from Stressgen (SPP-776). 
4.2.2 Single turnover ATPase assay and ATPase assay 
Single turnover ATPase assays and ATPase assays were performed as described in Section 3.2.2 
and 3.2.3, respectively, and as published (CYR et al. 1992; FEWELL et al. 2004). 
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4.2.3 Viral plaque assay 
Plaque assays (Figure 48) were modified from a previously published protocol (TREMBLAY et al. 
2001).  A total of 5x104 BSC40 cells were plated in 200 µL MEM-10% FBS in each well of a 
96-well plate and grown overnight.  Then, 1x105 pfu of the SV40 virus were added to an 
Multiplicity of Infection (MOI)=~2 and two wells were left uninfected as mock infection 
controls.  After 2 hrs, the medium was changed and DMSO or a test compound was added to 
each well.  All treatments were performed in duplicate.  After two 2 days, the medium was 
changed again and the compounds or DMSO were re-added.   After 2 additional days, the 96 
well plates were frozen at -20° and the cells were lysed by three successive freeze/thaw cycles to 
obtain a viral stock.  The viral stocks were diluted 1,000 and 10,000 fold in MEM-10% FBS.  
Then, 500 µL of the each dilution was added, in duplicate, to freshly confluent BSC40 cells in 6 
cm dishes.  After 2 hrs, the medium was removed and 4 mL of a 50/50 mixture of melted 1.8% 
Bacto-agar and 2x MEM lacking phenol red was added to the cells.  The agar/media overlay was 
repeated on day 4 and day 7, but neutral red was added to a final concentration of 50µg/mL on 
day 7.  Plaques were counted on day 8 and 9.   
4.2.4 In vitro DNA replication assays 
In vitro DNA replication assays were performed as previously described (CASTELLINO et al. 
1997).  Briefly, a timecourse was performed using 25 µL reactions that included 100 ng 
pUC.HSO, which contains the SV40 origin of replication, 90 µg HeLa cell extract, 500 ng TAg, 
50 mM creatine phosphate, 2.5 µg creatine phosphokinase, and 2.5µCi α32P-dCTP in 30 mM 
HEPES, pH 7.8, 7 mM MgCl2, 100 mM EDTA, 1 mM DTT, 4 mM ATP, 0.2 mM CTP, 0.2 mM  
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Figure 48:  Viral replication is monitored by a viral plaque assay.   
See text for details. 
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UTP, 0.2 mM GTP, 25 µM dCTP, 100 µM dATP, 100 µM dTTP, 100 µM dGTP.  Where 
indicated, equal volumes of DMSO or a test compound were added.  Reactions were incubated 
for 2 hrs at 37° and 5 µL aliquots were removed every 30 min and added to 24 µL of Stop 
Solution (0.5% SDS, 10 mM Tris, pH 8.0, 5 mM EDTA, 0.3 mg/mL tRNA, and 1 mg/mL 
proteinase K) for 1 hr at 37°.  Samples were placed on ice until the experiment was completed.  
The reactions were precipitated with ethanol, resolved on 1% agarose gel, and stained with 
ethidium bromide to verify equal DNA loading.  The gel was dried and incorporated nucleotide 
was determined by phosphorimager analysis on a Fujifilm BAS-2500.  When the effects of 
specific compounds were examined, half reactions were performed in triplicate, using similar 
conditions.  Reactions were incubated at 37° for 1 hr at which time 50µL Stop Solution was 
added. 
4.3 RESULTS 
4.3.1 Modulators of TAg J domain stimulation of Hsp70 differentially affect the activities 
of other molecular chaperones 
Since MAL3-101 inhibited breast cancer cell proliferation (Section 3.3.4), I wanted to determine 
if the compound could affect other processes that require the functional interactions between 
Hsp70s and J-proteins.  As mentioned previously, the J domain of TAg is required, through its 
interaction with Hsp70, for various aspects of viral replication.  In addition, MAL3-101 inhibits 
TAg, but not Ydj1p, stimulation of Ssa1p ATP hydrolysis, indicating that it may preferentially 
inhibit TAg J domain-dependent processes.  I also examined MAL2-11B, which inhibits TAg 
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stimulation of Ssa1p more profoundly than MAL3-101 and therefore might be a more potent 
inhibitor of TAg- dependent SV40 replication. 
I first wanted to better characterize MAL3-101 and MAL2-11B in ATPase assays using 
mammalian Hsp70 and Hsp90, which are the presumed intracellular targets of these compounds 
during polyomavirus infection.  Since DSG binds to Hsp70 and Hsp90 with similar affinities 
(NADEAU et al. 1994), it was possible that our chaperone modulators might also affect the 
ATPase activities of both of these chaperones.  I performed an ATPase assay using 10 µg of 
mammalian Hsp70 and 300 µM MAL3-101, MAL2-11B, and MAL3-51.  In these ATPase 
assays, the compounds were preincubated with Hsp70 for 15 minutes on ice to allow the 
compound and protein to interact.  ATP was added to initiate the reactions and the reactions were 
incubated at 30°.   As predicted, MAL3-101, which had no effect on endogenous Hsp70 ATP 
hydrolysis, had little effect on mammalian Hsp70 ATP hydrolysis.  In contrast, despite having no 
effect on Hsp70 ATP hydrolysis in a single turnover assay, MAL2-11B inhibited steady-state-
like Hsp70 ATPase activity between 1.4 and 2-fold (Table 14 and Figure 49A).  In spite of this 
modest affect, the response was concentration dependent as addition of 30 µM and 100 µM 
MAL2-11B reduced the inhibition of mammalian Hsp70 ATPase activity (Figure 49B).  These 
results suggest that MAL2-11B does not inhibit Hsp70 ATPase activity, but slightly inhibits 
another step in the ATPase cycle, such as ATP binding or release.  Control reactions performed 
with MAL3-51 showed that this compound also minimally altered Hsp70 ATPase activity 
between 1.1 and 1.4 fold (Table 14 and Figure 49A) 
I next tested the effect of 300 µM of each compound on the ATPase activity of 10 µg 
mammalian Hsp90 (Stressgen).  MAL2-11B slightly inhibited Hsp90 ATP hydrolysis by ~2.3 
fold, whereas both MAL3-51 and MAL3-101 inhibited Hsp90 by less than 1.3 fold (Table 14,  
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Table 14:  The effect of MAL2-11B, MAL3-51, and MAL3-101 on various ATPases.  
 DMSO MAL2-11B MAL3-51 MAL3-101 
Hsp70 100 (2) 100 (3) 
57 (2) 
67 (3) 
107 (2) 
70 (2) 
114 (3) 
93 (3) 
Hsp90 100 (2) 43 (2) 92 (2) 79 (2) 
TAg 100 (2) 100 (2) 
23 (2) 
9 (2) 
85 (2) 
103 (1) 
92 (2) 
100 (1) 
MCM 100 (3) 5 (3) 98 (3) 102 (3) 
Kinesin 100 (2) -a 95 (2) 91 (2) 
  
All reactions were normalized to the slope of the DMSO control, which was set to 100%.  Each 
line represents a set of independent experiments.  The number in parentheses represents 
independent reactions for each experiment.  a=See discussion. 
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Figure 49:  MAL2-11B slightly inhibits the ATPase activity of Hsp70 and Hsp90.   
The ATPase activities of (A) 10 µg mammalian Hsp70 and (C) 10 µg mammalian Hsp90 were 
determined in the presence of DMSO (red diamond), or 300 µM MAL2-11B (blue circles), 
MAL3-51 (purple squares), and MAL3-101 (green triangles).  (B) Mammalian Hsp70 ATPase 
activity was determined in the presence of DMSO (red diamonds) or 30 µM MAL2-11B (purple 
circles), 100 µM MAL2-11B (green circles), or 300 µM MAL2-11B (blue circles). 
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Figure 49C).  Since the structure of DSG was used to develop structural algorithms that led to the 
identification of these compounds and binds to Hsp70 and Hsp90 (NADEAU et al. 1994), it is not 
surprising that some of our derivatives would also similarly affect both chaperones.     
As mentioned previously, MAL3-101 inhibits TAg, but not Ydj1p, stimulation of Ssa1p 
ATP hydrolysis.  However, the J-protein specificity of MAL2-11B had not previously been 
examined.  I therefore tested the specificity of MAL2-11B on Ydj1p stimulation of Ssa1p in a 
single turnover assay.  Even though equimolar Ydj1p stimulated Ssa1p to a similar extent as 
TAg, 300 µM MAL2-11B had very little effect on Ydj1p stimulated Ssa1p ATP hydrolysis 
(Figure 50).  This indicates that like MAL3-101, MAL2-11B, may be specific for the TAg 
interaction with Hsp70.      
4.3.2 MAL2-11B drastically inhibits the AAA+ ATPases SV40 TAg and MCM2-7 
Since MAL2-11B slightly inhibited the ATPase activity of Hsp70 and Hsp90, I investigated 
whether MAL2-11B altered the activities of other ATPases.  I first tested the effect of the 
compounds on TAg ATPase activity using 1 µg TAg.  Surprisingly, 300 µM MAL2-11B 
inhibited TAg ATPase activity between 4.4 and 11 fold (Table 14, Figure 51A).  This was in 
contrast to MAL3-51 and MAL3-101, which altered TAg ATP hydrolysis by only 1.0-1.2 fold 
(Table 14, Figure 51A).  In fact, the levels of ATP hydrolysis after addition of MAL2-11B to 
TAg was similar to the level observed for the TAg ATPase mutant, 5061 (Figure 51A), which is 
replication defective (CASTELLINO et al. 1997).  Preliminary data suggest that MAL2-11B 
inhibition of TAg is concentration dependent (data not shown).  These results indicate that the 
effect of MAL2-11B on TAg is not limited to the J domain and extends to at least the ATPase 
domain. 
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Figure 50:  MAL2-11B does not inhibit Ydj1p stimulation of Ssa1p.   
A single turnover assay was used to monitor Ssa1p ATPase activity in the presence of Ydj1p.  In 
the presence of DMSO, endogenous Ssa1p ATPase activity (black squares) was stimulated by 
Ydj1p (red squares).  MAL2-11B had no effect on endogenous Ssa1p ATPase activity (blue 
triangles) or Ydj1p stimulated Ssa1p ATPase activity (green triangles). 
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Figure 51:  MAL2-11B dramatically inhibits the ATPase activity of TAg and MCM.   
The ATPase activity of (A) mammalian 10 µg TAg and (B) 5 µg yeast MCM was determined in 
the presence of DMSO (red diamond), or 300 µM MAL2-11B (blue circles), MAL3-51 (purple 
squares), and MAL3-101 (green triangles).  In (A) the TAg ATPase mutant, 5061, is shown in 
light blue diamonds. 
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Since MAL2-11B inhibited TAg ATPase activity, I hypothesized that MAL2-11B might inhibit 
the ATPase activity of related AAA+ ATPases, such as the yeast AAA+ ATPase, MCM2-7.  
MCM is a heterohexamer composed of six MCM subunits named MCM2-7, which is proposed 
to be the replicative helicase in eukaryotic cells (MAIORANO et al. 2006).  To test this hypothesis, 
5 µg MCM2-7 was combined with 300 µM of each compound in an ATPase assay.  MAL2-11B 
virtually abolished MCM ATPase activity by decreasing it to 9% of the DMSO control (Table 
14, Figure 51B).  However, MAL3-51 and MAL3-101 had virtually no affect on MCM ATPase 
activity.  These results suggest that MAL2-11B may be a general inhibitor of AAA+ ATPases. 
 To determine if MAL2-11B inhibited all ATPases, I tested 300 µM of each compound on 
10 µg kinesin in the ATPase assays.  Kinesin binds microtubules and uses ATP hydrolysis to 
move along the microtubules (VALENTINE and GILBERT 2007).  MAL3-51 and MAL3-101 did 
not affect kinesin ATPase activity at 300 µM (Table 14).  However, MAL2-11B had an 
unexpected action on the ATPase activity of kinesin.  As mentioned previously, the protein and 
compound are preincubated on ice in the absence of ATP, in the ATPase reactions.  When 300 
µM MAL2-11B was added to kinesin, it stimulated kinesin ATPase activity while on ice, since 
the zero timepoint was much higher than in the DMSO control.  However, at later timepoints, no 
additional ATP hydrolysis was observed.  To further explore this phenomenon, I titrated MAL2-
11B into the kinesin ATPase assays.  At 100 µM MAL2-11B, the initial ATP hydrolysis on ice 
was also observed, but to a much lower extent and additional ATP hydrolysis was still detected 
at the later timepoints.  These results made interpretation difficult (See Discussion).  Further 
experimentation is required to determine the effect of MAL2-11B on kinesin.  Nonetheless, these 
results indicate that MAL2-11B inhibits AAA+ ATPases and represents the first-in-its-class 
compound with this activity. 
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4.3.3 MAL2-11B inhibits SV40 replication 
SV40 replication requires nearly every domain in TAg, including the J domain and ATPase 
domain (COLLINS and PIPAS 1995; SIMMONS et al. 1993).  Since MAL2-11B inhibited the 
function of both the TAg ATPase and the ability of the J domain to activate the ATPase activity 
of Hsp70, I decided to test if MAL2-11B also inhibited SV40 replication using viral plaque 
assays.  The assay was set up so the entire SV40 replication process occurred in the presence of 
the compound.  While this assay is quite time-consuming, it has distinct benefits over other 
techniques.  First, it assays the entire cycle of viral replication.  Other techniques, both in vitro 
and in vivo, focus on specific stages of infection such as E2F release, p53 stabilization, DNA 
replication, or virion assembly (COLLINS and PIPAS 1995; SPENCE and PIPAS 1994b; SULLIVAN et 
al. 2004).  However, since TAg inhibitors could act at many stages in the viral life cycle, it was 
imperative to monitor all stages during SV40 infection.  This assay also measures the yield of 
functional viruses.  By comparison, Andrei and colleagues examined specific small molecule 
inhibitors of SV40 and murine polyomavirus replication by observing the cytopathic effect 
(CPE) on UC1-B or BS-C-1 cells after infection (ANDREI et al. 1997).  This required 
microscopically observing the distinct phenotypes of infected cells and counting cells displaying 
the phenotype.  To obtain an IC50 (concentration where the CPE of infected cells is half the 
DMSO control), many drug titrations were required.  This approach required extensive 
microscopic analysis of infected cells and extensive drug titrations, and did not quantify 
functional viral output.  Indeed, a secondary screen was required to determine if functional virus 
was produced.  In addition, the Bocchetta lab created a highthroughput ELISA assay that 
identified a novel small molecule that inhibited the interaction between p53 and TAg (CARBONE 
et al. 2003).  While this approach successfully monitored the p53 and TAg interaction, it did not 
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examine whether the identified molecules subsequently inhibited viral replication or 
tumorigenesis.   
In viral replication assays, BSC40 cells, a monkey kidney cell line permissive for SV40 
replication, were plated in 96 well plates at an MOI=~2.  This MOI allowed all cells to be 
infected with virus.  This ensured a consistent infection, but did not “force” the compounds to 
inhibit multiple SV40 viruses within one cell.  The infection proceeded for 2-3 hours before the 
medium was changed.  This allowed virus uptake independent of any effect of the compounds, 
and ensured any inhibition observed would be due to inhibition of viral replication, and not to 
inhibition of initial viral uptake.  In addition, the compounds were added in duplicate to the 
SV40 infected cells twice over the four day incubation.  The compound was added twice since 
the half-life of the compounds in the medium or cells at 37° is unknown.  If the compounds 
prevent late stages in viral replication, adding fresh compound halfway through infection might 
inhibit replication that otherwise wouldn’t occur.   
To first establish the efficacy of using plaque assays to screen for anti-viral compounds, I 
titrated cidofovir into the assay.  Cidofovir is a cytosine analog and has been shown to inhibit 
mouse polyomavirus and SV40 viral growth (ANDREI et al. 1997).  This compound is currently 
being examined in clinical trials for its ability to treat BKVAN in children (GORCZYNSKA et al. 
2005; HYMES and WARSHAW 2006).   As shown in Figure 52, cidofovir showed a concentration 
dependent effect on SV40 replication, and inhibited viral replication at ~5 µg/mL, which is 
similar to the published concentrations of 3.8 µg/mL.  At higher concentrations (1600 µg/mL), 
cidofovir killed the cells, which was visualized by loss of surface adhesion by the cells (data not 
shown). 
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Figure 52:  Cidofovir inhibits SV40 replication in a concentration dependent manner.   
Cidofovir was titrated onto SV40 infected BSC40 cells.  The cells were lysed, viral stocks were 
collected, and titrated onto fresh BSC40 cells.  After 7 days, the viable cells were dyed and total 
plaque forming units (PFU) were determined.  Example plates from each dilution are shown. 
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Next, I added MAL2-11B, MAL3-51, and MAL3-101 to viral infected, BSC40 cells in 
the plaque assay.  At 100 µM, MAL2-11B inhibited viral replication by ~4.5 fold, whereas 
MAL3-51 and MAL3-101 had little effect (Figure 53).  A slight, but not statistically significant, 
decrease in viral replication was also observed using 30 µM MAL2-11B (data not shown).  At 
this point, it is unknown if the reduction in viral replication is due to MAL2-11B inhibition of the 
TAg J domain, the ATPase domain, or an additional unknown phenomenon.  However, as 
previously mentioned, 100 µM MAL2-11B was sufficient to reduce TAg stimulation of Hsp70 
(Figure 45C), and preliminary data suggest that 100 µM MAL2-11B also inhibits TAg ATPase 
activity.   
One way to determine the mechanism of inhibition of viral replication inhibition is to use 
compounds that are selective inhibitors of the TAg J domain or of the ATPase domain.  For 
example, MAL3-101 inhibited the TAg J domain stimulation of Ssa1p and had no effect on TAg 
ATPase activity.  Unfortunately at 100 µM, MAL3-101 was unable to affect the Hsp70/TAg 
interaction (Figure 42A), which may explain why 100 µM MAL3-101 does not inhibit viral 
replication.  Unfortunately, I was unable to add higher concentrations of MAL3-101 since it 
precipitates out of solution (data not shown).  Nonetheless, these results imply that MAL2-11B 
inhibits viral replication and may be a novel inhibitor of polyomavirus infection.   
4.3.4 MAL-11B inhibits SV40 DNA replication in vitro 
I hypothesized that inhibition of SV40 replication by MAL2-11B was due to the inhibition of 
viral DNA replication.  DNA replication requires both the J domain and ATPase domain of TAg 
(CASTELLINO et al. 1997; SRINIVASAN et al. 1997).  While the J domain is also required for 
virion assembly, most TAg J domain mutants cannot replicate DNA and never proceed to the  
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Figure 53:  MAL2-11B inhibits SV40 replication.   
Three independent experiments, each with two independent viral infections, were performed in 
the presence DMSO or 100 µM MAL2-11B, MAL5-51, or MAL3-101.  The number of plaques 
per condition was averaged for each experiment and the DMSO control was normalized to one.  
Example plates from a single experiment are shown. 
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virion assembly stage of infection.  In addition, the in vitro replication assay is well established 
and has been used extensively to characterize specific defects in TAg mutants (CASTELLINO et al. 
1997; OTT et al. 2002).  Finally, the results from an in vitro replication assay can be correlated 
with data from in vivo DNA replication assays by isolation of viral DNA after infection.   
To test my hypothesis, I added MAL2-11B, MAL3-51, and MAL3-101 to in vitro SV40 
DNA replication assays.  Since TAg is the only viral proteins required for replication, I 
combined TAg, HeLa cell extract, radioactive nucleotide, and DMSO or test compound with a 
plasmid containing the SV40 origin of replication (see Section 4.2.4).  I removed aliquots every 
30 min for 2 hrs, precipitated the products, and resolved the DNA by agarose gel electrophoresis.  
As shown in Figure 54A, TAg was required for DNA replication, and the appearance of high 
molecular weight DNA increased over time.  However, the addition of MAL2-11B abolished 
DNA replication.  MAL2-11B also inhibited background DNA repair as evidence by the 
disappearance of the low molecular weight DNA ladder.  Next, the compounds were titrated into 
the DNA replication assay in triplicate and the reactions were stopped after 60 minutes.  As 
shown in Figure 54B, MAL3-51 and MAL3-101 had no significant effect on DNA replication, 
whereas MAL2-11B inhibited replication in a concentration dependent manner. 
I then hypothesized that MAL2-11B-like activity might be found in the other structurally 
related compounds discussed in Section 3.3.5.  As shown in Figure 55, I titrated two structurally 
related compounds, DMT002272 and DMT003036, into the in vitro replication assay.  These 
compounds were the product of Biginelli reactions and were identical to MAL2-11B except the 
aldehyde was varied.  These compounds also inhibited DNA replication, though to a lesser extent 
than MAL2-11B.  However, these effects correlate with the relative abilities of these molecules 
to decrease the TAg J domain stimulation of Ssa1p ATPase activity.  Future studies will test if  
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Figure 54:  MAL2-11B inhibits in vitro DNA replication.  
In vitro DNA replication assays were performed in the presence of DMSO or 300 µM of the 
indicated compound.  (A)  A replication time-course was performed and the replicated DNA was 
resolved on an agarose gel. The TAg ATPase mutant 5061 was tested as a control.  (B)  Three 
replicates of each condition were performed and quantified.  Compounds were tested at 30 µM, 
100 µM, and 300 µM.  
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Figure 55: MAL2-11B related compounds in the Biginelli acid class also inhibit in vitro DNA replication.   
An in vitro DNA replication assay was performed in the presence of the indicated compounds.  
The effect of the compounds was examined at tested in triplicate at 30 µM, 100 µM, and 300 
µM. 
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these compounds inhibit TAg ATPase activity or SV40 replication.  Taken together, my results 
indicate that MAL2-11B, and related compounds, inhibit SV40 DNA synthesis in vitro and may 
explain how MAL2-11B inhibits SV40 replication in vivo. 
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5.0  DISCUSSION 
Chaperones are essential for the maturation and localization of cellular proteins and are thus 
involved in nearly every aspect of cellular function.  Given this, it is not surprising that many 
common diseases are directly related to chaperone level and function in the cell (AMARAL 2004; 
BARRAL et al. 2004; JOLLY and MORIMOTO 2000; SMITH et al. 2005).  It is also not surprising 
that viruses have evolved the ability to corrupt chaperone function to allow viral replication.  
One example of this is seen with the SV40 protein, TAg, which is essential for viral replication 
and transformation (SRINIVASAN et al. 1997; SULLIVAN et al. 2000a).  One major goal of this 
dissertation was to further characterize the role of SV40 TAg in replication and cellular 
transformation.  To this end, I screened for novel TAg J domain interacting proteins using a yeast 
multi-copy suppressor screen.  While I did not identify any unknown TAg J domain interacting 
proteins, I did identify a novel connection between the yeast cell wall and the cytosolic 
chaperones Hsp40 and Hsp90 (Chapter 2.0).  A second goal of this dissertation was to identify 
small molecules that inhibited TAg J domain stimulation of Hsp70, which could then be used to 
inhibit SV40 replication and other Hsp70-associated diseases such as breast cancer.  I identified 
several classes of chaperone modulators, including ones that selectively inhibit TAg stimulation 
of Hsp70.  Select compounds in this class were shown to inhibit breast cancer cell proliferation 
(Chapter 3.0) or SV40 replication (Chapter 4.0).  In the following pages, I summarize the results 
from each project and discuss the importance of the data and future efforts. 
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5.1 A MULTI-COPY YEAST SUPPRESSOR SCREEN IDENTIFIES A ROLE FOR 
MOLECULAR CHAPERONES IN THE YEAST CELL WALL  
To identify novel TAg interacting proteins, I performed a yeast multi-copy suppressor screen.  I 
screened for multi-copy suppressors of the K53R temperature sensitive mutation in the TAg-
Ydj1p chimeric protein, T(K53R)-Ydj1p.  I chose to use this mutation because it was in helix III 
of the J domain and NMR perturbation studies using DnaJ (GREENE et al. 1998) suggested that 
the solvent-exposed region in helix three that is occupied by the K53 residue would not be in 
contact with Hsp70.  Since this mutation inhibited viral replication, transformation, and 
chaperone activity (FEWELL et al. 2002), I predicted that it interacted with a novel protein.  
Despite this, even if the K53R mutation unexpectedly disrupted the interaction with Hsp70, a 
yeast multi-copy suppressor screen might still identify proteins that act in concert with Hsp70, or 
in parallel pathways to this J-protein.    
As hoped, the yeast suppressor screen identified several genes that rescued to some 
degree the thermosensitive phenotype of ydj1Δ yeast expressing T(K53R)-Ydj1p.  Since we 
predicted that Hsp70 interacts with helix II of the TAg J domain, we were surprised that one of 
these genes was the Hsp70-encoding SSA1 gene.  There are two general explanations for this 
result.  First, it is possible that additional copies of Hsp70 in the cell “fix” the aberrant 
conformation conferred by the K53R mutation; second, higher levels of Hsp70 might improve 
the function of a protein or process that lies downstream of the K53R-induced phenotype.  In 
support of a direct interaction between Hsp70 with K53R, more recent NMR data suggests that 
Hsp70 interacts with additional residues in the polyomavirus J domain than in the DnaJ J 
domain, including residues on helix III (GARIMELLA et al. 2006).  My results suggest that Hsp70 
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also interacts with helix III of SV40 TAg and that the screen can identify J domain-interacting 
proteins. 
Another, weaker, suppressor of the T(K53R)-YDJ1 phenotype that we identified was 
CIS1.  In a previous study, CIS1 was identified as a suppressor of a cik1Δ phenotype (MANNING 
et al. 1997).  Cik1p cooperates with the Kar3p microtubule motor protein to catalyze karyogamy 
and chromosome segregation (PAGE and SNYDER 1992).   Uncovering CIS1 as a weak suppressor 
of the T(K53R)-YDJ1 phenotype may be indicative of a link between Ydj1p function and 
microtubule homeostasis.  In fact, Ssa1p and Ydj1p were previously suggested to be important 
for microtubule formation, and more specifically strains containing either an ssa1 temperature 
sensitive allele (ssa1-134) or that were deleted for YDJ1 showed irregular microtubule assembly 
at the non-permissive temperature after nocodazole treatment (OKA et al. 1998).  Moreover, both 
the ssa1-134 and ydj1Δ alleles exhibit synthetic interactions with tub4-1, which is a temperature 
sensitive allele in the gene encoding γ-tubulin.  Therefore, improved growth of the T(K53R)-
YDJ1-containing ydj1Δ strain by CIS1 over-expression may be due to the rescue of a residual 
microtubule defect.  Thus, it is unlikely that Cis1p is a novel TAg J domain interacting protein. 
One rationale for why the multi-copy suppressor screen did not identify novel TAg J 
domain interacting proteins is that I used a yeast genomic library.  I chose this library because 
the yeast genome is small and well annotated and I predicted that J domain interacting proteins 
would be conserved.  However, it is possible that over-expression of select mammalian proteins 
could rescue the temperature sensitive defect of T(K53R)-Ydj1p.  I therefore tested four 
mammalian proteins for the ability to restore growth of ydj1Δ yeast expressing T(K53R)-Ydj1p 
or ydj1Δ.  I first tested human HspBP1 and BAG-1S because these are NEFs (HOHFELD and 
JENTSCH 1997; KABANI et al. 2002b) that might stimulate Hsp70 in the presence of a defective 
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Ydj1p cochaperone.  Over-expression of these proteins did not improve growth in the ydj1Δ 
yeast expressing T(K53R)-Ydj1p.  Unexpectedly, BAG-1S partially restored growth in the ydj1Δ 
strain, suggesting that it can aid Hsp70 function in the absence of cochaperone.  I also tested the 
over-expression of Cul7, which may direct a TAg-interacting protein for ubiquitination and 
proteasomal degradation (ANDREWS et al. 2006; DIAS et al. 2002).  Cul7 is of further interest 
since the TAg interaction with Cul7 is involved in cellular transformation and Cul7 binds to the 
TAg J domain in the extended loop between alpha helix three and four, which is present in the 
chimeric T-YDJ1 construct used in my studies (KASPER et al. 2005).  It is currently unclear if the 
chaperone function of the J domain is required for Cul7 dependent transformation.  
Unfortunately, over-expression of Cul7 did not improve the growth of the ydj1Δ strains 
expressing T(K53R)-Ydj1p.  Interpretation of these results is difficult since there are many 
reasons why a mammalian protein could be non-functional in yeast.  Finally, I attempted to 
examine if over-expression of PKCη could restore growth of ydj1Δ yeast.  I predicted it would 
restore growth in ydj1Δ yeast since over-expression of PKC1 in ydj1Δ yeast cells improves 
growth and PKCη can functionally replace PKC1 in yeast (NOMOTO et al. 1997).  Unfortunately, 
over-expression of PKCη was toxic to the ydj1Δ yeast cells.  This could have been due to the 
high expression levels produced using the GPD promoter and these experiments should be 
repeated using a weaker promoter. 
Despite the fact that “Factor X” was not identified using this screen, the screen still 
revealed a novel connection between the cell wall and cytosolic chaperones (WRIGHT et al. 
2007). Specifically, I found that the growth of ydj1Δ and hsp82 temperature sensitive yeast is 
improved by conditions that restore the viability of cells with mutations in cell wall components 
or regulators of cell wall biogenesis.  I also found that the growth of these strains is hindered by a 
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compound that intercalates into the cell wall.  In addition, I discovered that the viability of the 
ydj1Δ and hsp82 temperature sensitive strains is improved by the over-expression of Mid2p—a 
cell wall component that is thought to sense the integrity of this structure and activates the PKC 
pathway when cell wall architecture is compromised (LEVIN 2005)—and by the over-expression 
of Pkc1p and activated components in the PKC pathway, which are known to trigger increased 
synthesis of cell wall components (IGUAL et al. 1996).  Previous work indicated that the PKC 
pathway induces the synthesis of cell wall glycoproteins and proteins involved in cell wall 
biosynthesis, including Fks1p and Fks2p (β1,3-glucan synthase) and Chs3p (chitin synthase) 
(JUNG and LEVIN 1999), and that Mid2p over-expression increases the chitin concentration in the 
cell wall (KETELA et al. 1999).  Indeed, we found that Mid2p over-expression is sufficient to 
thicken the cell wall in yeast lacking YDJ1, which provides a rationale for why we identified 
MID2 as the strongest suppressor of the ydj1Δ slow-growth phenotype. 
Besides identifying MID2 and the PKC pathway as moderate suppressors of the slow-
growth phenotype of ydj1Δ yeast, our screen uncovered several other genes with links to cell 
wall homeostasis and to the PKC pathway.  For example, Syp1p, was discovered as a suppressor 
of yeast profilin deletion (pfy1Δ) (MARCOUX et al. 2000) and Cis1p was uncovered as a 
suppressor of a cik1Δ yeast strain (MANNING et al. 1997).  Whereas Syp1p helps polarize actin 
patches, little else is known about Cis1p.  Both of these previously published screens also 
uncovered Mid2p and Rom2p—another upstream component of the PKC pathway—as 
suppressors, which suggest potential links between Syp1p and Cis1p and the PKC pathway.  In 
addition Cyc8p/Ssn6p, which is found in a co-repressor complex with Tup1p, regulates genes 
under a wide array of stress conditions, including growth in hypertonic media (PROFT et al. 2001; 
PROFT and STRUHL 2002).  Finally, SKN1 is a Golgi-resident protein with an ill-defined role in 
 227 
β1,6-glucan synthesis and is homologous to KRE6, which exhibits synthetic interactions with 
PKC1, MPK1, and MKK1/MKK2; moreover, Kre6p over-expression can rescue a pkc1Δ lysis 
defect (ROEMER et al. 1994).  In contrast, we were surprised to find that the over-expression of 
CHS5, which is involved in the transport of chitin synthase from the Golgi (SANCHATJATE and 
SCHEKMAN 2006), did not rescue the slow growth phenotype of ydj1Δ yeast. 
Interestingly, suppression of the ydj1Δ slow growth phenotype was copy number 
dependent.   For example, the over-expression of T(K53R)-YDJ1 gene partially restored growth 
of ydj1Δ yeast.  While the ydj1Δ strain has a slow growth phenotype at 30°, expression of 
T(K53R)-YDJ1 behind the moderate TEF promoter rescued the slow growth phenotype at 30°, 
but was temperature sensitive at 35°.  In addition, expression of T(K53R)-YDJ1 behind the strong 
GPD promoter allowed the growth of ydj1Δ yeast at both 35° and 37°.  These results suggest that 
T(K53R)-YDJ1 is  partially functional, which correlates with results on its in vitro  activity 
(FEWELL et al. 2002).  Since the only difference between these strains is T(K53R)-YDJ1 copy 
number, these results also indicate that the amount of Ydj1p is important for growth. 
Plasmid number was similarly essential for suppression of the T(K53R)-YDJ1 
temperature sensitive phenotype by many of the suppressors.  For example, SYP1 and CYC8 did 
not restore growth of the ydj1Δ strain expressing T(K53R)-Ydj1p when expressed on a CEN 
plasmid, but improved growth when copy number was increased by expression on a 2µ plasmid.  
Finally, the partial function of T(K53R)-Ydj1p was responsible for the discovery of extremely 
weak suppressors.  The ydj1Δ strain required expression of both T(K53R)-Ydj1p and the 
suppressors to even partially rescue growth at 35°.  This effect was also seen in the ydj1Δ strain 
independent of T(K53R)-YDJ1.  For example, when BCK1-20 and MKK1DD were expressed on a 
CEN plasmid, they were unable to improve the growth of the ydj1Δ strain (data not shown).  
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However, when BCK1-20 and MKK1DD were expressed on a 2µ plasmid, they were able to 
improve the growth if the ydj1Δ strain (Figure 20).  Knowing this, I predict that SKN1 would also 
improve the growth of the ydj1Δ strain if expressed on a 2µ plasmid.  Skn1p is involved in β,1-6 
glucan synthesis and is functionally homologous to Kre6p (ROEMER et al. 1993), which has 
genetic links to the PKC pathway.  I hypothesize that SKN1 was obtained in the screen because it 
strengthened the cell wall like the other suppressors, and not because it directly interacted with 
T(K53R)-Ydj1p.  Despite this, I still believe SSA1 and CIS1 are direct suppressors of the 
T(K53R)-YDJ1 phenotype as discussed above since increased copy number of Ssa1p is toxic to 
the ydj1Δ cells and CIS1 was expressed from a 2µ plasmid.  Immunoblots are needed to verify 
Cis1p expression level.  Cis1p expression could also be altered by expression behind several 
promoters to verify that increased expression does not rescue growth of the ydj1Δ strain. 
These studies leave several questions unanswered.  First, what is the role, if any, of Ssa1p 
in cell wall integrity?  In most instances Hsp40 function is intricately linked to Hsp70 function 
and does not function independent of Hsp70 in the Hsp90 complex.  Thus, we were surprised 
that over-expression of Mid2p or components in the PKC pathway failed to rescue the ssa1-45 
thermosensitive phenotype.  One interpretation of this result is that Hsp40 and Hsp90, but not 
Hsp70, play a role in cell wall biosynthesis, and we note that in vitro experiments suggested that 
Ydj1p and Hsp82p may hold PR in a hormone binding competent state independent of Ssa1p 
(HERNANDEZ et al. 2002).  However, another interpretation of this result is that allele-specific 
interactions underlie the ability of Mid2p and Pkc1p to improve the growth of ydj1Δ and hsp82, 
but not ssa1-45 yeast.  It is important to mention that the G170D and G313N mutations are in the 
Hsp82 ATPase domain and middle region, respectively (FLISS et al. 2000; NATHAN and 
LINDQUIST 1995), and have been shown to affect protein stability and Hsp82p client protein 
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activation (BOHEN 1995; LEE et al. 2002; YOUKER et al. 2004).  In contrast, the ssa1-45 allele 
encodes a P417L mutation in the peptide binding domain of Ssa1p (BECKER et al. 1996) and has 
been shown to compromise protein folding, translocation, and ER associated degradation 
(BECKER et al. 1996; KIM et al. 1998b; ZHANG et al. 2001).  Moreover, the hsp82 mutations 
reside in a strain that lacks chromosomal copies of HSP82 and HSC82, whereas the ssa1-45 
mutation resides in a strain that lacks the SSA2, SSA3, and SSA4 genes.  Unfortunately, no other 
tight ssa1 temperature sensitive strains exist in which we can further explore this phenomenon, 
and it is not clear how the necessary strain backgrounds for these studies impact the effects on 
cell wall integrity/signaling that we observed.   
These results also lead to a second question: What is the nature of the cell wall defect in 
ydj1Δ yeast?  As mentioned previously, pkc1Δ yeast have a thin cell wall, which is likely the 
cause of osmotic sensitivity.  However, as shown in Figure 35, the cell wall in ydj1Δ yeast is not 
thinner than in wild type yeast.  I propose that the cell wall of ydj1Δ yeast has reduced β1,6-
glucan relative to wild type yeast.  As described previously, 80-90% of the yeast cell wall is 
composed of β1,3-glucan and β1,6-glucan acts as the “glue” to hold it together.  While β1,3-
glucan and chitin are synthesized at the cell wall, it is unknown where β1,6-glucan is 
synthesized.  One hypothesis is that β1,6-glucan is synthesized in the secretory pathway since 
defects in many secretory proteins lead to a cell wall defect.  A second hypothesis is that a 
protein required for β1,6-glucan synthesis requires the secretory pathway for maturation.  Since 
Ydj1p is involved in translocation of nascent polypeptide chains into the ER (CAPLAN et al. 
1992), Ydj1p may also be involved in β1,6-glucan synthesis.  This is particularly intriguing since 
I identified SKN1 as a suppressor of T(K53R)-YDJ1 (and potentially ydj1Δ, see above).  I 
propose that the defect in the ydj1Δ strain is due to a decrease in the amount of β1,6-glucan, 
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which makes a weaker, but not thinner, cell wall.  This would be consistent with the EM data.  
To test this hypothesis I would determine the amount of each cell wall component in ydj1Δ and 
wild type cells, by isolating the total alkali-insoluble glucan and using zymolyase to remove the 
β1,3-glucan.  This process is relatively easy and the technique has been performed in many labs 
(MACHI et al. 2004; ROEMER et al. 1993).  If this hypothesis is correct, these results would be the 
first to implicate cytosolic chaperones in β1,6-glucan synthesis. 
 There are still many unanswered questions about the connections between the cell wall 
integrity pathways.  For example, it has been shown that activation of the HOG pathway leads to 
inactivation of the PKC pathway (MAGER and SIDERIUS 2002).  Also, several connections 
between the two pathways and molecular chaperones exist.  First, many kinases in all three 
pathways are probable Hsp90 substrates, such as Hog1p, Kss1p, and Mpk1p (MILLSON et al. 
2005) as shown by yeast two hybrid.  Second, the Hsp90 temperature sensitive strains have 
different phenotypes on medium with high sorbitol.  Two Hsp90 temperature sensitive mutants 
(T22I and G81S) are sensitive to high sorbitol, which is a phenotype consistent with mutations in 
HOG pathway members (YANG et al. 2006) and these mutants and two other Hsp90 temperature 
sensitive mutants (G170D and G313N) are sensitive to calcofluor white, which is indicative of 
mutations in the PKC pathway (YANG et al. 2006).  Third, I uncovered CYC8 as a suppressor of 
the ydj1Δ strain.  Cyc8p is a transcriptional repressor that is converted by Hog1p to an activator 
during osmotic stress.  
To address the degree of cross-talk between the pathways and their role in mediating the 
ydj1Δ phenotype, I over-expressed two genes from the HOG pathway (HOG1 and PBS2) and 
two genes from the SVG pathway (KSS1 and STE7).  None of these genes rescued the ydj1Δ 
slow growth phenotype.  Trivially, this could be due to lack of expression, though Hog1p 
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expression was verified by western blot analysis (Figure 22C).  Another hypothesis is that 
constitutively activated members of the pathways could restore growth in the ydj1Δ strain.  Most 
studies of the downstream members of the signaling pathways use strains with deletions of the 
upstream kinases that must express constitutively activated downstream components.  Without 
the upstream components, the wild type proteins are not properly phosphorylated in response to 
stress and are nonfunctional.  However, studies on the cross-talk between the pathways do not 
require strains with mutations in the upstream components and therefore do not require 
constitutively active proteins.  Nonetheless, it is possible that constitutively active forms of these 
kinases could rescue the ydj1Δ slow growth defect.  To further investigate this proposal in my 
system, I would test constitutively expressed versions of HOG1 and STE7 genes (YAAKOV et al. 
2003; YASHAR et al. 1995) to see if they rescue ydj1Δ yeast. 
Even though activation of the PKC pathway suppressed the ydj1Δ strain slow growth 
defect independent of T(K53R)-YDJ1, the results presented here suggest a putative connection 
between TAg J domain function and the PKC pathway.  Previous work demonstrated that TAg 
blocked the apoptotic response upon EGF withdrawal from mouse embryo cells (SLINSKEY et al. 
1999), and chemical inhibition of the PKC pathway also inhibited apoptosis (A. SLINSKEY and 
J. M. PIPAS, unpublished data).  In addition, the amount of an uncharacterized PKC 
phosphorylated substrate decreased in mouse intestines upon TAg expression (R. BEERMAN, 
M. T. SAENZ-ROBLES, J. M. PIPAS, unpublished data). While these results suggest a 
connection between TAg and PKC, much more work is clearly needed to define how the TAg J 
domain impacts the PKC pathway. 
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5.2 MAL3-101 AND RELATED COMPOUNDS INHIBIT BREAST CANCER CELL 
PROLIFERATION 
Since Hsp70s and Hsp40s are involved in a plethora of human diseases and since there are very 
few chaperone modulators that have been identified, I screened for novel modulators of Hsp70 
and Hsp40 activity.  Prior to these studies, only a few Hsp70s modulators, including the 
structurally similar DSG and R/1 compounds had been described.  DSG stimulated two different 
Hsp70s, Ssa1p and bovine Hsc70, in steady state assays, but had no effect on cochaperone 
stimulation by Ydj1p (BRODSKY 1999).  However, DSG lacked specificity as it bound Hsp70 and 
Hsp90 with similar affinities (NADEAU et al. 1994).  On the other hand, R/1 inhibited Ssa1p ATP 
hydrolysis in steady state assays and stimulated Ssa1p ATP hydrolysis in single turnover assays 
(FEWELL et al. 2001; FEWELL et al. 2004).  I was particularly interested in R/1 because it also 
inhibited TAg stimulation of Hsp70.  Unfortunately, R/1 is relatively large, insoluble, and 
difficult to obtain.  I hypothesized that compounds that were structurally similar to R/1 might 
have similar in vitro effects on Hsp70 and TAg.  The identification of structural analogs might 
allow for the identification of a structural motif responsible for chaperone modulating function 
and lead to the synthesis of more potent and soluble derivatives.  
We therefore obtained 30 compounds that were structurally similar to DSG and R/1 from 
the Wipf lab at the University of Pittsburgh and from the NCI.  Dr. Fewell tested the compounds 
for effects on endogenous Ssa1p ATPase activity using single turnover assays.  Since ATP is 
prebound to Hsp70, this assay is specific for ATP hydrolysis and does not measure ATP binding 
or release.  I then tested the effect of 12 of the compounds on TAg stimulation of Hsp70 ATPase 
activity.  I chose TAg as my model J-protein for two main reasons.  First, it is required for SV40 
replication and transformation and any compounds that modified TAg activity could be potential 
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treatments for any virus-induced disease.  Second, it is relatively easy to purify in high quantities 
and contains very few contaminants.  Three distinct classes of chaperone modulators were 
identified during the screen:   
Class 1.  Compounds in this class stimulated endogenous Ssa1p ATP hydrolysis and had 
an overall inhibitory effect on TAg stimulation of Ssa1p.  This class can be divided into two 
subclasses.  Class 1A is characterized by MAL3-55 which slightly stimulated the rate of Ssa1p 
ATP hydrolysis by 1.4 fold and inhibited TAg stimulation by 1.8 fold by decreasing both the 
initial slope and the overall amplitude.  It is likely that when the compound stimulates 
endogenous Ssa1p ATP hydrolysis this leads to a change in the protein that prevents complete 
stimulation by cochaperone (though the compounds could be directly interfering with the 
cochaperone as well).  One possibility is that the hydrophobic characteristics of the compounds 
in this class mimic peptide binding.  It would be interesting to perform single turnover assays in 
the presence of peptide and chaperone modulators.  An example of Class 1B is MAL3-90.  
Compounds in this class dramatically stimulate Ssa1p ATPase activity.  Addition of cochaperone 
leads to a “burst” which increases ATP hydrolysis to higher levels than with cochaperone alone.  
However, this is immediately followed by a decrease in amplitude and an overall inhibitory 
effect.  It has been previously shown that rapid stimulation of Hsp70 ATPase activity can lead to 
polymerization of the Hsp70 molecules (KING et al. 1999).  It is possible that the compounds 
stimulate Hsp70 polymerization and thus prevent the reaction from reaching completion.   
Class 2.  This class was exemplified by MAL3-101, which has no effect on Ssa1p ATP 
hydrolysis but inhibited TAg stimulated ATP hydrolysis.  There are two models that I propose 
for the mechanism of action of this class of compounds.  First, MAL3-101 may directly prevent 
interaction between the J domain and Hsp70.  I have begun to address this hypothesis by 
 234 
precipitating Ssa1p in the presence or absence of GST-Hlj1p-His and/or MAL3-101.  
Preliminary results suggest that MAL3-101 does not interfere with the interaction between the 
two chaperones.  However, the low MAL3-101 concentration used and potential for MAL3-101 
J domain specificity make interpretation of these results difficult.  A second possibility is that 
MAL3-101 interferes with the stimulation of Hsp70 independent of chaperone-cochaperone 
interaction.  The most-straightforward way to differentiate between these two models is to 
determine the binding site of the compound on Hsp70 or the J-protein.  In collaboration with Dr. 
E. Zuiderweg at the University of Michigan, these experiments are in progress. 
Class 3.  Some compounds tested, such as MAL3-51, had little effect on either the Ssa1p 
ATPase activity or TAg stimulated ATPase activity.  Despite the fact these compounds had little 
effect on chaperone activity, compounds in this class will help identify a minimal functional 
group required for chaperone modulation.  Since there are only slight differences between each 
compound’s structure, the changes that disrupt the chaperone modulating activity of these 
compounds may help us to identify which regions of the other compounds are necessary for 
function. 
The complexity of the compounds and the distinct classes has made determination of an 
SAR difficult.  As a next step toward this goal, I decided to examine a set of six compounds that 
were half the mass of previous compounds, but had many structural components in common.  If 
these compounds affected chaperone activity, they could represent the minimal pharmocophore 
required for chaperone modulation.  I tested these compounds in an Ssa1p single turnover assay 
in the presence or absence of TAg.  Five of the compounds had similar kinetics as members of 
Class 1B described earlier.  These compounds stimulated endogenous Ssa1p ATPase activity and 
initially increased TAg stimulation of Ssa1p, but decreased the overall amplitude of the reaction. 
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The sixth compound was a member of Class 2 and selectivity inhibited TAg stimulation of 
Ssa1p.  These compounds may represent the minimal pharmocophore of their respective classes. 
Since these compounds had a much lower mass, and thus were more likely to be soluble 
than previously identified compounds, I decided to test them in an in vivo assay to see if they 
could modulate Hsp70 activity in vivo.  I also decided to test MAL3-101 since previous evidence 
using in vitro translocation assays suggested that it was membrane permeable (FEWELL et al. 
2004).  Yeast ER translocation requires two sets of Hsp70/Hsp40 chaperones, the cytosolic 
chaperones, Ssa1p and Ydj1p, and the ER luminal Kar2p and Sec63p (CAPLAN et al. 1992; 
DESHAIES et al. 1988; ROTHBLATT et al. 1989; VOGEL et al. 1990).  In translocation assays, 
MAL3-101 inhibited pre-pro-α-factor (ppαF) translocation, suggesting that one, or both, of these 
chaperone pairs is inhibited by MAL3-101.  However, translocation assays were performed with 
ppαF denatured with 8 M urea, which eliminates the need of Ssa1p or Ydj1p during 
translocation.  Even with denatured ppαF, MAL3-101 inhibited translocation, which suggested 
that the compound is membrane permeable and interferes with the interaction between Kar2p 
and Sec63p. 
I chose to test the compounds using a breast cancer cell proliferation assay.  In this assay, 
the compounds are added to actively growing cells and after several days the total number of 
living cells is determined using the colorimetric indicator, MTS.  The cell proliferation assay was 
chosen to test the compounds for several reasons. First it is high throughput which is important 
for studying large numbers of compounds.  Since the single turnover assays are not high 
throughput, the cell proliferation assay could serve as a primary screen for compound activity 
and the single turnover could be a secondary assay to determine chaperone modulation.  Second, 
the cell proliferation assay requires the compounds to be membrane permeable and also allows 
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testing a variety of cell lines.  I chose to examine the effects of the compounds on breast cancer 
cell proliferation since these cells over-express Hsp70 and may be susceptible to modulation of 
Hsp70 activity.  In fact, reduction of Hsp70 levels by antisense RNA is sufficient to induce 
breast cancer cell apoptosis (NYLANDSTED et al. 2000). 
Guangyu Zhu from the Day lab at the University of Pittsburgh examined the 6 
compounds with the putative minimal pharmocophores and MAL3-101 for their effects on the 
proliferation of SK-BR-3 breast cancer cells.  The six Hsp70 modulators identified in the second 
round of screening had no effect on SK-BR-3 cells, but MAL3-101 inhibited proliferation of two 
different breast cancer cell lines, SK-BR-3 and MDA-MB-468, in the low micromolar range.  
These cell lines have been shown to be susceptible to Hsp70 antisense RNA treatment 
(NYLANDSTED et al. 2000).  To test MAL3-101 specificity, G. Zhu used the WI-38 fibroblast cell 
line, which when treated with Hsp70 antisense RNA, did not undergo apoptosis (NYLANDSTED et 
al. 2000).  Unexpectedly, MAL3-101 also inhibited WI-38 cell proliferation at similar 
concentrations.  However, MAL3-101 is not universally toxic as it does not inhibit the 
proliferation of BSC40 cells (see below). This indicates that MAL3-101 is not specific for breast 
cancer cells, but this may be in part due to the relatively low compound affinity.  Potentially, 
more soluble or potent MAL3-101 derivatives may increase specificity. 
I propose several models for the mechanism of MAL3-101 inhibition of cellular 
proliferation.  First, the compound might be inhibiting chaperone-dependent cell growth.  As 
previously described chaperones play important roles in most cell processes and it would not be 
surprising if reduction in Hsp70 activity was sufficient to slow cellular growth or even stall 
growth at a particular stage in the cell cycle.  This hypothesis could be tested by determining 
relative DNA content in the cells using flow cytometry.  Second, it is possible that the MAL3-
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101 initiates apoptosis.  Unpublished results from the Chiosis lab suggest that MAL3-101 
initiates apoptosis in the SK-BR-3 cell line as indicated by caspase-3 and PARP cleavage and 
caspase-3 activation.  Regardless of which model is correct, it is also possible that MAL3-101 
acts independently of Hsp70/J-proteins in the cell, and affects another, unknown, target.  Some 
specificity studies have been performed and will be discussed in more detail below.  However, it 
is clear that MAL3-101 does not affect all ATPases as it has minimal effect on mammalian 
Hsp70, mammalian Hsp90, TAg, MCM, or kinesin ATPase activity. 
To obtain additional structural information on MAL3-101 and to attempt to find more 
soluble, potent compounds, 42 derivatives of MAL3-101 were synthesized (WERNER et al. 2006) 
and tested in the breast cancer proliferation assay using the SK-BR-3 cell line.  These results 
were then correlated to in vitro affects on Hsp70 ATPase activity and TAg stimulation of Hsp70.  
The compounds that inhibited breast cancer proliferation fell into distinct chemical classes, and 
this was directly related to chaperone modulation.  The classes are discussed in detail below. 
Class A.  Biginelli acids.  These compounds are the product of a Biginelli reaction, and 
were not subsequently reacted in an Ugi reaction.  The aldehyde group used in the Biginelli 
reaction was varied to obtain structural diversity.  These compounds had no effect on breast 
cancer cell proliferation, though they had similar effects on MAL3-101 in the single turnover 
assays; i.e., they had no effect on Ssa1p ATP hydrolysis, but inhibited TAg stimulation of Ssa1p.  
It is unlikely that a lack of membrane permeability is responsible for the lack of effect on breast 
cancer cells because MAL2-11B is represented in this class, and as described below, this 
compound inhibited viral replication in vivo.  Further characterization of this class will be 
discussed below. 
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Class B.  Biginelli esters.  These compounds are also the product of only a Biginelli 
reaction, except the Biginelli reactions utilized several esters instead of aldehydes to obtain 
structural diversity.  These compounds had no effect on breast cancer cell proliferation and had 
novel effects in the single turnover assays.  These compounds stimulated Ssa1p ATP hydrolysis, 
but had no effect J domain stimulation of Ssa1p.  These compounds represent a unique class of 
chaperone modulators not discovered in previous screens. 
Class C. Ugi 1.  These compounds were the products of successive Biginelli and Ugi 
reactions.  The Biginelli reactants were the compounds from Class A, which were then reacted in 
an Ugi condensation reaction.  Most compounds in this class inhibited breast cancer proliferation 
with a GI50 lower than 10 µM.  These compounds had very similar effects as MAL3-101 in 
relation to both endogenous Ssa1p ATP hydrolysis and TAg stimulated ATP hydrolysis.  Thus, it 
is likely that the Ugi reaction is important for conferring the ability of the compounds to inhibit 
breast cancer cell proliferation. 
Class D. Ugi 2.  These compounds were also the products of successive Biginelli and Ugi 
reactions.  However, these reactions had variations in the aldehyde group of the Ugi reaction, not 
in the Biginelli reaction.  These compounds did not inhibit breast cancer proliferation.  This 
indicates that for inhibition of breast cancer cell proliferation, the compounds are not tolerant to 
alterations in the aldehyde group of the Ugi reaction.  These compounds had effects that were 
reminiscent of Class 1B of compounds.  They generally stimulated Ssa1p ATP hydrolysis quite 
profoundly, and stimulated the initial TAg stimulation of Hsp70, before inhibiting the overall 
amplitude of the reaction.  This suggests that the aldehyde group is important to stimulate Ssa1p 
ATP hydrolysis. At this point, their mechanism of action is unclear.  The effects of these 
compounds were reminiscent of the five compounds previously tested in the breast cancer 
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proliferation assays, JB-78, JB-99, JB-102, JB-116, and MAL2-216.  Consistent with this 
classification, none of these compounds inhibited breast cancer cell proliferation. 
Class E.  Ugi-3.  Compounds in this class also were the products of successive Biginelli 
and Ugi reactions and utilized the same starting Biginelli product as the Ugi-2 class of 
compounds.  However, in this class, the amine group was varied in the reaction instead of the 
aldehyde group.  Compounds in this class had a variety of phenotypes, and some compounds 
inhibited breast cancer cell proliferation.  Compounds that inhibited breast cancer cell 
proliferation had effects that were similar to compounds in the Ugi-1 class that also inhibited 
breast cancer cell proliferation. 
Based on the data from the Chiosis lab on MAL3-101 (see above), I predict that the 
MAL3-101 derivatives that inhibit breast cancer cell proliferation will induce cellular apoptosis.  
Three assays could be utilized that easily detect apoptosis: Terminal Transferase-Mediated dUTP 
Nick End-Labeling Method (TUNEL), DNA laddering, and caspase activation.  TUNEL assays 
monitor cleavage of DNA by labeling the 3’ end of DNA fragments, whereas DNA laddering 
assays monitor DNA cleavage monitored on an ethidium bromide stained agarose gel.  Finally, 
the activation of caspases can be determined by incubating cell lysates with a synthetic caspase 
substrate linked to a reporter protein.  Substrate cleavage, and thus caspase activity, can be 
measured by colorimetric output or by fluorometry 
 For all in vivo studies three major caveats need to be mentioned.  First, if compounds 
have no effect on cell proliferation, the most trivial explanation is that sufficient quantities of the 
compound are not membrane permeable.  This is a distinct possibility with these compounds 
since many of the compounds are not very soluble and precipitate out of solution when added at 
high concentrations into the assays.  This concern can be partially addressed by synthesizing 
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compounds with lower mass that are more soluble.  Second, the compounds could be cleaved or 
modified upon entry into the cell, which could complicate any SAR analysis.  Thus, the 
functional motif that we ultimately identify might not directly act on the target protein.  Third, 
the in vitro system may examine a target for the compound that is irrelevant in vivo.  Thus, it is 
possible that chaperone modulation is only a secondary effect.  One way to identify the novel 
proteins that interact with the compounds would be to affix the compounds to beads, co-
precipitate any interacting proteins and use mass spectrometry to determine the protein identity.  
A similar approach was used to show that DSG interacts with Hsp70 (NADLER et al. 1992).  
However this approach requires a large quantity of compound, assumes the protein target is 
abundant in the cell, and may not detect transient interactions.  
5.3 MAL2-11B INHIBITS SV40 REPLICATION AND SV40 DNA SYNTHESIS 
Through my efforts, I have also identified a novel inhibitor of SV40 replication.  This compound, 
MAL2-11B, and a related compound, MAL3-101, inhibit TAg J domain stimulation of Hsp70 
ATP hydrolysis.  Despite these similarities, MAL3-101 had virtually no effect on viral 
replication.  To better understand the difference between MAL2-11B and MAL3-101 and 
identify the mechanism by which MAL2-11B inhibited SV40 replication, I analyzed compound 
specificity on several ATPases.  I determined that MAL2-11B, but not MAL3-101 slightly 
inhibited the endogenous ATPase activity of the mammalian chaperones, Hsp70 and Hsp90.  
Surprisingly, MAL2-11B (but not MAL3-101) drastically inhibited both TAg and MCM ATPase 
activity.  Since the TAg ATPase domain, but not the TAg J domain is required for in vitro DNA 
replication, I tested the effects of the compounds on DNA replication and determined that 
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MAL2-11B abolished DNA replication.  Based on these studies, I conclude that MAL2-11B 
inhibits SV40 replication by inhibiting TAg ATPase activity and subsequently DNA replication. 
 Since I screened for inhibitors of J domain stimulation of Hsp70, the discovery that one 
of these compounds (MAL2-11B) was also a TAg ATPase inhibitor was surprising.  One 
possibly is that MAL2-11B binds at two locations in TAg and thus inhibition of the J domain and 
ATPase are distinctly different phenomena.  Another possibility is that MAL2-11B completely 
unfolds the TAg monomer, thus preventing activity of all TAg domains.  This is unsatisfying 
because the J and ATPase domains are independent and are connected by a flexible linker; it is 
also difficult to imagine how a small molecule interaction at one site allosterically disrupts a 
separate domain.  Another, more satisfying explanation is that MAL2-11B inhibits 
hexamerization.  In the absence of ATP, TAg exists at an equal level of dimer and hexamer in 
solution, which is converted to hexamer in the presence of ATP.  Currently, we do not know the 
oligomerization state of TAg that functions in single turnover assays, though some data suggests 
it is a hexamer.  First, as TAg is titrated into the single turnover assay, the initial rate of ATP 
hydrolysis increases.  However, at very low concentrations of TAg, this effect is no longer 
apparent, suggesting a threshold for stimulation (data not shown).  One possibility is that this 
represents the threshold for hexamerization.  Second, single turnover experiments with several 
N-terminal TAg truncation mutants suggest there are two distinct classes of TAg mutations.  An 
N-terminal truncation with the first 500 amino acids stimulates Ssa1p with near wild type 
efficiency.  However, TAg mutants with only the first 136 or 260 amino acids have virtually no 
activity in the single turnover assay (data not shown).  Fine mapping by Jacklynn Moskow, in the 
Pipas lab at the University of Pittsburgh, suggests that any TAg N-terminal construct that 
contains the J domain through the zinc binding region is sufficient for stimulating Ssa1p ATP 
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hydrolysis (J. Pipas, personal communication).  This suggests hexamerization is required for 
activity, but hypotheses about protein length and buffer effects need to be addressed. 
I was equally surprised by MAL2-11B inhibition of MCM ATPase activity.  However, 
both MCM and TAg are AAA+ ATPases, and TAg has known helicase activity and MCM is a 
presumed helicase (MAIORANO et al. 2006).  Matt Bochman, in the Schwacha lab at the 
University of Pittsburgh has shown that 300 µM MAL2-11B abolishes MCM binding to ssDNA, 
and MAL3-51 and MAL3-101 have no effect (personal communication).  These reactions were 
performed in the presence of ATPγS, since ATP binding is sufficient for ssDNA binding.  One 
possibility is that MAL2-11B competes with ATP at the nucleotide binding site.  In support of 
this hypothesis, M. Bochman performed competition experiments and showed that decreasing 
ATPγS in the reactions made MAL2-11B more effective at preventing ssDNA binding.  Another 
possibility is that MAL2-11B affects the structure of the hexamer.  This could be addressed by 
performing immunoprecipitations in the presence or absence of MAL2-11B and determining if 
the interactions between the proteins are affected. 
The final ATPase tested was kinesin.  This ATPase was chosen because it was unrelated 
to the previous ATPases tested and fairly abundant in the cell.  As mentioned earlier, MAL2-11B 
had a very different effect on kinesin than on the other ATPases.  As opposed to inhibiting 
kinesin ATPase activity, MAL2-11B appeared to dramatically stimulate its ATPase activity 
while on ice, in a concentration dependent manner.  More experiments are required before these 
data are completely understood.  However, it is clear that MAL2-11B activity differs between 
ATPases, and does not globally inhibit the activities of all enzymes. 
Since MAL2-11B inhibited both the TAg ATPase activity and TAg J domain stimulation 
of Hsp70, it was unsurprising that MAL2-11B inhibited viral replication.  These results also 
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correlated with inhibition of DNA replication in vitro.  Based on the biochemical data, several 
models can be proposed.  It is most likely that the inhibition of SV40 replication is due to the 
inhibition of the TAg ATPase activity since MAL3-101 did not inhibit replication (though this 
could be due to the concentration tested).  This is also supported by the results from the in vitro 
DNA replication assay, which does not require the TAg J domain for replication (COLLINS and 
PIPAS 1995; WEISSHART et al. 1996).  Three other possibilities remain.  First, inhibition of SV40 
replication could be independent of TAg and dependent on another, unknown, protein.  Second, 
SV40 replication could be inhibited at a stage in the SV40 life cycle that occurs before DNA 
replication, such as virion disassembly or cell cycle initiation.  Finally, MAL2-11B could kill the 
cells.  However, G. Zhu from the Day lab has shown that BSC40 cell proliferation is unaffected 
by MAL2-11B, MAL3-51, or MAL3-101. 
There are several stages of the SV40 life cycle that are known to require Hsp70 or the 
TAg J domain which are potential targets of MAL2-11B.  These included: disassembly of viral 
capsids, initiation of the cell cycle via E2F release, DNA replication, and virion assembly 
(CHROMY et al. 2006; CRIPE et al. 1995; SPENCE and PIPAS 1994b; SRINIVASAN et al. 1997; 
SULLIVAN et al. 2000a).  I chose to test DNA replication first for three reasons.  First, this 
process was one of the few that also required the TAg ATPase domain.  Second, the in vitro 
replication assay is relatively quick and easy to perform.  Third, the results of the in vitro 
replication assay could be verified by determining viral DNA yield in vivo.  Addition of MAL2-
11B virtually abolished DNA replication in a concentration dependent manner.  Similar results 
were also seen with chemically related compounds.  In fact, MAL2-11B inhibited the 
background repair synthesis that is normally seen in the in vitro replication assay, which suggests 
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that it may also interfere with additional cellular factors.  This, however, is unsurprising based on 
the previously discussed in vitro data.  
Unfortunately, the in vitro replication assay does not address the specificity of drug 
action.  The in vitro replication assay uses HeLa cell lysate to provide the necessary cellular 
“machinery” for replication, and theoretically MAL2-11B could inhibit any protein required for 
replication.  This may be especially relevant if MAL2-11B is not specific for TAg and interferes 
with other ATPases.  Therefore, the Fanning lab at Vanderbilt University has included MAL2-
11B in their in vitro replication assays and MAL2-11B also inhibits TAg-dependent replication 
(personal communication).  These assays use purified components, instead of cell lysate, and the 
only protein components of the reaction are hRPA, topoisomerase I, pol-prim, and TAg.  Future 
MAL2-11B titrations into the Fanning lab replication assay will determine if MAL2-11B inhibits 
replication at similar concentrations, which would suggest the inhibition of DNA synthesis in my 
DNA replication experiments is solely due to the inhibition of TAg ATPase activity.  Formally, 
MAL2-11B may also inhibit the activities of hRPA, topoisomerase I, or pol-prim, but since these 
proteins are not ATPases, this is not expected.  
Based on previous data several hypotheses exist for the mechanism of MAL2-11B 
inhibition of DNA replication.  First, MAL2-11B could inhibit the J domain’s role in DNA 
replication.  However, the role of the J domain in replication is unclear and it is not required for 
in vitro DNA replication.  Second, it is possible that MAL2-11B inhibits the TAg helicase 
activity.  This requires ATP hydrolysis by the TAg ATPase domain and DNA binding to the 
DNA binding domain.  As discussed previously, MAL2-11B inhibits TAg ATPase activity and 
MCM ssDNA binding activity, so either of these hypotheses is viable.  Based on above studies, a 
third possibility is that TAg is unable to hexamerize in the presence of compound.  As mentioned 
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previously, there is evidence that TAg hexamerization is required for TAg stimulation of Ssa1p 
in the single turnover assay.  Also, ssDNA binding and helicase activity require TAg 
hexamerization.  To see if this is the case, I will add MAL2-11B to in vitro TAg hexamerization 
assays that monitor hexamerization in the presence of ATP (CASTELLINO et al. 1997).  
 One major concern with these studies is the lack of MAL2-11B specificity.  This 
complicates the interpretation of the in vivo data and may cause secondary effects during 
treatment.  I am particularly interested in determining if the effect of MAL2-11B on chaperones, 
independent of TAg, is important for inhibition of viral replication.  Chaperones are often 
upregulated in response to viral replication and MAL2-11B could inhibit these chaperones’ 
activity.  Thus, I plan to determine the levels of Hsp70 and Hsp90 before and after viral infection 
and determine if MAL2-11B alters these levels.  In addition, I plan to determine if modulation of 
Hsp90 activity by GA can inhibit viral replication.  Together, these experiments will examine the 
role that the chaperones play in viral replication independent of the TAg J domain. 
 Finally, perhaps the best way to address specificity is to screen for compounds that are 
specific TAg inhibitors and that do not interfere with the ATPase activities of other proteins.  I 
can visualize several different assays that could be used to screen for novel SV40 inhibitors.  
Perhaps the easiest way is to screen for inhibitors of TAg ATPase activity, and counterscreen for 
compounds that do not affect a second ATPase, such as Hsp70.  The in vitro replication assays 
could also be adapted to a high throughput system and could be used to screen for compounds 
that inhibit DNA replication.  Unfortunately, compounds that inhibit aspects of replication 
independent of TAg would also be identified, and isolated compounds would need to be 
counterscreened using in vitro DNA replication assay with purified components.  
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Taken together, these results suggest that I have identified two strikingly different classes 
of J-protein modulators.  The first class is represented by MAL3-101 and the Ugi-1 and Ugi-3 
derivatives of MAL3-101.  These compounds inhibit J-protein stimulation of Hsp70 and breast 
cancer cell proliferation.  However, they do not inhibit SV40 propagation or SV40 DNA 
replication.   The second class is represented by MAL2-11B and the Biginelli acid derivatives of 
MAL3-101.  These compounds also inhibit J-protein stimulation but have no effect on breast 
cancer cell proliferation.  In addition, MAL2-11B inhibits various ATPases, including the AAA+ 
ATPases, TAg and MCM.  It is likely that the inhibition of viral replication is independent of J-
protein stimulation of Hsp70, and may be due to inhibition of hexamerization.  It is currently 
unclear how these compounds are handled intracellularly, but it is certainly possible that these 
compounds target different proteins.  Much future research should be directed at further 
characterization of these different classes in vivo and in vitro.  I predict that the future study of 
these and related compounds will yield viable treatment options for breast cancer and 
polyomavirus infection. 
 
(HATA et al. 1998; NICOLET and CRAIG 1989; PEARL and PRODROMOU 2006; RODRIGUEZ-
NAVARRO et al. 2004; ROELANTS et al. 2004; ROEMER et al. 1993; SINGLETON 1997; WILLIAMS 
and TRUMBLY 1990; ZHOU et al. 1993) 
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